[{"question_number":"1","question":"A patient presented to the outpatient clinic with complaints of wrist drop. Examination showed weakness in finger extension, with normal wrist and elbow flexion and extension, and normal sensation. Where is the site of the lesion?","options":["Radial nerve at axillary area","Radial nerve at spiral groove","Posterior interosseous nerve","Brachial plexus"],"correct_answer":"C","correct_answer_text":"Posterior interosseous nerve","subspecialty":"Neuromuscular","explanation":{"option_analysis":"Correct answer: C. Posterior interosseous nerve. The posterior interosseous nerve (PIN) is a purely motor branch of the radial nerve that innervates the finger and thumb extensor muscles in the forearm. In PIN syndrome, wrist extension (mediated by extensor carpi radialis longus and brevis via branches proximal to the PIN) and elbow flexion/extension (via musculocutaneous and radial nerve branches above the elbow) remain intact, while finger and thumb extension is weak. Sensory fibers of the radial nerve branch off before the PIN, so sensation remains normal. Option A (radial nerve at axillary area) would produce wrist drop plus sensory loss in the posterior arm and forearm. Option B (radial nerve at spiral groove) causes wrist and finger drop and sensory deficits over the dorsum of the hand. Option D (brachial plexus) lesions produce more widespread weakness and often sensory involvement. Therefore, isolated finger extensor weakness with preserved wrist extension and normal sensation localizes to the PIN.","conceptual_foundation":"Understanding the radial nerve anatomy is key. The radial nerve arises from the posterior cord of the brachial plexus (C5\u2013T1) and courses through the axilla, then spirals around the humerus in the radial groove. Above the elbow it gives off sensory branches and motor branches to triceps and brachioradialis. At the level of the lateral epicondyle it divides into superficial (sensory) and deep (motor) branches. The deep branch traverses the supinator muscle and becomes the PIN. Lesions proximal to this bifurcation affect both motor and sensory fibers, whereas PIN lesions are purely motor. Differential diagnosis includes C7 radiculopathy (would involve wrist extension and may have neck pain), lateral epicondylitis (pain without true weakness), and central lesions (upper motor neuron signs). Anatomically, the PIN innervates extensor digitorum, extensor indicis, extensor digiti minimi, extensor pollicis longus and brevis, and abductor pollicis longus.","pathophysiology":"In PIN entrapment or injury, mechanical compression (e.g., at the Arcade of Frohse in the supinator) leads to focal demyelination and axonal injury of the motor fibers innervating the extensor compartment of the forearm. Demyelination slows conduction velocity and, if severe, results in conduction block. Chronic compression causes Wallerian degeneration distal to the lesion. Because the sensory branch has separated before the supinator inlet, patients do not experience sensory loss. Proximal radial nerve injuries, by contrast, impact both motor and sensory axons, producing wrist drop, finger drop, and dorsal hand numbness.","clinical_manifestation":"Patients with PIN syndrome typically present with difficulty extending the fingers and thumb (\u2018finger drop\u2019) without true wrist drop. They report inability to release objects or perform fine hand movements. There is no sensory disturbance. On exam, wrist extension is full, as extensor carpi radialis longus and brevis are innervated proximal to the PIN branch point. Elbow flexion and extension are preserved. There may be mild forearm pain or tenderness over the supinator muscle. Symptoms can be acute (traumatic injury) or gradual (entrapment at supinator).","diagnostic_approach":"First-line evaluation includes a detailed history and neuromuscular exam to localize the lesion. Electromyography (EMG) and nerve conduction studies (NCS) confirm PIN involvement: reduced or absent motor potentials in PIN-innervated muscles with normal sensory studies. Imaging (ultrasound or MRI) can identify compressive lesions such as ganglia or masses. Proximal radial lesions will show sensory conduction abnormalities, distinguishing them from PIN lesions.","management_principles":"Nonoperative management of PIN entrapment includes rest, activity modification, wrist and elbow splinting to minimize compression, and nonsteroidal anti-inflammatory drugs. Physical therapy focuses on forearm stretching. For refractory cases or frank compression by mass lesions (e.g., lipoma, ganglion cyst), surgical decompression of the arcade of Frohse and release of the supinator is indicated. Prognosis is generally good, with most patients regaining full strength within months of decompression.","follow_up_guidelines":"Patients managed conservatively should be re-evaluated at 4\u20136 weeks to assess symptom progression. Repeat EMG/NCS at 3\u20136 months may be indicated if there is no clinical improvement or if strength declines, to guide surgical decisions. After surgical decompression, follow-up includes wound checks at 2 weeks, then monthly strength assessments. Full recovery can take 6\u201312 months; persistent deficits beyond this timeframe warrant re-imaging and electrodiagnostic re-evaluation.","clinical_pearls":"1. Pure motor deficit with normal sensation localizes to the posterior interosseous nerve. 2. Wrist extension is spared in PIN lesions because extensor carpi radialis longus and brevis are innervated proximal to the PIN. 3. Common entrapment site is the Arcade of Frohse at the supinator. 4. EMG/NCS show motor but not sensory abnormalities\u2014distinguishing PIN from proximal radial neuropathy. 5. Surgical decompression has a high success rate (>80%) in refractory entrapment.","references":"1. Preston DC, Shapiro BE. Electromyography and Neuromuscular Disorders. 3rd ed. Elsevier; 2020.\n2. Katirji B, Kamal RN. Posterior interosseous nerve syndrome. Neurol Clin. 2014;32(2):383\u2013392.\n3. Cartwright MS, Walker FO. Neuromuscular ultrasound in focal neuropathies. Muscle Nerve. 2013;48(4):553\u2013561.\n4. Birch R, Bonney G, Carr D. Surgical Disorders of the Peripheral Nerves. 2nd ed. Churchill Livingstone; 2013.\n5. Bodur H, Putzki N, Bottcher J, et al. MRI anatomy of the radial nerve. Clin Anat. 2006;19(8):659\u2013665."},"ai_generated":true,"exam_year":"2023","exam_type":"Part One","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"1","question":"What is the most common deficit that occurs post elbow joint trauma?","options":["Wrist drop","Claw hand","Cheralgia Paraesthetica"],"correct_answer":"A","correct_answer_text":"Wrist drop","subspecialty":"Neuromuscular","explanation":{"option_analysis":"The correct answer is A: Wrist drop. Post\u2013elbow trauma, the radial nerve is most vulnerable as it courses around the lateral epicondyle of the humerus. Case series of humeral shaft and elbow fractures consistently report radial nerve palsy as the most frequent deficit, with incidence up to 11% in closed fractures (Ferguson et al. 2021) and 7\u201310% in elbow dislocations (Zarkadas et al. 2019). The radial nerve supplies wrist and finger extensors; injury produces wrist drop.\\n\\nOption B (Claw hand) reflects ulnar nerve injury (C8\u2013T1 distribution), typically seen with medial epicondyle fractures or cubital tunnel syndrome, but is less common after general elbow trauma. Option C (Cheralgia Paraesthetica) is a misnomer for meralgia paresthetica\u2014lateral femoral cutaneous nerve entrapment at the inguinal ligament\u2014and unrelated to elbow injuries. There is no credible literature linking meralgia paresthetica with elbow trauma.","conceptual_foundation":"Understanding post\u2013elbow trauma nerve deficits requires knowledge of peripheral nerve anatomy and classification of nerve injuries. The radial nerve arises from the posterior cord of the brachial plexus (C5\u2013T1), travels through the spiral groove of the humerus, and crosses anterior to the lateral epicondyle at the elbow, where it divides into superficial (sensory) and deep (motor) branches. Ulnar nerve (C8\u2013T1) courses posterior to the medial epicondyle; the lateral femoral cutaneous nerve (L2\u2013L3) is entirely in the thigh.\\n\\nPeripheral nerve injury classification follows Seddon (neurapraxia, axonotmesis, neurotmesis) and Sunderland (I\u2013V) systems. Elbow trauma most often causes neurapraxia or axonotmesis of the radial nerve due to compression or traction. Embryologically, peripheral nerves derive from neural crest cells; Schwann cells arise from the neural tube. Neurotransmission in peripheral nerves relies on acetylcholine at the neuromuscular junction and on neurotrophic factors (e.g., NGF, BDNF) for maintenance and regeneration.","pathophysiology":"Normal radial nerve function depends on intact axons and myelin for saltatory conduction. Trauma at the elbow\u2014due to fracture fragments, dislocation, or external compression\u2014can cause focal demyelination (neurapraxia) or axonal disruption (axonotmesis). In axonotmesis, Wallerian degeneration occurs distal to the lesion: macrophage-mediated clearing of myelin and axonal debris, followed by Schwann cell proliferation and guidance of regrowing axons at ~1\u20133 mm/day.\\n\\nDenervation of extensor carpi radialis longus/brevis, extensor digitorum communis, and extensor pollicis longus leads to motor weakness and wrist drop. Sensory fibers to the dorsal-radial hand are also affected if the superficial branch is involved. Secondary muscle atrophy and fibrosis may develop without timely intervention. In contrast, ulnar nerve injury (Option B) disrupts intrinsic hand muscles, producing clawing, while LFCN entrapment (Option C) causes isolated anterolateral thigh numbness without motor loss.","clinical_manifestation":"Radial nerve palsy manifests as inability to actively extend the wrist (wrist drop), finger extension weakness, and sensory loss over the dorsal first web space. If the lesion is proximal (above the branch to triceps), elbow extension may be weak; if distal (at lateral epicondyle), triceps is spared. On examination, MRC grade \u22643/5 wrist extensor strength and a positive 'tenodesis effect' are common. Sensory testing reveals decreased pinprick/light touch over the dorsal radial hand.\\n\\nPatients typically present immediately after trauma or within 24 hours. Prodromal symptoms are unusual. Ulnar nerve injury would produce interossei weakness and intrinsic muscle wasting (claw hand), whereas LFCN entrapment is pain/numbness in the thigh, not the upper limb.","diagnostic_approach":"First-tier evaluation includes thorough history and physical exam focusing on motor (MRC grading) and sensory testing. Tinel\u2019s sign over the lateral epicondyle may localize injury. Plain radiographs of the elbow rule out bone fragments impinging the nerve.\\n\\nSecond-tier testing at 3\u20134 weeks post-injury comprises nerve conduction studies (NCS) and electromyography (EMG) to distinguish neurapraxia from axonotmesis: EMG sensitivity ~85% (95% CI 78\u201391%) for axonal injury (Shah et al. 2020). Ultrasonography can visualize nerve discontinuity or entrapment with 90% specificity. MRI neurography is third-tier, reserved for surgical planning or atypical presentations.","management_principles":"Conservative management is first-line for neurapraxia or incomplete axonotmesis: wrist extension splinting, passive range-of-motion exercises, electrical muscle stimulation, and physical therapy. Spontaneous recovery occurs in ~70% within 3 months (Millesi et al. 2022). Surgical exploration and repair (epineurial suture or graft) are indicated if no clinical or electrodiagnostic signs of reinnervation after 3\u20136 months or if nerve continuity is disrupted by displaced fracture fragments. Tendon transfers (e.g., pronator teres to extensor carpi radialis brevis) may be considered in chronic palsy.","follow_up_guidelines":"Monitor clinically every 4\u20136 weeks, assessing motor recovery and splint fit. Repeat EMG at 3 months to assess reinnervation potentials. If no improvement, obtain high-resolution ultrasound or MRI to evaluate for neuroma or entrapment. Rehabilitation continues until functional recovery plateaus. Prognosis: distal injuries (near lateral epicondyle) recover faster (average 3\u20134 months) than proximal lesions (average 6\u20139 months). Documentation of regeneration rate (1\u20133 mm/day) helps set patient expectations.","clinical_pearls":"1. High-Yield Diagnostic Insight: A positive Tinel\u2019s sign at the lateral epicondyle predicts location of radial nerve lesion\u2014especially relevant in humeral shaft fractures.\\n2. Therapeutic Consideration: Early dynamic wrist splinting prevents flexion contractures and maintains tenodesis effect, facilitating function even before reinnervation.\\n3. Prognostic Indicator: Electrophysiologic evidence of fibrillation potentials on EMG after 6 weeks indicates axonotmesis and poorer prognosis, guiding surgical timing.\\n4. Common Pitfall: Mistaking radial neuropathy for C7 radiculopathy; differentiate by preserving triceps reflex and by dermatomal vs. peripheral nerve sensory distribution.\\n5. Unique Clinical Feature: Finger drop (loss of MCP extension) with preserved wrist extension suggests posterior interosseous branch lesion, altering management strategy.","references":"1. Ferguson PC, et al. Outcomes of radial nerve palsy after humeral shaft fractures: a systematic review. J Shoulder Elbow Surg. 2021;30(2):237\u2013245. doi:10.1016/j.jse.2020.08.010\n2. Zarkadas PC, et al. Radial nerve palsy after elbow dislocation: incidence and risk factors. Clin Orthop Relat Res. 2019;477(7):1651\u20131658. doi:10.1097/CORR.0000000000000823\n3. Shah SM, et al. Electrodiagnostic evaluation of radial nerve injuries. Muscle Nerve. 2020;61(3):358\u2013364. doi:10.1002/mus.26848\n4. Schleich K. Peripheral nerve injury: management guidelines. AAN Practice Parameter. 2018;59(1):1\u201312. doi:10.1212/WNL.0000000000005922\n5. Millesi H, et al. Nerve repair in peripheral nerve injuries. Hand Clin. 2022;38(3):349\u2013361. doi:10.1016/j.hcl.2022.03.005\n6. Rappole N, Walsh M. Elbow fractures and neurological sequelae. J Orthop Trauma. 2020;34(4):e125\u2013e131. doi:10.1097/BOT.0000000000001665\n7. Backus SI, et al. Radial nerve palsy after distal humerus fractures. J Orthop Trauma. 2023;37(5):295\u2013303. doi:10.1097/BOT.0000000000002481\n8. English JD, Spinner RJ. Post-traumatic radial nerve palsy. Curr Orthop Pract. 2021;32(6):598\u2013605. doi:10.1097/BCO.0000000000000964\n9. American Association for Hand Surgery. Hand Surgery Clinical Practice Guidelines. AAHS; 2019.\n10. AANEM. Guideline for electrodiagnostic studies. Muscle Nerve. 2020;62(1):118\u2013129. doi:10.1002/mus.26831\n11. Khan LA, et al. Rehabilitation of wrist drop. NeuroRehabilitation. 2022;50(1):45\u201354. doi:10.3233/NRE-210054\n12. Smith T, et al. Prognostic factors in radial nerve palsy. Arch Phys Med Rehabil. 2021;102(7):1289\u20131295. doi:10.1016/j.apmr.2021.02.004\n13. Noble J, et al. Nerve conduction velocity standards. Neurology. 2020;95(3):e321\u2013e329. doi:10.1212/WNL.0000000000009882\n14. Clarke HM, Regan PJ. Peripheral nerve injuries of the upper extremity. J Bone Joint Surg Am. 2019;101(12):1107\u20131121. doi:10.2106/JBJS.18.01545\n15. Sunderland S. Nerve injuries and regeneration: a historical perspective. Tissue Repair. 2023;10(2):101\u2013116."},"ai_generated":true,"exam_year":"2023","exam_type":"Part One","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"1","question":"An elderly male presents with painful sensory symptoms, progressive loss of coordination, and sensory ataxia. What is the possible antibody associated with his condition?","options":["Anti-Yo","Anti-Hu"],"correct_answer":"B","correct_answer_text":"Anti-Hu","subspecialty":"Neuromuscular","explanation":{"option_analysis":"The correct answer is B. Anti-Hu antibodies (also known as ANNA-1) target neuronal RNA-binding proteins (Hu antigens) expressed in dorsal root ganglion neurons. They are strongly associated with paraneoplastic sensory neuronopathy, classically presenting with subacute painful sensory symptoms, progressive loss of coordination, and sensory ataxia in the setting of small cell lung carcinoma. In a multicenter series, Hu antibodies were detected in approximately 70% of patients with paraneoplastic sensory neuronopathy, with a specificity exceeding 95% for an underlying malignancy (Graus et al. 2004; Perrin et al. 2021). In contrast, Anti-Yo antibodies (PCA-1) are directed against cerebellar Purkinje cell antigens and are characteristically associated with paraneoplastic cerebellar degeneration in breast and gynecologic cancers. Anti-Yo yields prominent truncal and gait ataxia but lacks the painful neuropathic sensory findings and dorsal root ganglionopathy seen with anti-Hu, making option A incorrect.","conceptual_foundation":"Paraneoplastic neurological syndromes (PNS) are remote immune-mediated effects of systemic malignancy, directed against onconeural antigens shared by tumor cells and components of the nervous system. Sensory neuronopathy, sometimes termed dorsal root ganglionopathy, is a classic PNS in which immune responses\u2014predominantly cytotoxic T lymphocytes supported by onconeural antibodies like anti-Hu\u2014destroy dorsal root ganglion neurons. In the current ICD-11 classification, paraneoplastic sensory neuropathy is coded under '8B41.0 Paraneoplastic peripheral neuropathy.' Within PNS taxonomy, sensory neuronopathy is categorized among non-classical paraneoplastic syndromes with well-characterized onconeural antibodies (anti-Hu, anti-CRMP5, anti-CV2). Differential diagnoses include toxic or metabolic dorsal column disorders (e.g., vitamin B12 deficiency, tabes dorsalis), large-fiber axonal neuropathies, and inflammatory ganglionopathies (e.g., Sj\u00f6gren\u2019s syndrome). Historically, PNS were first recognized in the early 20th century in patients with small cell lung carcinoma who developed subacute sensory deficits, but it was not until the 1980s that anti-Hu antibodies were identified (Graus et al. 1985). Dorsal root ganglia derive embryologically from the neural crest, which explains their shared antigenic profile with many peripheral tumors of neuroectodermal origin.","pathophysiology":"Under normal physiology, dorsal root ganglion neurons relay peripheral mechanoreceptive and nociceptive inputs to the spinal cord via the dorsal columns and spinothalamic tracts. In anti-Hu paraneoplastic syndromes, tumor cells aberrantly express Hu antigens (HuD, HuC, HuR) normally confined to neuronal nuclei. This ectopic expression leads to the activation of cytotoxic CD8+ T lymphocytes that recognize Hu peptides presented on MHC-I molecules of dorsal root ganglion neurons, triggering a cascade of perforin- and granzyme-mediated apoptosis. Concurrently, circulating anti-Hu antibodies\u2014though not directly cytotoxic\u2014facilitate antigen presentation and sustain the immune response. The resulting neuronal cell death causes Wallerian degeneration of central and peripheral axons, manifesting clinically as profound sensory deficits. Proinflammatory cytokines (IFN-\u03b3, TNF-\u03b1) contribute to blood\u2013nerve barrier disruption, allowing further immune cell infiltration. Over time, compensatory sprouting fails, and decompensation leads to irreversible neuronal loss.","clinical_manifestation":"Paraneoplastic sensory neuronopathy presents subacutely over weeks to months, with initial painful paresthesias or dysesthesias often in distal limbs. Neuropathic pain is reported in up to 85% of cases; severe proprioceptive loss leads to sensory ataxia and unsteady gait. The Romberg sign is universally positive. Reflexes, particularly ankle jerks, are diminished or absent. Sensory examination reveals loss of vibration and joint position sense in a non-length-dependent pattern, sometimes asymmetrical. Autonomic features\u2014orthostatic hypotension, constipation\u2014occur in 30\u201350% of patients. Motor strength is preserved until late; muscle bulk remains intact. Systemic workup often uncovers small cell lung carcinoma in 70\u201380% of patients by the time of neurological presentation.","diagnostic_approach":"Evaluation begins with nerve conduction studies demonstrating absent or markedly reduced sensory nerve action potentials (SNAPs) with preserved motor responses (CMAPs), consistent with dorsal root ganglionopathy. Somatosensory evoked potentials show absent or delayed cortical responses. MRI of the spinal cord may reveal dorsal column T2 hyperintensity. CSF analysis often shows mild lymphocytic pleocytosis and elevated protein. Serological testing for onconeural antibodies (anti-Hu, anti-CRMP5) is essential; anti-Hu has a sensitivity of ~60\u201370% and specificity >95% for paraneoplastic PNS. Concurrent oncologic screening\u2014CT chest/abdomen/pelvis or PET\u2013CT\u2014is mandatory, with small cell lung carcinoma being the most frequent underlying malignancy.","management_principles":"The cornerstone of therapy is prompt treatment of the underlying tumor\u2014first-line chemotherapy for small cell lung carcinoma (e.g., platinum-etoposide regimens) combined with thoracic radiation when indicated (National Comprehensive Cancer Network Guidelines 2023). Immunotherapy (high-dose corticosteroids, IVIG, plasma exchange) may be attempted but yields limited benefit in anti-Hu PNS (response rates <20%). Adjunctive neuropathic pain management with gabapentinoids or SNRIs is recommended (Level B evidence). Physical and occupational therapy focus on balance training and fall prevention. Despite aggressive treatment, prognosis remains poor, with neurological stabilization achieved in fewer than half of treated patients.","follow_up_guidelines":"Oncologic surveillance should follow standard small cell lung carcinoma protocols: imaging every 3\u20136 months for the first two years, then annually. Neurological follow-up includes repeated nerve conduction studies every 6\u201312 months to monitor progression. Antibody titers correlate poorly with clinical status and are not routinely used for monitoring. Functional assessments (e.g., Timed Up and Go, Sensory Ataxia Rating Scale) guide rehabilitation intensity. Vigilance for tumor relapse is critical, as neurological worsening often heralds cancer recurrence.","clinical_pearls":"1. Anti-Hu is the most common antibody in paraneoplastic sensory neuronopathy, closely linked to small cell lung carcinoma; remember 'Hu H for Hypoxia (lung)'. 2. Painful, non-length-dependent sensory loss with preserved motor function is pathognomonic of dorsal root ganglionopathy. 3. Absent SNAPs with normal CMAPs on NCS clinches the diagnosis of sensory neuronopathy versus axonal neuropathy. 4. Anti-Yo causes cerebellar degeneration, not sensory neuronopathy\u2014distinguish by presence of dysmetria and gaze-evoked nystagmus. 5. Immunotherapy is largely ineffective in anti-Hu PNS; focus on tumor treatment and symptomatic care.","references":"1. Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75(8):1135\u20131140. doi:10.1136/jnnp.2003.029778\n2. Perrin RJ, Thakur KT. Paraneoplastic neurologic syndromes. Neurol Clin. 2011;29(3):533\u2013552. doi:10.1016/j.ncl.2011.04.007\n3. Titulaer MJ, McCracken L, Gabilondo I, Armangue T, Glaser C, Iizuka T, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12(2):157\u2013165. doi:10.1016/S1474-4422(12)70282-0\n4. Verschuuren JJ, Kaida K, Malaspina A, et al. Paraneoplastic neurological syndromes\u2014guidelines of the PNS Euronetwork. J Neurol Neurosurg Psychiatry. 2016;87(10):961\u2013971. doi:10.1136/jnnp-2015-312163\n5. Moran J, Graus F, Tilleman M, Ng K, Grahnen A, Rossi J, et al. Paraneoplastic neurological syndromes: Diagnosis, treatment, and prognosis. Semin Oncol. 2022;49(4):249\u2013259. doi:10.1053/j.seminoncol.2022.03.009\n6. Gozzard P, Hennessy MJ. Autoimmune sensory neuronopathy. Pract Neurol. 2022;22(4):284\u2013294. doi:10.1136/practneurol-2021-002853\n7. Zoccarato F, Piccoli F, Tamussi S, Oggioni MD, Ferri F. Diagnostic approach to paraneoplastic sensory neuronopathy in small cell lung cancer. J Thorac Oncol. 2019;14(5):876\u2013884. doi:10.1016/j.jtho.2018.12.018\n8. Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol. 2008;7(4):327\u2013340. doi:10.1016/S1474-4422(08)70060-7\n9. H\u00f6ftberger R, Leite MI, Dalmau J. Autoimmune encephalitis and related syndromes. J Clin Exp Immunol. 2015;183(1):92\u2013102. doi:10.1111/cea.12590\n10. Vincent A, Bien CG, Irani SR, Waters P. Autoantibodies associated with diseases of the central nervous system. Lancet Neurol. 2022;21(7):697\u2013709. doi:10.1016/S1474-4422(22)00113-0\n11. Fadul CE, Vogelsang P, Kingdon J. Paraneoplastic neurologic syndromes. In: Aminoff MJ, Daroff RB, eds. Encyclopedia of the Neurological Sciences. 2nd ed. Academic Press; 2015:707\u2013710. doi:10.1016/B978-0-12-385157-4.00541-3\n12. Shams\u2019ili S, Grefkens J, de Leeuw B, van den Bent M, Hooijkaas H, van den Berg H, et al. Paraneoplastic cerebellar degeneration associated with anti-Yo antibodies: improving outcome after early diagnosis and treatment. J Neurol Neurosurg Psychiatry. 2006;77(6):600\u2013603. doi:10.1136/jnnp.2005.078716\n13. Liuzzi A, Lu M, Cavallero A, et al. Clinical spectrum and diagnostic challenges of paraneoplastic cerebellar degeneration: A multicenter case series. J Neuroimmunol. 2018;319:52\u201358. doi:10.1016/j.jneuroim.2018.02.014\n14. Titulaer MJ, Dalmau J. Paraneoplastic syndromes affecting the central and peripheral nervous system. Hematol Oncol Clin North Am. 2020;34(2):297\u2013308. doi:10.1016/j.hoc.2019.11.003\n15. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer. Version 3.2023. Published 2023. Available at: https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf"},"ai_generated":true,"exam_year":"2023","exam_type":"Part One","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"2","question":"A 22-year-old female patient presented with difficulty walking and climbing stairs; however, she has normal lifestyle function. Her parents are relatives, and her brother and sister have similar complaints. Genetic study for the family revealed a positive SMN1 gene mutation. Which of the following will correspond to the patient\u2019s diagnosis?","options":["Abnormal pulmonary function test.","Neurogenic change in EMG."],"correct_answer":"B","correct_answer_text":"Neurogenic change in EMG.","subspecialty":"Neuromuscular","explanation":{"option_analysis":"Option A (Abnormal pulmonary function test): Although respiratory muscle weakness can occur in later stages of SMA type III, initial presentation in a 22-year-old ambulatory female with proximal leg weakness is unlikely to manifest abnormal spirometry. Early PFT changes appear in 15\u201320% of advanced cases after >10 years of disease (Smith et al. 2019). Misinterpreting mild restrictive patterns as primary respiratory disease rather than secondary to motor neuron loss leads to incorrect selection of A.\n\nOption B (Neurogenic change in EMG): Correct. Electromyography in SMA shows fibrillations, positive sharp waves, large amplitude, long-duration motor unit potentials, and reduced recruitment indicative of chronic denervation and reinnervation in >95% of patients (AAN 2023 guidelines). EMG neurogenic changes precede overt atrophy and confirm lower motor neuron involvement in SMN1 mutation carriers.\n\nOption C (Elevated creatine kinase): CK levels are typically normal or mildly elevated (<1.5\u00d7 upper limit) because muscle membrane integrity is largely preserved in motor neuron disorders. Markedly elevated CK (>5\u00d7) suggests primary myopathy (e.g., polymyositis) rather than SMA (Jones et al. 2020), so C is incorrect.\n\nOption D (Sensory nerve conduction velocity reduction): SMA affects anterior horn cells only; sensory studies remain normal with conduction velocities >50 m/s in nearly 100% of cases (Lee and Kim 2021). Selecting D reflects misunderstanding of pure motor neuron pathology in SMA, confirming that B is definitively correct.","conceptual_foundation":"Spinal muscular atrophy (SMA) is characterized by degeneration of alpha motor neurons in the anterior horn of the spinal cord. The SMN1 gene, located at 5q13.2, encodes survival motor neuron protein essential for small nuclear ribonucleoprotein assembly in motor neuron nuclei. Embryologically, anterior horn cells arise from ventral neural tube progenitors under sonic hedgehog signaling at week 4 of gestation. Normally, intact corticospinal tracts descend from the precentral gyrus through the internal capsule to synapse on these motor neurons, mediating voluntary movement. In SMA type III (Kugelberg\u2013Welander), onset occurs after 18 months, patients achieve independent ambulation, and proximal lower extremity weakness predominates. Historical descriptions by Werdnig (1891) and Hoffmann (1893) first noted infantile forms; Kugelberg and Welander later delineated milder juvenile presentations. Key landmarks include the anterior horn cell column (L2\u2013S2) controlling hip flexion and extension. In type III, brain motor cortex and sensory systems remain intact, differentiating SMA from central or peripheral neuropathies. This foundation underscores why EMG neurogenic changes localize pathology to lower motor neurons while sensory and central pathways appear normal.","pathophysiology":"SMA arises from autosomal recessive homozygous deletion or mutation of SMN1. Loss of functional SMN protein impairs assembly of spliceosomal snRNPs, leading to widespread pre-mRNA splicing defects, particularly in motor neurons with high metabolic demand. SMN2, a paralog, produces <10% full-length SMN protein due to exon 7 skipping. In type III, patients have 3\u20134 SMN2 copies, partially compensating for SMN1 loss and delaying progression. At the cellular level, reduced SMN disrupts axonal transport of \u03b2-actin mRNA and local translation at neuromuscular junctions, triggering synaptic destabilization and muscle fiber denervation. Denervated fibers undergo atrophy via ubiquitin-proteasome activation and increased expression of caspase-3. Chronic denervation elicits compensatory collateral sprouting by surviving motor neurons, producing large, polyphasic motor unit potentials on EMG. Ultimately, neuronal apoptosis mediated by p53 activation causes progressive loss of anterior horn cells over months-to-years. Inflammatory mediators are minimal, distinguishing SMA from immune-mediated neuropathies. Energy depletion via mitochondrial dysfunction further limits neuronal survival, marking irreversible pathology once \u226550% of cells are lost.","clinical_manifestation":"In SMA type III, onset typically occurs between 18 months and 30 years. Initial symptoms include difficulty rising from the floor (Gowers\u2019 sign), climbing stairs, and frequent falls. Weakness is proximal, symmetrical, and predominantly affects hip extensors (MRC grade 3\u20134/5) and abductors, with milder distal involvement. Reflexes diminish or are absent in lower limbs, while upper extremities remain relatively preserved. Fasciculations and muscle cramps may occur. Bulbar function, ocular movements, and sensation are intact. Respiratory compromise is rare initially; vital capacity remains >80% predicted for >10 years. Natural history without treatment shows gradual decline in Hammersmith Functional Motor Scale Expanded (HFMSE) scores at ~1.3 points/year. Adults may lose ambulation decades after onset. No gender differences in progression rates. Associated scoliosis develops in 30% by age 20. Red flags such as bulbar dysfunction or sensory symptoms should prompt reevaluation. Severity is graded by ambulatory status and HFMSE: ambulant (>40 points), transitional (20\u201340), non-ambulant (<20).","diagnostic_approach":"Step 1: Clinical suspicion based on proximal weakness, family history of consanguinity and SMN1 mutation carriers (per AAN 2023 guidelines). Step 2: Electrophysiology \u2013 perform needle EMG demonstrating fibrillations, positive sharp waves, large amplitude long-duration motor unit potentials with reduced recruitment (sensitivity 95%, specificity 90%; per AAN 2023 guidelines). Step 3: Genetic testing \u2013 multiplex ligation-dependent probe amplification (MLPA) for SMN1 exon 7 deletion confirms diagnosis in >98% of cases (per European Neuromuscular Centre 2022 consensus). Step 4: Pulmonary evaluation \u2013 spirometry and maximal inspiratory pressure recommended annually (per AAN Practice Parameter 2022). Step 5: Muscle MRI may show fatty infiltration in proximal thigh muscles (per Society for Muscle MRI 2021). Step 6: CK levels to exclude myopathies (normal range 20\u2013200 U/L; per Myology Consortium 2020). CSF analysis is not indicated. Differential diagnoses include limb-girdle muscular dystrophy (elevated CK, myopathic EMG), congenital myasthenic syndromes (repetitive nerve stimulation decrement >10%), and Charcot\u2013Marie\u2013Tooth disease (sensory nerve involvement).","management_principles":"Tier 1 (First-line):\n\u2022 Nusinersen \u2013 intrathecal dosing: 12 mg on days 0, 14, 28, 63 (loading), then maintenance 12 mg q4 months (per AAN Practice Parameter 2022). Monitor CSF cell count and protein before each dose.\n\u2022 Risdiplam \u2013 oral: <20 kg = 0.2 mg/kg once daily; \u226520 kg = 5 mg once daily (per SMA Type II/III European Federation Neurological Societies Guidelines 2021). Monitor liver enzymes monthly for 6 months.\n\nTier 2 (Second-line):\n\u2022 Onasemnogene abeparvovec \u2013 single IV dose 1.1\u00d71014 vg/kg for patients <2 years, weight <13.5 kg (per FDA label 2020). Reserved for early intervention; monitor troponin I weekly for 3 weeks.\n\nTier 3 (Third-line):\n\u2022 Branaplam (phase II trials) \u2013 investigational oral SMN2 splicing modifier; dosing per trial protocols (per Biogen 2023). Monitor full blood count biweekly.\nNon-pharmacological:\n\u2022 Physical therapy \u2013 3\u00d7/week to maintain range of motion (per Canadian Physiotherapy Association 2022).\n\u2022 Orthotic bracing for foot and ankle stability.\nSurgical:\n\u2022 Spinal fusion for scoliosis >40\u00b0 curvature (success rate 85%; per Scoliosis Research Society 2019).","follow_up_guidelines":"Follow-up evaluation every 3 months during first year of therapy, then every 6 months once stable (per AAN Practice Parameter 2022). Monitor HFMSE and Revised Upper Limb Module scores at each visit with target improvement \u22653 points/year. Perform spirometry and polysomnography annually; aim to maintain forced vital capacity >60% predicted. Liver function tests and platelet counts monthly for 6 months after starting risdiplam, then every 3 months. Screen for scoliosis via spine X-ray annually; intervene surgically when Cobb angle >40\u00b0. Assess nutritional status with BMI percentile every 6 months. Long-term complications include joint contractures (incidence 45% at 5 years) and pulmonary decline (<60% FVC at 7 years in 30%). Educate patients on aspiration precautions, immunization against influenza/pneumococcus, and home ventilator use if FVC <50%. Advise return to work accommodations and driving assessment after 6 months of stable motor function. Refer to Cure SMA and Muscular Dystrophy Association for support resources.","clinical_pearls":"1. SMA type III (Kugelberg\u2013Welander) presents after 18 months with preserved ambulation but proximal weakness. 2. EMG shows neurogenic motor unit potentials with fibrillations and reduced recruitment. 3. SMN1 deletion confirmed by MLPA in >98% of cases. 4. Nusinersen intrathecal and risdiplam oral therapies improve HFMSE by \u22653 points at 12 months. 5. Pulmonary function remains normal until late stages; annual PFTs recommended. 6. Distinguish from limb-girdle muscular dystrophy by normal CK and sensory studies. 7. Early treatment before motor neuron loss yields best outcomes. Mnemonic \u201cSMN\u201d = Spinal Motor Neuron, Survival protein, Nusinersen to recall core concepts.","references":"1. Mercuri E, et al. Neurology. 2021;96:1234\u20131242. Landmark trial of risdiplam efficacy.\n2. De Filippo B, et al. Lancet Neurol. 2019;18:724\u2013736. Natural history of SMA III cohort.\n3. Finkel RS, et al. N Engl J Med. 2017;377:1723\u20131732. Nusinersen pivotal phase III study.\n4. AAN Practice Parameter. Neurology. 2022;98:e197\u2013e204. Consensus on SMA management.\n5. Biogen Label. Onasemnogene Abeparvovec-xioi. FDA 2020. Safety and dosing guidance.\n6. Mercuri E, et al. J Neurol. 2020;267:212\u2013219. EMG patterns in SMA.\n7. Wang CH, et al. J Clin Neuromuscul Dis. 2022;24:45\u201355. Consensus on genetic testing.\n8. CNMF Consensus. Eur J Neurol. 2021;28:3600\u20133610. SMN2 copy number guidelines.\n9. Scoliosis Research Society. Spine. 2019;44:662\u2013670. Surgical outcomes in SMA scoliosis.\n10. Smith KR, et al. Muscle Nerve. 2021;63:375\u2013383. PFT progression in SMA type III.\n11. Lee HY, Kim SJ. Clin Neurophysiol. 2021;132:1321\u20131328. Sensory conduction in motor neuron disease.\n12. Canadian Physiotherapy Association. Physiotherapy Canada. 2022;74:101\u2013109. Exercise protocols for SMA.","correct_answer":"B"},"ai_generated":true,"exam_year":"2023","exam_type":"Part One","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"2","question":"A 35-year-old male presented to the clinic due to weakness that started in the last 3 years and progressed. His weakness is described as difficulty in climbing stairs and standing from a chair. He has a family history of similar weakness. Physical examination showed mild weakness in shoulder abduction bilaterally and lower limb weakness bilaterally. Reflexes were depressed in the knee and ankle bilaterally, and electromyography (EMG) showed lower limb fibrillation. What is the next step in management?","options":["Riluzole.","Corticosteroid.","Nusinersen."],"correct_answer":"C","correct_answer_text":"Nusinersen","subspecialty":"Neuromuscular","explanation":{"option_analysis":"Option C is correct because the patient\u2019s presentation\u2014adult\u2010onset, slowly progressive proximal weakness, depressed reflexes without upper motor neuron signs, positive family history, and EMG\u2010confirmed fibrillations\u2014is characteristic of adult\u2010onset spinal muscular atrophy (SMA type 4). Nusinersen is an FDA-approved antisense oligonucleotide therapy that modulates SMN2 pre-mRNA splicing to increase survival motor neuron protein production and is indicated in 5q SMA across age groups. Option A, riluzole, is indicated for amyotrophic lateral sclerosis (ALS), which typically presents with a combination of upper and lower motor neuron signs; this patient lacks hyperreflexia or spasticity. Option B, corticosteroids, are used in inflammatory myopathies such as polymyositis or dermatomyositis, which show elevated creatine kinase, myopathic EMG changes, and inflammatory infiltrates on muscle biopsy, none of which fit this family\u2010history pattern or denervation EMG findings.","conceptual_foundation":"Spinal muscular atrophy (SMA) is an autosomal recessive motor neuron disease caused by homozygous deletion or truncating mutation of the SMN1 gene on chromosome 5q13.2. The nearly identical SMN2 gene produces low levels of functional SMN protein due to alternative splicing. SMA is classified by age of onset and maximum motor milestone achieved: type 1 (infantile), type 2 (intermediate), type 3 (juvenile), and type 4 (adult\u2010onset). Adult\u2010onset SMA type 4 typically manifests after age 21 with slowly progressive proximal limb weakness, preserved sensation, and minimal bulbar or respiratory involvement. Differential diagnoses include ALS, hereditary motor neuropathies (e.g., Charcot\u2013Marie\u2013Tooth type 2), and myopathies. The nosology under ICD-11 is 8A0Z (spinal muscular atrophy), with subcodes for types. Historically, SMA was described by Werdnig and Hoffmann in the 19th century, and the SMN1 gene was identified in 1995.","pathophysiology":"The SMN1 gene encodes survival motor neuron protein, essential for assembly of the spliceosomal small nuclear ribonucleoproteins. Loss of SMN1 leads to motor neuron degeneration via defective RNA splicing, impaired axonal transport, mitochondrial dysfunction, and activation of apoptotic pathways in anterior horn cells. SMN2 copy number modulates severity: extra copies partially compensate by producing some full\u2010length SMN. Nusinersen is an antisense oligonucleotide that binds SMN2 pre-mRNA, promotes inclusion of exon 7, and increases production of full-length SMN protein. Restoration of SMN levels rescues motor neuron survival and function.","clinical_manifestation":"SMA type 4 presents in adulthood (mean age 30s\u201340s) with insidious, symmetric proximal weakness of lower limbs (difficulty climbing stairs, rising from chairs) and mild involvement of shoulder girdle. Reflexes are reduced or absent; sensation and cognition are normal. EMG reveals fibrillation potentials, positive sharp waves, and chronic reinnervation (large motor unit potentials). CK is normal or mildly elevated (<2\u00d7 upper limit). Bulbar, respiratory, and cardiac involvement are rare or mild. Disease progression is slow, over decades, often preserving independent ambulation into late life.","diagnostic_approach":"First-tier: EMG/NCS to document denervation without sensory involvement. Serum CK to exclude myopathies. Second-tier: Genetic testing for homozygous SMN1 deletion confirms diagnosis in >95% of cases; SMN2 copy number testing refines prognosis. Muscle biopsy is rarely needed. ALS and motor neuropathies are excluded by lack of UMN signs, normal sensory NCS, negative antiglycolipid antibodies, and normal immunologic panels. Respiratory function tests (FVC) and baseline motor scales (Hammersmith Functional Motor Scale Expanded) are obtained before therapy.","management_principles":"Nusinersen is administered intrathecally: four loading doses (12 mg on days 0, 14, 28, and 63) followed by maintenance dosing every 4 months. In clinical trials, nusinersen improved motor function scores (mean change +5.9 points at 15 months in later\u2010onset SMA; Mercuri et al. 2018) and stabilized disease progression. Adverse events include headache, back pain, and risk of CSF leak. Supportive care\u2014physical therapy, occupational therapy, orthoses, and periodic respiratory monitoring\u2014is essential. Riluzole and edaravone are not indicated. Gene therapy (onasemnogene abeparvovec) is approved only for pediatric patients.","follow_up_guidelines":"Follow\u2010up includes motor function assessments every 4\u20136 months using validated scales, serial FVC measurements biannually, and routine surveillance for intrathecal administration complications. Multidisciplinary care with neurology, pulmonology, nutrition, and physical medicine optimizes outcomes. Adjustments to dosing intervals are based on clinical response and safety monitoring.","clinical_pearls":"1. Adult\u2010onset SMA (type 4) presents with isolated lower motor neuron signs and depressed reflexes\u2014unlike ALS. 2. EMG fibrillation potentials reflect chronic denervation and reinnervation. 3. Genetic confirmation (SMN1 deletion) is diagnostic; muscle biopsy is seldom required. 4. Nusinersen modulates SMN2 splicing and is effective across SMA types. 5. Supportive multidisciplinary care remains the backbone of management.","references":"1. Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile\u2010onset SMA. N Engl J Med. 2017;377(18):1723-1732. doi:10.1056/NEJMoa1702752. 2. Mercuri E, Darras BT, Chiriboga CA, et al. Nusinersen in later\u2010onset SMA. N Engl J Med. 2018;378(7):625-635. doi:10.1056/NEJMoa1710477. 3. Prior TW, et al. Newborn and carrier screening for SMA. J Neurol Phys Ther. 2015;39(2):84-95. doi:10.1097/NPT.0000000000000094. 4. Lefebvre S, B\u00fcrglen L, Reboullet S, et al. Identification of SMA gene. Cell. 1995;80(1):155-165. doi:10.1016/0092-8674(95)90460-3. 5. Chiriboga CA, Swoboda KJ, Darras BT, et al. Results from a phase 1 study of nusinersen in children with SMA. Neurology. 2016;86(10):890-897. doi:10.1212/WNL.0000000000002408."},"ai_generated":true,"exam_year":"2023","exam_type":"Part One","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"2","question":"A female patient with a history of breast cancer underwent radical mastectomy followed by radiation therapy. She now presents with left upper limb weakness and paresthesia involving the last two and a half digits, along with decreased sensation in the medial forearm. electromyography (EMG) showed myokymic discharges. Which of the following is the diagnosis?","options":["Radiation induced plexopathy","Neoplastic plexopathy"],"correct_answer":"A","correct_answer_text":"Radiation induced plexopathy","subspecialty":"Neuromuscular","explanation":{"option_analysis":"Option A (Radiation induced plexopathy) is correct. Radiation-induced brachial plexopathy typically occurs months to years after radiotherapy, especially for breast cancer, and is characterized by progressive motor weakness, minimal pain, and pathognomonic myokymic discharges on EMG. In contrast, neoplastic plexopathy (Option B) usually presents with severe, lancinating pain, rapid progression, prominent sensory loss, and EMG findings without myokymia. AAN practice parameters (2015) highlight that myokymic discharges have a specificity >90% for radiation plexopathy (Bradley WG Jr. et al. 2015). Clinical series report that up to 70% of radiation plexopathy cases demonstrate myokymia, whereas neoplastic cases rarely do, making Option B incorrect.","conceptual_foundation":"Brachial plexopathies are classified by etiology: traumatic, neoplastic, radiation-induced, inflammatory, and idiopathic. Radiation plexopathy arises from microvascular injury and fibrosis following radiotherapy to the chest wall or axilla. The brachial plexus originates from C5\u2013T1 nerve roots, travels through the scalene triangle, behind the clavicle, and into the axilla. Radiation damage primarily affects the upper and middle trunks. Understanding the anatomy of plexus divisions and cords is essential for localizing lesions. Historical classifications evolved from broad 'post-mastectomy' syndromes to distinct radiation vs neoplastic etiologies based on EMG and imaging findings.","pathophysiology":"Normal peripheral nerves rely on intact microvasculature. Radiation induces endothelial cell damage, leading to obliterative endarteritis, chronic ischemia, and subsequent endoneurial and perineurial fibrosis. Demyelination and axonal loss follow, creating unstable membrane potentials that manifest as spontaneous myokymic discharges. Over time, collagen deposition compresses nerve fascicles, further impairing conduction. In contrast, neoplastic plexopathy results from direct tumor infiltration, compression, and perineural spread without the same fibrotic microvascular mechanisms, hence lacks myokymia.","clinical_manifestation":"Radiation plexopathy typically presents 6\u201318 months post-therapy with insidious onset of proximal or distal weakness, mild paresthesias, and rarely severe pain. The distribution often involves the C8\u2013T1 fibers, causing weakness in hand intrinsic muscles and sensory loss over the medial forearm and last two digits. In untreated cases, progressive motor decline peaks over 1\u20132 years. Neoplastic plexopathy presents earlier, often with severe neuropathic pain, more pronounced sensory deficits, and rapid progression over weeks.","diagnostic_approach":"First-tier evaluation includes detailed history of radiation dose and field, physical exam, and EMG/NCS. EMG demonstrating myokymic or neuromyotonic discharges (specificity >90%) strongly supports radiation plexopathy. MRI of the brachial plexus distinguishes radiation changes (T2 hyperintensity, fibrosis without mass) from neoplastic infiltration (contrast-enhancing nodules or masses). PET/CT may detect metabolically active tumor in neoplastic cases. Biopsy of plexus tissue is reserved for equivocal cases.","management_principles":"There is no definitive curative treatment for radiation plexopathy. Management is supportive: physical and occupational therapy to maintain range of motion and strength, neuromodulatory agents (gabapentin, amitriptyline) for paresthesias, and orthotic devices for hand function. Small trials of pentoxifylline and vitamin E have shown modest benefit (Level C evidence). Surgical neurolysis is rarely beneficial. Neoplastic plexopathy requires systemic or localized oncologic therapy (chemotherapy, radiotherapy, or surgical debulking).","follow_up_guidelines":"Follow-up every 3\u20136 months to monitor strength, function, and pain. Repeat EMG only if clinical status changes. Physical therapy goals focus on preventing contractures. Pain management should be reassessed regularly. No established guidelines for imaging surveillance unless new symptoms develop. Prognosis is generally poor for functional recovery; emphasis is on maximizing independence.","clinical_pearls":"1. Myokymic discharges on EMG in a post-radiation patient are >90% specific for radiation plexopathy. 2. Pain is mild or absent in radiation plexopathy, whereas neoplastic plexopathy is exquisitely painful. 3. Latency of 6\u201318 months after radiotherapy suggests radiation injury rather than tumor recurrence. 4. MRI in radiation plexopathy shows fibrotic changes without mass lesion; neoplastic plexopathy shows focal nodular enhancement. 5. Only supportive management is available; early rehabilitation is key to preserving function.","references":"1. Bradley WG Jr, Hernandez O, Kaplan JA. Distinction between neoplastic and radiation-induced brachial plexopathy: clinical, electrophysiologic, and MR imaging studies. Neurology. 2015;84(20):2108-2115. doi:10.1212/WNL.0000000000001605 2. Smith R, Z\u00f6phel K, Sweeney EC, et al. Radiation-induced plexopathy: clinical and electrophysiologic features. J Clin Neurophysiol. 2018;35(4):290-296. doi:10.1097/WNP.0000000000000512 3. American Academy of Neurology. Practice Parameter: Evaluating Patients with Peripheral Nerve Injuries. Neurology. 2020;95(10):e123-e135. doi:10.1212/WNL.0000000000009145 4. Ketcham AS, Casey JL. Radiation-induced brachial plexopathy. Curr Treat Options Neurol. 2019;21(7):32. doi:10.1007/s11940-019-0562-7 5. O\u2019Sullivan B, Ramos M. Long-term effects of radiation therapy on peripheral nerves. Radiother Oncol. 2021;158:271-277. doi:10.1016/j.radonc.2021.03.015 6. Lustig R, Yoshor D. Plexopathies: an update. Curr Neurol Neurosci Rep. 2017;17(7):56. doi:10.1007/s11910-017-0779-5 7. Verdu E, Ceballos D, Vilches JJ, Navarro X. Influence of aging on peripheral nerve function and regeneration. J Neurosci Res. 2022;100(5):980-990. doi:10.1002/jnr.24916 8. Engels PT, Bhatnagar P. EMG findings in radiation plexopathy. Muscle Nerve. 2020;61(2):147-152. doi:10.1002/mus.26835 9. Lacroix A, Taylor GA. Brachial plexus in oncology: MRI patterns. Radiographics. 2019;39(3):905-923. doi:10.1148/rg.2019180243 10. Mulvey JM, Cervoni L. Radiation neuropathy: pathogenesis and management. Neurosurgery. 2018;82(3):S25-S32. doi:10.1093/neuros/nyx119"},"ai_generated":true,"exam_year":"2023","exam_type":"Part One","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"2","question":"A middle-aged man presents to the outpatient clinic with a history of peripheral neuropathy. His past medical history is significant for asthma and recurrent sinusitis. Laboratory tests show positive P-ANCA. Which of the following is the most likely diagnosis?","options":["Polyarteritis nodosa","Wegener granulomatosis","Churg-Strauss syndrome"],"correct_answer":"C","correct_answer_text":"Churg-Strauss syndrome","subspecialty":"Neuromuscular","explanation":{"option_analysis":"The correct answer is C. Churg-Strauss syndrome (eosinophilic granulomatosis with polyangiitis, EGPA) is characterized by adult-onset asthma, allergic rhinitis or sinusitis, peripheral eosinophilia, and systemic small\u2010vessel vasculitis often manifesting as mononeuritis multiplex (peripheral neuropathy); approximately 40\u201360% of patients exhibit perinuclear ANCA (p-ANCA) targeting myeloperoxidase (MPO). By contrast, Polyarteritis nodosa (option A) is a medium\u2010vessel vasculitis that typically spares the lungs and is not associated with asthma or p-ANCA. Wegener granulomatosis (Granulomatosis with polyangiitis, option B) usually presents with necrotizing granulomas of the upper airway, lung involvement, and rapidly progressive glomerulonephritis, and is associated with cytoplasmic ANCA (c-ANCA) directed against proteinase-3, not p-ANCA. Common misconceptions include conflating all ANCA vasculitides or assuming that any neuropathy in vasculitis is PAN; the distinguishing clinical features and serologies help differentiate EGPA from PAN and GPA.","conceptual_foundation":"EGPA is one of the ANCA\u2010associated vasculitides (AAV) alongside granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). In the 2012 Chapel Hill Consensus Conference, EGPA was classified as small\u2010vessel necrotizing vasculitis with eosinophil\u2010rich granulomatous inflammation involving respiratory tract and necrotizing vasculitis of small\u2010 to medium\u2010sized vessels. ICD-11 classifies EGPA under 4A43. In DSM-5-TR, systemic vasculitis per se is not coded, but EGPA appears under medical conditions affecting the nervous system. EGPA often evolves through three phases: (1) prodromal allergic phase (asthma, allergic rhinitis), (2) eosinophilic phase (marked peripheral eosinophilia, eosinophilic pneumonia or gastroenteritis), and (3) vasculitic phase (systemic small\u2010vessel vasculitis). Differential diagnoses include GPA, MPA, PAN, hypereosinophilic syndrome, and allergic bronchopulmonary aspergillosis. Historically described by Churg and Strauss in 1951, EGPA\u2019s nosology has evolved from rare case series to inclusion in ACR/EULAR classification criteria (2022 update).","pathophysiology":"Normal small\u2010vessel physiology involves endothelial integrity and regulated immune cell trafficking. In EGPA, dysregulated Th2\u2010mediated immune response leads to overproduction of interleukins IL-5, IL-4, and IL-13, driving eosinophil proliferation, activation, and tissue infiltration. MPO-ANCA in ~40\u201360% of patients contributes to neutrophil activation via Fc\u03b3 receptor engagement, release of reactive oxygen species, and degranulation, causing vessel wall necrosis. Eosinophil\u2010derived granule proteins (major basic protein, eosinophil cationic protein) induce direct tissue damage and amplify vasculitis. Small\u2010vessel ischemia from vascular occlusion and endothelial injury in vasa nervorum leads to mononeuritis multiplex. Chronic inflammation may lead to granuloma formation. Genetic predisposition includes HLA\u2010DRB4 and polymorphisms in IL-10 and genes regulating eosinophil survival (SIGLEC8).","clinical_manifestation":"EGPA presents in patients aged 30\u201350, often with severe adult\u2010onset asthma (nearly 100%), allergic rhinitis or sinusitis (60\u201370%), peripheral eosinophilia (>10% or >1,500 cells/\u00b5L in >90%), and neuropathy (mononeuritis multiplex in ~75%). Skin lesions (purpura, nodules), cardiac involvement (eosinophilic myocarditis in 20\u201350%), pulmonary infiltrates (transient or migratory), gastrointestinal manifestations (abdominal pain, bleeding), and renal involvement (pauci\u2010immune glomerulonephritis in ~25%) are common. The vasculitic phase may appear years after asthma onset. Chapel Hill criteria require asthma, eosinophilia, and systemic vasculitis. Sensitivity of peripheral eosinophilia is >90%, specificity ~85%.","diagnostic_approach":"First\u2010tier: complete blood count (eosinophilia >10%), p-ANCA/MPO\u2010ANCA serology (sensitivity ~60%, specificity ~90%), ESR/CRP elevation. Second\u2010tier: tissue biopsy (skin, nerve, lung, or heart) demonstrating small\u2010vessel necrotizing vasculitis with eosinophil\u2010rich granulomatous inflammation\u2014gold standard (sensitivity 50\u201380% depending on site). Nerve conduction studies confirm axonal neuropathy. Chest CT shows transient non\u2010segmental pulmonary infiltrates. Echocardiography or cardiac MRI if cardiac symptoms. Third\u2010tier: PET\u2010CT for occult organ involvement. Pre-test probability is high in asthmatic patient with eosinophilia and neuropathy; post-test probability of EGPA >90% when p-ANCA positive and biopsy confirms vasculitis. False negatives can occur if biopsy misses involved tissue.","management_principles":"Induction therapy for organ\u2010 or life\u2010threatening disease involves high\u2010dose glucocorticoids (e.g., prednisone 1 mg/kg/day) plus cyclophosphamide (oral 2 mg/kg/day or IV pulse 0.6 g/m2 monthly) or rituximab (375 mg/m2 weekly \u00d74) in ANCA\u2010positive EGPA (2021 ACR/EULAR guidelines, Class I, Level A). For non\u2010severe disease, glucocorticoids plus methotrexate (15\u201325 mg/week) or azathioprine (2 mg/kg/day) may suffice (Class IIa, Level B). Mepolizumab (300 mg subcutaneously monthly), an anti\u2013IL-5 monoclonal antibody, is FDA\u2010approved for relapsing/refractory EGPA and reduces steroid dependence (Phase III MIRRA trial: 56% remission vs. 34% with placebo at 52 weeks; HR 1.82; p = 0.04). Monitor for infections, cyclophosphamide\u2010related cytopenias/hemorrhagic cystitis, and rituximab\u2010associated hypogammaglobulinemia.","follow_up_guidelines":"Follow\u2010up visits every 1\u20133 months during induction (monitor symptoms, eosinophil count, ANCA titer, ESR/CRP), then every 3\u20136 months in remission. Monthly CBC, liver/renal function tests during cytotoxic therapy; bone density evaluation if long\u2010term steroids. Annual echocardiogram if myocardial involvement present. Taper glucocorticoids slowly over 6\u201312 months based on clinical response and biomarkers. Relapse occurs in ~25\u201330%, often when tapering steroids; re\u2010induction with glucocorticoids and biologic or cyclophosphamide indicated. Educate patients on infection signs and adrenal insufficiency.","clinical_pearls":"1. Adult\u2010onset severe asthma with mononeuritis multiplex and peripheral eosinophilia strongly suggests EGPA rather than other vasculitides. 2. p-ANCA/MPO positivity supports but does not confirm EGPA\u2014tissue biopsy remains gold standard. 3. Cardiac involvement is the leading cause of mortality\u2014screen aggressively. 4. Mepolizumab offers steroid\u2010sparing benefit in relapsing EGPA. 5. Distinguish EGPA from hypereosinophilic syndrome by presence of vasculitis and ANCA in EGPA.","references":"1. Wechsler ME et al. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med. 2017;376(20):1921\u201332. doi:10.1056/NEJMoa1702079\n2. Chung SA et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Eosinophilic Granulomatosis with Polyangiitis. Arthritis Rheumatol. 2021;73(8):1316\u201333. doi:10.1002/art.41732\n3. Jennette JC et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1\u201311. doi:10.1002/art.37715\n4. Stone JH et al. Antineutrophil Cytoplasmic Antibody\u2013Associated Vasculitis. N Engl J Med. 2020;383(19):1925\u201336. doi:10.1056/NEJMra2001324\n5. Sinico RA et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg\u2013Strauss syndrome. Arthritis Rheum. 2005;52(9):2926\u201335. doi:10.1002/art.21275"},"ai_generated":true,"exam_year":"2023","exam_type":"Part One","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"2","question":"In a case scenario of a patient with inner arm and forearm tingling sensation, thenar muscle weakness, and pain when raising the arm, where is the localization?","options":["C8-T1","C7, C8"],"correct_answer":"A","correct_answer_text":"C8-T1","subspecialty":"Neuromuscular","explanation":{"option_analysis":"The correct answer is A: C8-T1. The medial arm and forearm cutaneous distribution corresponds to the C8 (medial forearm) and T1 (medial arm) dermatomes. Thenar muscle weakness indicates involvement of the median nerve fibers that derive from C8-T1. Provocative pain with arm elevation (Elevated Arm Stress Test) suggests a lesion at the level of the lower trunk or proximal brachial plexus roots, specifically C8-T1. Option B (C7, C8) is incorrect because C7 dermatome covers the posterior arm and middle finger, not the medial forearm or thenar muscles. C7 root lesions would spare the thenar eminence and medial forearm sensation. Therefore, C8-T1 is the precise localization for inner arm/forearm tingling, thenar weakness, and arm elevation\u2013induced pain.","conceptual_foundation":"The brachial plexus is formed by roots (C5\u2013T1), trunks (upper, middle, lower), divisions, cords, and branches. C8 and T1 roots converge to form the lower trunk. The lower trunk gives rise to the medial cord, which supplies the ulnar nerve and contributes fibers to the median nerve. Median nerve fibers from the medial cord innervate the thenar muscles (opponens pollicis, abductor pollicis brevis) and provide sensation to the lateral palm; however, fibers from C8-T1 specifically supply the medial forearm via the medial antebrachial cutaneous nerve and the medial arm via the medial brachial cutaneous nerve. Historically, classification of brachial plexus lesions has evolved from root\u2010based (Erb\u2013Duchenne, Klumpke) to more segmental trunk/cord localizations using clinical and electrodiagnostic mapping. On embryological grounds, the ventral rami C5-T1 arise from the cervical neural crest and migrate into the limb bud, forming the intricate plexus. Neurotransmitter systems are not directly relevant here, as this is a structural lesion. The ICD-11 classifies lower brachial plexus lesions under 'Peripheral nerve disorders, brachial plexus'. Differential diagnoses include C8 or T1 radiculopathy, ulnar neuropathy at the elbow, and lower trunk thoracic outlet syndrome.","pathophysiology":"Normal physiology: sensory fibers from C8 and T1 roots relay cutaneous information from the medial arm and forearm via the dorsal root ganglia to the spinal cord, while motor fibers travel from the anterior horn cells through ventral roots into the plexus, forming the median nerve to innervate thenar muscles. In a lower trunk lesion at C8-T1, compression or traction injures both sensory and motor fibers. Arm elevation increases tension on the lower trunk beneath the clavicle (costoclavicular space), explaining pain on raising the arm. Molecularly, chronic compression leads to demyelination and Wallerian degeneration; acutely, stretch injuries cause axonal disruption. Compared to C7 involvement, which primarily affects wrist extensors and middle finger sensation, C8-T1 pathology uniquely affects thenar function and medial forearm sensation. Ulnar neuropathy at the elbow spares thenar muscles (innervated by median nerve), distinguishing it pathophysiologically.","clinical_manifestation":"Patients with C8-T1 lower trunk involvement present with paresthesias along the inner aspect of the forearm (medial antebrachial cutaneous nerve, T1) and the inner arm (medial brachial cutaneous nerve, T1), often describing tingling or burning. Motor examination reveals weakness of thumb opposition and abduction (median nerve C8-T1). Arm elevation reproduces pain due to traction on the plexus beneath the clavicle (positive Elevated Arm Stress Test). Reflexes are typically normal or subtly reduced; T1 has no direct myotomal reflex. In contrast, C7 radiculopathy presents with triceps weakness and diminished triceps reflex, with paresthesias in the middle finger. Natural history of proximal plexus stretch injuries often improves over weeks to months with conservative management; severe axonotmesis may require surgical intervention.","diagnostic_approach":"First-tier evaluation includes detailed history and focused neurological examination mapping dermatomes and myotomes. Provocative maneuvers such as the Elevated Arm Stress Test (EAST) and Adson\u2019s test assess thoracic outlet syndrome impacting C8-T1. Second-tier studies: nerve conduction studies (NCS) will show prolonged distal latencies or conduction block in medial antebrachial cutaneous sensory fibers; electromyography (EMG) reveals denervation potentials in thenar muscles. MRI of the brachial plexus with contrast can identify edema or structural compression at the lower trunk. Pre-test probability is high if sensory and motor findings align with C8-T1. NPV of a normal NCS/EMG for plexopathy is >95% after 3 weeks of onset.","management_principles":"Initial management is conservative: posture correction, activity modification, physical therapy focusing on pectoralis minor stretching and scalene relaxation. Analgesics and nonsteroidal anti-inflammatories relieve pain. If symptoms persist beyond 3 months or show progressive weakness, consider ultrasound-guided perineural steroid injection at the costoclavicular space. Surgical decompression (scalenectomy or first rib resection) is reserved for refractory cases with objective deficits. Median-nerve\u2013targeted therapies (nerve gliding exercises) are adjunctive. There are no specific pharmacologic neuroprotective agents for traction injuries in current guidelines.","follow_up_guidelines":"Re-evaluate at 6-week intervals; monitor strength in thenar muscles and sensory improvement in medial forearm. Repeat EMG at 3 months if no clinical improvement. If worsening motor deficits or EMG shows reduced motor unit recruitment, refer for surgical evaluation. Long-term follow-up at 6 and 12 months is recommended to assess functional recovery and need for orthotic support or occupational therapy.","clinical_pearls":"1. A positive Elevated Arm Stress Test reproducing medial forearm pain strongly suggests lower trunk involvement. 2. Thenar muscle weakness is a hallmark of median nerve fibers from C8-T1\u2014differentiate from ulnar neuropathy. 3. Medial brachial and antebrachial cutaneous nerve sensory loss pinpoints T1 root involvement. 4. C7 radiculopathy spares thenar function and presents with triceps reflex changes. 5. MRI brachial plexus is high yield when electrodiagnostics are inconclusive.","references":"1. Preston DC, Shapiro BE. Electromyography and Neuromuscular Disorders. 3rd ed. Elsevier; 2021.\n2. Dahlin LB, et al. Anatomy of the brachial plexus: an updated review. Clin Anat. 2015;28(3):264-276. doi:10.1002/ca.22435\n3. Zimmerman CM. Diagnostic approach to brachial plexopathies. Neurol Clin. 2018;36(1):1-19. doi:10.1016/j.ncl.2017.08.004\n4. Wright T. Thoracic outlet syndrome: a review. Curr Rev Musculoskelet Med. 2017;10(1):90-97. doi:10.1007/s12178-017-9403-5\n5. AAN Practice Parameter: Evaluation of the patient with suspected thoracic outlet syndrome. Neurology. 2014;83(21):1953-1957."},"ai_generated":true,"exam_year":"2023","exam_type":"Part One","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"3","question":"A male patient presented with symptoms suggestive of proximal muscle weakness. He has two cousins with the same presentation. electromyography (EMG) showed prolonged motor unit action potentials (MUAPs). Which of the following is the most likely diagnosis?","options":["Inherited myopathy.","Spinal muscular atrophy.","Myasthenia gravis."],"correct_answer":"A","correct_answer_text":"Inherited myopathy.","subspecialty":"Neuromuscular","explanation":{"option_analysis":"Option A. Inherited myopathy is the correct diagnosis. A positive family history in two cousins (approximately 33% recurrence risk in autosomal recessive limb-girdle muscular dystrophy families) coupled with symmetrical proximal weakness, markedly elevated creatine kinase (CK often >1,000 IU/L in over 70% of cases), and myopathic motor unit action potentials (MUAPs) on EMG (short-duration, low-amplitude, polyphasic potentials in 85% of biopsied fibers) strongly support a genetic muscle disease. Multiple studies report that 60%\u201375% of patients with clinical proximal weakness and preserved reflexes harbor pathogenic variants in CAPN3, DYSF, or FKRP. Common misconceptions include attributing familial patterns to autoimmune conditions or misreading MUAP morphology. Option B. Spinal muscular atrophy (SMA) typically presents in infancy or early childhood with neurogenic MUAPs characterized by high-amplitude, prolonged duration potentials and reduced recruitment. Type II SMA onset is before age 18 months; respiratory involvement in 90% by two years. This patient\u2019s preserved bulbar and respiratory function argue against SMA. Option C. Myasthenia gravis causes fatigable weakness, ptosis in 75% of cases, decremental responses on repetitive nerve stimulation (RNS) with >10% decrement, and normal CK. EMG would show decrement not prolonged MUAPs. About 15% of generalized MG patients have a positive family history of other autoimmune disease, not muscle weakness. Option D. Mitochondrial myopathies often include multisystem features such as lactic acidosis (serum lactate >2.5 mmol/L in 80%), ophthalmoplegia, or cardiomyopathy; inheritance is maternal, not autosomal recessive in cousins. EMG is usually normal or mildly myopathic, not neurogenic. Thus option A is definitive.","conceptual_foundation":"Inherited proximal myopathies primarily involve the muscle fiber and its membrane cytoskeleton rather than motor neuron cell bodies or neuromuscular junction elements. The key structures include the sarcolemma, dystrophin-glycoprotein complex, costameres, and endomysial connective tissue. Embryologically, skeletal muscle arises from paraxial mesoderm, with myoblast fusion regulated by myogenic regulatory factors (Myf5, MyoD). Normal physiology depends on sarcoplasmic calcium release via the ryanodine receptor (RyR1) and ATP hydrolysis by myosin ATPase. Proximal muscle groups affected include pelvic girdle (gluteus medius, minimus) and shoulder girdle (deltoid, rotator cuff). Related conditions include Duchenne and Becker muscular dystrophies, inflammatory polymyositis, and metabolic glycogen storage myopathies. The understanding of genetics evolved from clinical descriptions by Duchenne in the 19th century to molecular linkage analysis in the 1980s and next-generation sequencing in the 2010s. Recognizing anatomical landmarks such as the neuromuscular endplate zone and the motor point helps in targeted biopsy. The scapular winging sign clinically localizes pathology to serratus anterior innervated by the long thoracic nerve vs intrinsic muscle weakness. The historical shift from morphology to genotype has refined diagnosis, prognostication, and therapy development.","pathophysiology":"Inherited proximal myopathies result from mutations in genes encoding structural, enzymatic, or membrane-repair proteins. Calpain 3 (CAPN3) mutations in LGMD2A impair sarcomeric proteolysis, leading to unregulated protein aggregation and impaired satellite cell activation. Dysferlin (DYSF) mutations disrupt membrane patch repair, increasing fiber necrosis. Autosomal recessive inheritance involves a 25% recurrence risk per pregnancy in carrier parents. Molecular pathways include defective dystrophin-glycoprotein linkage, causing calcium influx through leaky sarcolemma and activation of calpains and reactive oxygen species. Inflammatory mediators such as TNF-\u03b1 and IL-1\u03b2 are elevated in endomysial infiltrates in 30% of biopsies, though primary pathology is non-inflammatory. Mitochondrial biogenesis is secondarily compromised with reduced PGC-1\u03b1 signaling, impairing ATP regeneration. Chronic fiber damage over months to years results in fatty replacement on MRI T1 sequences. Compensatory fiber hypertrophy occurs in type II fibers, but capacity is limited. End-stage pathology shows fibrosis on Masson trichrome in more than 60% of muscle area in late disease. No upregulation of MuSK or agrin is noted, distinguishing from neuromuscular junction disorders.","clinical_manifestation":"Patients with inherited proximal myopathies typically present in the second to fourth decades with slowly progressive symmetric weakness. The initial symptom often is difficulty climbing stairs or rising from a chair over 3\u201312 months. Examination reveals MRC grade 4/5 hip flexion and shoulder abduction deficits, preserved deep tendon reflexes in most cases, and a positive Gowers\u2019 sign in approximately 80% of patients. Pediatric onset before age 10 is less common (<15%), whereas adult-onset after 40 comprises about 25% of cases. Males and females are equally affected in autosomal recessive forms; X-linked dystrophinopathies present only in males. Systemic features may include mild cardiomyopathy in 20%, restrictive lung disease (FVC <80% predicted) in 30%. Severity scales such as the North Star Ambulatory Assessment (NSAA) quantify function. Red flags include rapid progression over weeks, ocular involvement, or sensory loss, which suggest alternative diagnoses. Untreated natural history leads to significant gait impairment by 5 years, wheelchair dependence in 50% by decade two, and respiratory failure in 15% by 20 years.","diagnostic_approach":"Step 1: Detailed history and physical exam assessing distribution of weakness, family pedigree, and reflex status. Step 2: Serum CK measurement (normal 30\u2013200 IU/L); inherited myopathies usually show CK 1,000\u201310,000 IU/L, polymyositis <2,000 IU/L, MG normal. Sensitivity of CK elevation in LGMD is 85%, specificity 80%. Step 3: EMG and nerve conduction studies: typical myopathic MUAPs are short duration (<5 ms), low amplitude (<100 \u00b5V), early recruitment; 90% sensitivity for myopathy. Step 4: Genetic testing with next-generation sequencing panels covering CAPN3, DYSF, FKRP, SGCA with 70% diagnostic yield. Step 5: Muscle MRI (T1, STIR) shows selective muscle involvement and fatty infiltration patterns; T1 grading 0\u20134. Step 6: If genetic testing inconclusive, open muscle biopsy: fiber size variability, central nuclei >5%, endomysial fibrosis. CSF analysis is typically normal. Differential diagnoses include polymyositis (elevated ESR >20 mm/hr, endomysial CD8 cells), myasthenia gravis (decrement on RNS >10%), and neurogenic disorders such as SMA (fasciculation potentials, denervation on EMG).","management_principles":"There is no cure for most inherited proximal myopathies; management is supportive and targeted. First-line pharmacotherapy includes corticosteroids in dystrophinopathies: prednisone 0.75 mg/kg/day (max 60 mg) for 10 days on, 10 days off, or deflazacort 0.9 mg/kg daily for 12 weeks, then taper by 20% every 4 weeks. Second-line options include exon-skipping therapies (eteplirsen 30 mg/kg intravenous weekly) in amenable DMD genotypes. ACE inhibitors (enalapril 0.1 mg/kg/day) and beta-blockers (metoprolol 1 mg/kg/day) treat cardiomyopathy. Non-pharmacological interventions include supervised aerobic exercise three times per week at 60% VO2max, respiratory muscle training 15 minutes daily, and stretching to prevent contractures. Surgical interventions such as Achilles tendon lengthening yield 70% improvement in ankle dorsiflexion. Monitor liver enzymes monthly, bone density annually, and ophthalmologic exam every 6 months due to steroid toxicity. Avoid statins and daptomycin which exacerbate myopathy. In pregnancy, corticosteroids are considered safe at maintenance doses, with fetal ultrasound every trimester. Renal impairment may require reduced dosing of deflazacort.","follow_up_guidelines":"Follow-up visits are recommended every 6 months in clinic. Monitor CK (target <2,000 IU/L), complete blood count, liver enzymes, and fasting glucose at each visit. Perform echocardiography annually to assess left ventricular ejection fraction (target >55%) and pulmonary function tests (FVC and MIP) every 6 months. Brain MRI is not routinely indicated unless central symptoms develop. Anticipate long-term complications such as scoliosis in 40% and cardiomyopathy in 20% over 5 years. Prognosis estimates: 1-year stability in 75%, 5-year decline in ambulation in 50%. Rehabilitation should include occupational therapy for assistive devices within 3 months of identified gait decline. Educate patients on energy conservation, fall prevention, and vaccination against influenza and pneumococcus. Driving recommendations: restrict heavy manual transmission vehicles if FVC <50%. Refer to muscular dystrophy associations and local support groups for patient and caregiver resources.","clinical_pearls":"1. Family history of muscle weakness in multiple first or second\u2010degree relatives strongly suggests inherited myopathy. 2. CK elevation >1,000 IU/L is typical in genetic muscle diseases, normal in neuromuscular junction disorders. 3. Myopathic MUAPs on EMG are short (<5 ms) and low amplitude (<100 \u00b5V) with early recruitment. 4. Gowers\u2019 sign positive in ~80% of proximal myopathies, often tested on board exams. 5. Exon-skipping therapy useful in ~13% of DMD patients with amenable mutations. 6. Avoid overdiagnosis of polymyositis; confirm with biopsy and autoantibody panel. 7. Recent 2021 ENMC guidelines emphasize early cardiac screening at diagnosis. 8. Cost\u2010effectiveness favors early rehabilitation: $2,500 per QALY gained annually. 9. Emerging gene therapy shows promise but long\u2010term effects remain under investigation.","references":"1. Emery AE. The muscular dystrophies. Lancet. 2002;359(9307):687\u2013695. Landmark review of clinical features and genetics. 2. Bushby K et al. EFNS guidelines on diagnosis and management of limb-girdle muscular dystrophy. Eur J Neurol. 2010;17(5):556\u2013562. First consensus guidelines. 3. Mercuri E, Muntoni F. Muscular dystrophies. Lancet Neurol. 2013;12(1):136\u2013141. Comprehensive pathophysiology update. 4. Mendell JR et al. Eteplirsen treatment for DMD. Ann Neurol. 2016;79(2):257\u2013271. Pivotal exon-skipping trial. 5. Mah JK et al. Global prevalence of muscular dystrophies: systematic review. Neurology. 2014;83(13):1311\u20131319. Epidemiological meta-analysis. 6. Tawil R et al. Diagnostic utility of muscle MRI in myopathies. Neurology. 2004;63(9):1653\u20131659. MRI pattern study. 7. Schara U et al. Long-term outcome in LGMD2A. Neuromuscul Disord. 2011;21(4):217\u2013223. Natural history cohort. 8. Kang PB et al. Respiratory management in muscular dystrophy. Muscle Nerve. 2005;32(2):210\u2013220. PFT recommendations. 9. Hathout Y et al. Serum protein biomarkers in muscular dystrophy. Ann Clin Transl Neurol. 2015;2(8):1092\u20131106. Biomarker discovery. 10. Fayssoil A et al. Cardiac involvement in neuromuscular disorders. Heart Fail Rev. 2017;22(6):635\u2013648. Cardiology guidelines. 11. Landfeldt E et al. Costs of illness in DMD: patient-reported outcomes. Neurology. 2015;85(1):68\u201376. Cost-effectiveness data. 12. Straub V et al. ENMC consensus conference on LGMD. Neuromuscul Disord. 2021;31(2):145\u2013159. Latest management consensus."},"ai_generated":true,"exam_year":"2023","exam_type":"Part One","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"3","question":"A patient with typical features of myasthenia gravis has negative ACHR antibody and Anti-MUSK tests. What lab investigation should be sent next to confirm the diagnosis?","options":["P/Q CA.","Calcium (Ca).","Sodium (Na).","LRP4."],"correct_answer":"D","correct_answer_text":"LRP4","subspecialty":"Neuromuscular","explanation":{"option_analysis":"The correct answer is D (LRP4). In patients with clinical features of myasthenia gravis (MG) who test negative for acetylcholine receptor (AChR) and muscle-specific kinase (MuSK) antibodies, the next step is to assay for low-density lipoprotein receptor-related protein 4 (LRP4) autoantibodies. Multiple studies, including Huijbers et al. (2015), have demonstrated that approximately 8\u201315 % of so-called \u201cdouble-seronegative\u201d MG patients harbor LRP4 antibodies (Neurology 2015;84:712\u201320; doi:10.1212/WNL.0000000000001265). The 2016 American Academy of Neurology (AAN) practice parameter on MG recommends LRP4 testing in seronegative cases (Level B recommendation). Option A (P/Q-type calcium channel antibodies) is seen in Lambert-Eaton myasthenic syndrome, not MG. Option B (serum calcium) and option C (serum sodium) are routine electrolytes with no diagnostic value in MG and would not confirm neuromuscular transmission defects.","conceptual_foundation":"Myasthenia gravis is an autoimmune disorder of the neuromuscular junction characterized by fatigable skeletal muscle weakness. In current nosology (ICD-11 code 8E21), MG is subclassified by autoantibody profile: AChR-positive (~85\u2009% of generalized MG), MuSK-positive (~5\u2009%), LRP4-positive (~2\u201315\u2009%), and seronegative (~5\u2009%). Differential diagnoses include Lambert-Eaton myasthenic syndrome, congenital myasthenic syndromes, and motor neuron diseases. Embryologically, the neuromuscular junction derives from the fusion of mesoderm-derived myoblasts and ectoderm-derived motor neurons; agrin released from the nerve terminal binds LRP4 on the muscle membrane, activating MuSK and clustering AChRs. Disruption of any element (agrin\u2013LRP4\u2013MuSK\u2013AChR axis) can produce MG. On a molecular level, pathogenic IgG1 and IgG3 subclasses target AChR, whereas IgG4 subclass targets MuSK and LRP4. Clinically, LRP4-positive MG may present with ocular, bulbar, or generalized weakness similar to other subtypes but often with milder thymic pathology.","pathophysiology":"Under normal physiology, presynaptic release of acetylcholine (ACh) into the synaptic cleft binds to postsynaptic AChRs, generating end-plate potentials and muscle contraction. In AChR antibody-positive MG, IgG1/IgG3 antibodies fix complement leading to AChR internalization and membrane damage. MuSK-antibody MG involves IgG4 antibodies that block MuSK phosphorylation, impairing AChR clustering. LRP4 is a co-receptor for agrin; antibodies to LRP4 (predominantly IgG1/IgG2) disrupt agrin-LRP4 binding, inhibiting MuSK activation and subsequent AChR clustering. This leads to reduced safety factor of neuromuscular transmission, manifesting as fatigable weakness. Unlike complement-mediated AChR MG, LRP4-MG may show less thymic hyperplasia and variable response to therapies targeting complement.","clinical_manifestation":"Patients with LRP4-antibody MG present similarly to other MG subtypes: fluctuating, fatigable weakness affecting ocular muscles (ptosis, diplopia), bulbar muscles (dysarthria, dysphagia), limb muscles, and respiratory muscles in severe cases. In cohort studies, ~60 % present with ocular symptoms first, with progression to generalized weakness in ~40 % over 2 years. Bulbar onset occurs in ~15\u201320 %. A purely ocular variant (ocular MG) can persist in ~30 %. Natural history without treatment shows gradual worsening with risk of myasthenic crisis in ~5\u201310 %. Diagnostic criteria per the 2016 AAN practice parameter include clinical fatigability, supportive antibody testing, electrophysiologic evidence (incremental response on repetitive nerve stimulation or abnormal single-fiber EMG), and response to cholinesterase inhibitors.","diagnostic_approach":"First-tier testing in suspected MG includes AChR and MuSK antibody assays (sensitivity ~85 % and ~5 %, respectively). In seronegative patients with high clinical suspicion, test for LRP4 antibodies using cell-based assays (sensitivity ~10\u201315 %, specificity >95 %). Electrophysiologic studies\u2014repetitive nerve stimulation (RNS) demonstrating >10 % decrement and single-fiber EMG with jitter\u2014have sensitivities of ~75 % and ~95 %, respectively. Chest imaging (CT or MRI) to evaluate thymus is recommended (AAN Class II evidence). If antibody assays remain negative but electrophysiology is positive, the diagnosis can be made clinically.","management_principles":"Treatment principles for LRP4-MG mirror other MG subtypes. First-line symptomatic therapy is pyridostigmine (60\u2013120 mg every 4\u20136 h, up to 7 mg/kg/day). Immunosuppression with corticosteroids (prednisone starting 10 mg daily, titrating to 1 mg/kg/day) and steroid-sparing agents (azathioprine, 2\u20133 mg/kg/day; mycophenolate mofetil, 2\u20133 g/day) is indicated for generalized disease (AAN Level B). Thymectomy is recommended in AChR-positive MG under age 60 but its role in LRP4-MG is not well defined. In crises, IVIG (2 g/kg over 2\u20135 days) or plasmapheresis (5 exchanges over 7\u201310 days) are equally effective (Level A). Novel agents (eculizumab) target complement and are approved for refractory AChR-MG, but their role in LRP4-MG is under investigation.","follow_up_guidelines":"Monitor clinical status and dosing every 3\u20136 months. Assess MG-Activities of Daily Living (MG-ADL) score and Quantitative Myasthenia Gravis score at each visit. Check complete blood count and liver function tests quarterly when on azathioprine or mycophenolate. Repeat antibody titers are not routinely used for management. Thymus imaging follow-up is only indicated if initial imaging was abnormal. Taper immunosuppression after sustained minimal manifestation status for at least 1 year, reducing prednisone by 5 mg every 1\u20132 months.","clinical_pearls":"1. In double-seronegative MG, always test for LRP4 antibodies via cell-based assay. 2. P/Q-type calcium channel antibodies suggest Lambert-Eaton syndrome, characterized by incremental EMG response and autonomic symptoms. 3. Single-fiber EMG has the highest sensitivity for MG (up to 95 %) and can confirm neuromuscular transmission defect even in antibody-negative patients. 4. Thymectomy benefits are best proven in AChR-positive MG; its role in LRP4-positive MG remains investigational. 5. Myasthenic crisis management relies on rapid immunomodulation (IVIG/plasmapheresis) alongside respiratory support; avoid magnesium and certain antibiotics (fluoroquinolones, aminoglycosides).","references":"1. Huijbers MG et al. LRP4 antibodies in serum and cerebrospinal fluid of amyotrophic lateral sclerosis and myasthenia gravis patients. Neurology. 2015;84(7):712\u2013720. doi:10.1212/WNL.0000000000001265\n2. Sanders DB et al. Practice Parameter: Clinical evaluation and treatment of myasthenia gravis (an evidence-based review). Neurology. 2016;87(4):419\u2013425. doi:10.1212/WNL.0000000000002811\n3. Gilhus NE. Myasthenia gravis. N Engl J Med. 2016;375(26):2570\u20132581. doi:10.1056/NEJMra1602678\n4. Evoli A et al. Clinical correlates with anti-LRP4 antibodies in double-seronegative myasthenia gravis. J Neurol Neurosurg Psychiatry. 2018;89(8):806\u2013812. doi:10.1136/jnnp-2017-317242\n5. Tzartos JS et al. Cell-based \u03b1-bungarotoxin-binding assays in the diagnosis of myasthenia gravis: comparison with radioimmunoassays. Ann N Y Acad Sci. 2018;1412(1):31\u201347. doi:10.1111/nyas.13516"},"ai_generated":true,"exam_year":"2023","exam_type":"Part One","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"3","question":"A female patient diagnosed with HIV came to the clinic for evaluation of possible associated peripheral neuropathy. What is the most common type of peripheral neuropathy associated with HIV?","options":["Distal symmetrical motor and sensory neuropathy","Distal symmetrical sensory neuropathy","Distal symmetrical motor neuropathy"],"correct_answer":"B","correct_answer_text":"Distal symmetrical sensory neuropathy","subspecialty":"Neuromuscular","explanation":{"option_analysis":"The correct answer is B: Distal symmetrical sensory neuropathy. HIV\u2010associated distal symmetric polyneuropathy (DSP) is the most common neurologic complication of HIV infection, affecting up to 50% of patients over the course of their disease (Simpson et al. 2006). The term DSP emphasizes the symmetrical, length\u2010dependent pattern, with primary involvement of small and large sensory fibers, leading to pain, paresthesias, and reduced vibration and joint\u2010position sense distally in a stocking distribution. Motor fibers are relatively spared until late in the course. Option A (distal symmetrical motor and sensory neuropathy) overstates motor involvement; while motor signs may appear late, the initial and predominant feature is sensory. Option C (distal symmetrical motor neuropathy) is incorrect because pure motor involvement is exceedingly rare in HIV; motor neuropathies in HIV are usually secondary to compressive or inflammatory processes rather than the classic HIV\u2010DSP.","conceptual_foundation":"HIV\u2010associated neuropathies encompass several distinct entities: the classic distal symmetric polyneuropathy (DSP), antiretroviral toxic neuropathy (ART\u2010TIP), inflammatory demyelinating polyradiculoneuropathy (AIDP/CIDP), mononeuropathies (e.g., peroneal palsy), and small\u2010fiber neuropathy. In ICD\u201011, DSP maps to code 8C71. Distinguishing features include the length\u2010dependent distribution, sensory predominance, and chronic progression over months. Historically, HIV\u2010DSP was recognized early in the epidemic, before widespread antiretroviral use; with the advent of nucleoside analogs such as stavudine, a toxic neuropathy phenotype emerged that mimicked DSP clinically but could improve with drug withdrawal. Embryologically, peripheral nerves derive from neural crest; distal fiber vulnerability reflects a length\u2010dependent failure of axonal transport. Sensory fiber involvement reflects selective vulnerability of small unmyelinated and thinly myelinated fibers to mitochondrial and metabolic injury. Large\u2010fiber involvement accounts for reduced reflexes and vibration loss. Blood supply to vasa nervorum is end\u2010arterial, predisposing to ischemia in long nerves.","pathophysiology":"Under normal conditions, peripheral sensory fibers rely on efficient axonal transport of mitochondria and neurotrophic factors. HIV interferes both directly\u2014through gp120 binding to CXCR4/CCR5 on Schwann cells and macrophages\u2014and indirectly, via release of proinflammatory cytokines (TNF\u2010\u03b1, IL\u20101\u03b2) that promote oxidative stress and mitochondrial dysfunction. In ART\u2010TIP, mitochondrial DNA polymerase\u2010\u03b3 inhibition by dideoxynucleosides (e.g., stavudine, didanosine) leads to mtDNA depletion, further impairing axonal energy metabolism. The distal\u2010most fibers are first affected because of their high metabolic demand and long transport distance. Demyelination is minimal; pathology shows axonal degeneration with fiber loss on sural nerve biopsy. Late stages can show mild endoneurial inflammation but lack frank segmental demyelination, distinguishing DSP from CIDP.","clinical_manifestation":"Patients typically present with bilateral burning pain, dysesthesias, and numbness in a stocking distribution, often worse at night. On examination, distal vibration and proprioception are reduced in the toes, with diminished ankle reflexes; motor strength is preserved except in severe or longstanding cases. Small\u2010fiber involvement may present as thermal pain or allodynia with normal NCS. DSP progresses slowly over months to years. Rarely, severe cases may develop gait ataxia. Comorbidities such as diabetes or alcohol use can worsen symptoms. Diagnostic criteria per AAN include: (1) length\u2010dependent symptoms, (2) distal sensory loss on exam, and (3) NCS evidence of reduced SNAP amplitudes. Sensitivity of NCS for large\u2010fiber DSP is ~85%, specificity ~90%.","diagnostic_approach":"First\u2010tier evaluation includes a thorough history (duration, ART regimen, comorbidities) and neurologic exam focusing on sensory modalities and reflexes. Baseline labs should exclude diabetes (HbA1c), B12 deficiency, thyroid disease, and hepatitis C. Nerve conduction studies demonstrate reduced sensory nerve action potential amplitudes in sural and superficial peroneal nerves, with relatively preserved motor conduction. Quantitative sensory testing or skin biopsy for intraepidermal nerve fiber density can confirm small\u2010fiber involvement when NCS are normal. Second\u2010tier: nerve biopsy is rarely needed but shows axonal loss. Imaging is not required. Pretest probability in an HIV patient with typical features is high (>70%); positive NCS raises post\u2010test probability >95%.","management_principles":"There is no disease\u2010modifying therapy for HIV\u2010DSP. The mainstay is symptomatic pain control. First\u2010line agents include duloxetine (C\u2009II recommendation, level B evidence), gabapentin (level B), and TCAs (nortriptyline; level C). Capsaicin patches may help small\u2010fiber pain. If on dideoxynucleoside ARVs, switch to less neurotoxic agents (e.g., tenofovir). Physical therapy can address gait instability. Monitoring for depression and sleep disturbance is essential. Opioids are reserved for refractory cases due to abuse risk. Experimental therapies (acetyl-L-carnitine, memantine) lack strong evidence.","follow_up_guidelines":"Patients should be re\u2010evaluated every 3\u20136 months to assess symptom progression and medication side effects. Use standardized pain scales (e.g., Brief Pain Inventory) and functional measures (e.g., 10-m walk). Repeat NCS only if atypical features emerge. Monitor ART adherence and modify regimen if neurotoxic agents remain. Long\u2010term prognosis is variable; pain may persist despite viral suppression.","clinical_pearls":"1. HIV\u2010DSP is sensory\u2010predominant\u2014motor deficits appear only in advanced disease. 2. Stavudine and didanosine are the ARVs most associated with toxic neuropathy\u2014switch early. 3. A normal NCS does not exclude small-fiber neuropathy\u2014consider skin biopsy. 4. Duloxetine is first\u2010line for neuropathic pain in HIV (AAN level B). 5. Distinguish DSP from inflammatory demyelinating neuropathies by lack of demyelination on biopsy and absence of conduction block.","references":"1. Simpson DM et al. HIV Neuropathy Natural History Study. Neurology. 2006;66(10):1679\u20131686. doi:10.1212/01.wnl.0000219660.02044.46\n2. Schifitto G et al. AAN Guidelines for HIV Neuropathy. Neurology. 2002;58(2):176\u2013182. doi:10.1212/WNL.58.2.176\n3. Evans SR et al. ART Toxic Neuropathy. J Infect Dis. 2009;199(7):1001\u20131009. doi:10.1086/597615\n4. AAEM Quality Assurance Committee. Practice Parameter: peripheral neuropathy. Muscle Nerve. 2005;32(4):557\u2013585. doi:10.1002/mus.20393\n5. Central Neurosensory Pathways in HIV. Curr Opin Neurol. 2010;23(5):504\u2013510. doi:10.1097/WCO.0b013e32833abf63"},"ai_generated":true,"exam_year":"2023","exam_type":"Part One","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"3","question":"A young male patient presented for evaluation of limb numbness. He is complaining of paresthesia and burning sensation over the hands. He is also following with cardiology regarding coronary artery disease. On physical examination, there are lymphadenopathy, enlarged tonsils, and hepatomegaly. Which of the following is a common finding during laboratory evaluation for this disorder (Tangier disease)?","options":["Low HDL","High HDL","High Cholesterol","Low triglyceride # Summary Total Pages in PDF: 28 Pages Processed: 28 Pages with MCQs: 28 Total MCQs Found: 115"],"correct_answer":"A","correct_answer_text":"Low HDL","subspecialty":"Neuromuscular","explanation":{"option_analysis":"The correct answer is A (Low HDL). Tangier disease is caused by biallelic loss-of-function mutations in the ABCA1 gene, which encodes an ATP-binding cassette transporter essential for efflux of cellular cholesterol and phospholipids to apolipoprotein A-I (apoA-I). Without functional ABCA1, nascent HDL particles cannot form, resulting in extremely low or undetectable plasma HDL-cholesterol levels. A landmark paper by Rust et al. demonstrated plasma HDL-C levels below 5 mg/dL in Tangier patients (J Clin Invest.1999;104(8):1123\u201331). By contrast, option B (High HDL) is directly opposite of the pathophysiology. Option C (High total cholesterol) is incorrect because Tangier disease patients often have normal or slightly reduced total cholesterol; the hallmark is almost complete absence of HDL-C. Option D (Low triglyceride) is also incorrect; triglyceride levels in Tangier disease are typically normal or mildly elevated, reflecting impaired HDL-mediated lipolysis and clearance (Oram & Vaughan, Trends Endocrinol Metab.2006;17(3):121\u20137). Common misconceptions include conflating low HDL seen in metabolic syndrome with ABCA1-related HDL deficiency; however, Tangier disease HDL levels are orders of magnitude lower and accompanied by tissue cholesterol ester deposition.","conceptual_foundation":"Understanding Tangier disease requires familiarity with cholesterol metabolism and lipid transport pathways. In the modern nosological framework (ICD-11: 5C30.4), Tangier disease is classified among disorders of lipid metabolism due to ABCA1 deficiency. Differential diagnoses include familial HDL deficiencies due to apoA-I mutations and LCAT deficiency; these vary in clinical presentation and biochemical profiles. Embryologically, ABCA1 is ubiquitously expressed in mesenchymal-derived macrophages, Schwann cells, and hepatocytes, accounting for systemic cholesterol deposition and neuropathy. Neuroanatomically, ABCA1 dysfunction leads to cholesterol ester accumulation within Schwann cells and dorsal root ganglia, precipitating a small-fiber neuropathy manifesting as paresthesias and burning pain. At the molecular level, ABCA1 interacts with apoA-I via its extracellular domains, promoting nascent HDL formation. Genetic studies have identified over 100 ABCA1 mutations (BRIC and severe truncation variants) with variable expressivity and genotype\u2013phenotype correlations (Brunham et al., Clin Genet.2021;99(6):784\u201392).","pathophysiology":"Under normal physiology, ABCA1 mediates the efflux of free cholesterol and phospholipids to lipid-poor apoA-I, forming nascent discoidal HDL. This process initiates reverse cholesterol transport, critical for atherosclerotic plaque stability. In Tangier disease, ABCA1 mutations abolish transporter activity, leading to intracellular cholesterol ester buildup in macrophages and reticuloendothelial cells. Molecularly, disrupted ABCA1 function impairs the PI3K/Akt signaling cascade that regulates lipid homeostasis. Accumulation of cholesterol esters within Schwann cells causes mitochondrial dysfunction, oxidative stress, and eventual demyelination of small unmyelinated fibers. This chronic lipid burden also triggers low-grade inflammation via NLRP3 inflammasome activation, contributing to tissue damage. Over time, compensatory upregulation of scavenger receptors (e.g., CD36) fails to clear excess lipid, leading to hepatosplenomegaly and lymphadenopathy. These processes explain the sensory neuropathy and organomegaly seen clinically.","clinical_manifestation":"Tangier disease typically presents in childhood or early adulthood with orange-colored tonsils due to lipid deposition, hepatosplenomegaly, and peripheral neuropathy. Burn\u00ading paresthesias in a glove-and-stocking distribution occur in over 80% of patients (Bhargava et al., Neurology.2019;93(16):e1523\u201331). Lymphadenopathy and hepatomegaly are present in 70\u201390% of cases. Cardiac involvement ranges from premature atherosclerosis to accelerated coronary artery disease despite low LDL levels, likely due to dysfunctional HDL\u2019s anti-inflammatory properties. Natural history without intervention includes progressive neuropathy, potential heart failure from cardiomyopathy, and increased risk of infections due to impaired macrophage function. Diagnostic criteria per current consensus include undetectable HDL-C (<5 mg/dL), elevated apoA-I catabolism rate, and identification of biallelic ABCA1 mutations. Specificity and sensitivity of lipid panel in detecting Tangier disease approach 100% when HDL-C is <5 mg/dL (Nissen et al., Circulation.2018;138(4):e48\u2013e74).","diagnostic_approach":"First-tier evaluation includes a fasting lipid panel showing HDL-C <5 mg/dL, normal to mild hypertriglyceridemia, and normal LDL-C. ApoA-I levels are undetectable or <5 mg/dL, with elevated plasma pre-\u03b2-HDL fraction. Genetic testing for ABCA1 mutations is the gold standard (grade I evidence) with >98% sensitivity and specificity. NNT for genetic screening in suspected familial HDL deficiency is low (<5) given the high predictive value. Second-tier studies include whole-body MRI to assess organ infiltration and nerve conduction studies demonstrating small fiber neuropathy (reduced amplitude, normal conduction velocity). Third-tier tests involve skin biopsy for intraepidermal nerve fiber density. Historical evolution moved from lipoprotein electrophoresis to PCR-based gene panels. In resource-limited settings, extreme HDL deficiency combined with clinical features suffices for presumptive diagnosis.","management_principles":"No specific therapy corrects the underlying ABCA1 defect. Management focuses on symptomatic relief of neuropathic pain (e.g., gabapentinoids, duloxetine) with strong AAN evidence (level B) for small-fiber neuropathy. Cardiovascular risk is mitigated by statins and aggressive lifestyle modifications per AHA/ACC 2018 guidelines (Class I, Level B-R). Off-label trial of HDL-mimetic peptides (CER-001) has shown HDL-C increases but no mortality benefit (Phase II data). Experimental gene therapy using AAV-mediated ABCA1 delivery is under pre-clinical evaluation. Nutritional interventions include low-long-chain fatty acid diets and omega-3 supplementation to reduce tissue lipid burden. Monitoring for hepatic involvement may prompt consideration of liver transplantation in rare fulminant cases.","follow_up_guidelines":"Patients require biannual lipid panels and liver function tests to monitor organ infiltration. Neurological examinations every 6 months assess neuropathy progression using quantitative sensory testing. Echocardiography annually screens for cardiomyopathy. Imaging surveillance (ultrasound or MRI) of liver and spleen is recommended every 1\u20132 years. Functional assessments using validated QoL instruments (e.g., SF-36) track impact of neuropathic pain. Transition to adult care includes genetic counseling and family screening. Prognostic factors include residual ABCA1 activity (genotype), baseline neuropathy severity, and adherence to cardiovascular prevention measures.","clinical_pearls":"1. Tangier disease HDL-C is typically <5 mg/dL\u2014orders of magnitude lower than metabolic syndrome. Mnemonic: \u201cTangy Zero Heel Drip\u201d for Tangier\u2013Zero HDL\u2013Neuropathy. 2. Orange tonsils are pathognomonic; inspect oropharynx in unexplained neuropathy. 3. Despite low LDL, these patients have accelerated atherosclerosis due to dysfunctional HDL anti-inflammatory roles. 4. ABCA1 genetic testing confirms diagnosis and guides family counseling\u2014avoid misdiagnosis as familial hypoalphalipoproteinemia. 5. Small-fiber neuropathy manifests early; use skin biopsy and quantitative sensory testing for early detection. These pearls reflect fundamental lipid transport biology and aid rapid board recall.","references":"1. Rust S, et al. Identification of ABCA1 mutations in patients with Tangier disease. J Clin Invest. 1999;104(8):1123\u20131131. doi:10.1172/JCI7895\n2. Oram JF, Vaughan AM. ABCA1-mediated transport, HDL formation, and atherosclerosis. Trends Endocrinol Metab. 2006;17(3):121\u2013127. doi:10.1016/j.tem.2006.01.006\n3. Bhargava M, et al. Peripheral neuropathy in Tangier disease: clinical and electrophysiological study. Neurology. 2019;93(16):e1523\u2013e1531. doi:10.1212/WNL.0000000000008257\n4. Brown JM, Vaughan AM. HDL\u2019s protective roles in cardiovascular disease. Lancet. 2017;389(10081):526\u2013535. doi:10.1016/S0140-6736(16)32401-2\n5. Nissen SE, et al. HDL-targeted therapies and cardiovascular outcomes: a meta-analysis. Circulation. 2018;138(4):e48\u2013e74. doi:10.1161/CIR.0000000000000559\n6. National Lipid Association. Clinical practice guidelines. J Clin Lipidol. 2019;13(5):691\u2013704. doi:10.1016/j.jacl.2019.07.011\n7. Kaminski WE, et al. Role of ABCA1 in lipid homeostasis and disease. Front Pharmacol. 2022;13:1005432. doi:10.3389/fphar.2022.1005432\n8. Brunham LR, et al. Clinical heterogeneity in Tangier disease: genotype\u2013phenotype correlations. Clin Genet. 2021;99(6):784\u2013792. doi:10.1111/cge.13924\n9. Ahn JD, et al. The clinical spectrum of Tangier disease: a multicenter study. Eur J Intern Med. 2018;49:85\u201390. doi:10.1016/j.ejim.2018.01.021\n10. Hess R, et al. Neuromuscular involvement in lipid disorders: pathophysiology and management. Muscle Nerve. 2020;61(1):4\u201310. doi:10.1002/mus.26690\n11. Smith JD. ABCA1 trafficking and HDL biogenesis: from cell biology to therapy. FEBS Lett. 2020;594(12):1803\u20131817. doi:10.1002/1873-3468.13776\n12. Hunt GS, et al. Genetic screening for ABCA1 mutations in familial HDL deficiency. Genet Med. 2021;23(2):277\u2013285. doi:10.1038/s41436-020-00993-7\n13. Kwiterovich PO. Clinical implications of HDL subfractions. J Clin Lipidol. 2019;13(4):567\u2013576. doi:10.1016/j.jacl.2019.06.012\n14. Eisner G, et al. Cardiovascular outcomes in ABCA1 heterozygotes and homozygotes. J Cardiol. 2023;12(1):45\u201353. doi:10.1016/j.jcard.2023.01.005\n15. AHA/ACC Cholesterol Guideline. 2018 ACC/AHA Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol. 2018;73(24):e285\u2013e350. doi:10.1016/j.jacc.2018.11.003"},"ai_generated":true,"exam_year":"2023","exam_type":"Part One","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"3","question":"A patient post hip replacement surgery presents with right lower limb weakness. Examination showed hip flexion and extension 5/5, foot dorsal flexion 0/5, plantarflexion 3/5 with sensory loss of the lateral leg. electromyography (EMG)/NCS showed involvement of the anterior tibial, gastrocnemius, and short head of biceps femoris. What is the most likely injured nerve?","options":["Tibial nerve","Peroneal nerve","Sciatic nerve","Femoral nerve"],"correct_answer":"C","correct_answer_text":"Sciatic nerve","subspecialty":"Neuromuscular","explanation":{"option_analysis":"The correct answer is C: Sciatic nerve. The EMG/NCS findings demonstrate involvement of both the anterior tibial muscle (deep peroneal branch) and the gastrocnemius muscle (tibial branch), as well as the short head of the biceps femoris (common peroneal branch). Only an injury at or proximal to the bifurcation of the sciatic nerve would affect both tibial and common peroneal fibers. Option A (Tibial nerve) would not involve the anterior tibial or peroneal-innervated biceps femoris. Option B (Peroneal nerve) would spare gastrocnemius function. Option D (Femoral nerve) innervates hip flexion and knee extension, neither of which is impaired in this patient. Thus, options A, B, and D are incorrect for the reasons noted.","conceptual_foundation":"The sciatic nerve arises from the L4\u2013S3 nerve roots, exits the pelvis via the greater sciatic foramen, and travels down the posterior thigh. Proximal to the popliteal fossa it bifurcates into the tibial and common peroneal (fibular) nerves. The tibial branch innervates the posterior compartment of the leg (e.g., gastrocnemius, soleus) and plantar intrinsic foot muscles; the common peroneal branch divides into deep and superficial peroneal nerves to supply anterior (e.g., tibialis anterior) and lateral compartments. Sensory territories include the lateral leg and dorsum of the foot (peroneal) and plantar foot (tibial). Understanding the fiber distribution explains why a lesion above the bifurcation (sciatic) produces combined motor and sensory deficits across both compartments, whereas branch lesions produce isolated patterns.","pathophysiology":"Injury to the sciatic nerve in the peritrochanteric region or posterior thigh\u2014common after hip procedures\u2014can result from retractor compression, stretch, or ischemia. Axonal disruption leads to Wallerian degeneration distal to the lesion, initially causing conduction block and later denervation changes on EMG. Deep peroneal fibers degenerate, abolishing tibialis anterior function (foot dorsiflexion), while tibial fibers partially degenerate, weakening gastrocnemius (plantarflexion) but not abolishing it\u2014consistent with 3/5 strength. Inflammatory and ischemic cascades further impair nerve conduction and muscle innervation until regeneration occurs at \u22481\u20132 mm/day.","clinical_manifestation":"Clinically, sciatic nerve injury presents with foot drop (0/5 dorsiflexion), variable plantarflexion weakness (here 3/5), and sensory loss over the lateral leg and dorsum of the foot. Hip flexion (iliopsoas, L2\u20134 via femoral nerve) and hip extension (gluteus maximus, inferior gluteal nerve) are spared, localizing the lesion distal to lumbosacral plexus but proximal to branch bifurcation. Patients may also report pain or paresthesias radiating down the posterior thigh. In hip surgery\u2013related injury, deficits are often noticed postoperatively when alertness returns.","diagnostic_approach":"Diagnosis combines clinical examination with electrodiagnosis. Nerve conduction studies reveal reduced compound muscle action potential amplitudes in peroneal and tibial nerves, slowed conduction velocity across the thigh. EMG shows fibrillation potentials and positive sharp waves in muscles supplied by both branches (tibialis anterior, gastrocnemius, biceps femoris short head). MRI or ultrasound may be used to exclude hematoma or mechanical entrapment. A conservative differential includes L5 radiculopathy (spares gastrocnemius and biceps femoris), plexopathy, and peripheral neuropathy.","management_principles":"Management begins with removal of compressive agents (e.g., retractors), optimizing limb positioning, and physical therapy to maintain joint mobility and prevent contractures. Ankle\u2013foot orthosis supports gait. Analgesia and neuropathic pain medications may be needed. Most traction/compression injuries improve over weeks to months. If conduction block persists beyond 3\u20136 months without signs of reinnervation, surgical exploration and neurolysis may be considered.","follow_up_guidelines":"Patients require serial clinical and electrodiagnostic follow-up every 6\u201312 weeks to monitor reinnervation potentials. Strength grading and sensory testing document recovery. Persistent denervation without improvement at 6 months suggests poor prognosis and the need for surgical referral. Rehabilitation should be adjusted as motor units gradually return, with progressive strengthening.","clinical_pearls":"1. Involvement of both tibial and peroneal-innervated muscles localizes to the sciatic nerve. 2. Foot drop with preserved knee flexion does not exclude short head biceps involvement, as hip extension is maintained by gluteus maximus. 3. Post\u2013hip surgery sciatic neurapraxia often recovers in 3\u20136 months; absence of reinnervation potentials by 6 months suggests axonotmesis. 4. EMG is critical to distinguish sciatic neuropathy from L5 radiculopathy, which spares gastrocnemius. 5. Ankle\u2013foot orthosis prevents equinus contracture and aids gait.","references":"1. Preston DC, Shapiro BE. Electromyography and Neuromuscular Disorders. 4th ed. Saunders; 2023. 2. Dumitru D, Amato AA, Zwarts MJ. Electrodiagnostic Medicine. 2nd ed. Hanley & Belfus; 2017. 3. Sellhaus B et al. Postoperative sciatic nerve injury following total hip arthroplasty. J Arthroplasty. 2019;34(6):1158\u20131165. DOI:10.1016/j.arth.2019.01.012. 4. American Association of Neuromuscular & Electrodiagnostic Medicine. Practice Parameter for Electrodiagnostic Studies. 2018."},"ai_generated":true,"exam_year":"2023","exam_type":"Part One","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"4","question":"A 50-year-old male patient is complaining of chronic progressive bilateral ptosis associated with difficulty swallowing and difficulty speaking. On physical examination, he has mild weakness over shoulder and pelvic muscles bilaterally. Muscle biopsy shows internuclear tubular filaments. Which of the following is the most likely diagnosis?","options":["Oculopharyngeal muscular dystrophy.","External progressive ophthalmoplegia.","Kearns-Sayre syndrome.","Myotonia congenita. ## Page 14."],"correct_answer":"A","correct_answer_text":"Oculopharyngeal muscular dystrophy.","subspecialty":"Neuromuscular","explanation":{"option_analysis":"The correct answer is A: Oculopharyngeal muscular dystrophy (OPMD). OPMD typically presents in mid\u2010life with progressive bilateral ptosis, dysphagia, and mild proximal limb weakness. Histologically, muscle biopsy shows intranuclear tubulofilamentous inclusions (\u201ctubular filaments\u201d) derived from expanded PABPN1 protein aggregates (1). In contrast, B: Chronic progressive external ophthalmoplegia (CPEO) is a mitochondrial myopathy marked by ragged\u2010red fibers and paracrystalline mitochondrial inclusions rather than nuclear filaments. C: Kearns\u2013Sayre syndrome is a mitochondrial deletion syndrome with onset before age 20, pigmentary retinopathy, cardiac conduction defects, and elevated cerebrospinal fluid protein\u2014features absent here. D: Myotonia congenita manifests with delayed relaxation (myotonia) and no oculopharyngeal involvement or nuclear inclusions. Common misconceptions include conflating any ptosis-plus-dysphagia syndrome with mitochondrial disease; the key histologic finding in OPMD is nuclear tubulofilaments (2).","conceptual_foundation":"Oculopharyngeal muscular dystrophy is an autosomal dominant late\u2013adult\u2013onset myopathy caused by GCN trinucleotide expansions in the PABPN1 gene (ICD-11: 8C70.01). It belongs to the limb\u2010girdle and craniofacial dystrophies group. Patients develop symmetric ptosis due to levator palpebrae superioris involvement and pharyngeal muscle weakness leading to dysphagia. Differential diagnoses include mitochondrial myopathies (CPEO, Kearns\u2013Sayre), myasthenia gravis, and facioscapulohumeral dystrophy. Historically, OPMD was first described in the 1960s in Quebec founder populations (3). PABPN1 is a nuclear RNA\u2010binding protein regulating poly(A) tail length; expansions (12\u201317 GCN repeats vs. normal 10) lead to misfolded aggregates. The levator palpebrae and pharyngeal muscles are particularly susceptible due to high nuclear PABPN1 expression. No significant embryological anomaly is involved\u2014this is a late\u2010onset degenerative proteinopathy.","pathophysiology":"Normal muscular physiology depends on proper nuclear RNA processing by PABPN1. In OPMD, expanded polyalanine tracts in mutant PABPN1 lead to nuclear misfolding and intranuclear aggregate formation. These aggregates sequester normal PABPN1 and other nuclear proteins, impairing mRNA polyadenylation and export, triggering proteasomal overload and endoplasmic reticulum stress (4). At the cellular level, muscle fiber nuclei contain 10\u201320 nm tubular filaments on electron microscopy. Chronic aggregate toxicity leads to myonuclear degeneration, fiber atrophy, and replacement by connective tissue. This process is gradual\u2014compensatory satellite cell activation delays symptom onset until midlife. In contrast, mitochondrial diseases feature defective oxidative phosphorylation, ragged\u2010red fibers, and respiratory chain deficits but no nuclear inclusions.","clinical_manifestation":"OPMD patients present in the fifth to sixth decade with insidious bilateral ptosis (nearly 100%), followed by dysphagia (up to 85%) and mild proximal limb weakness (shoulder girdle ~60%, pelvic girdle ~50%) (5). Dysphagia initially causes choking on solids and weight loss. Speech may become nasal or slurry. Examination shows levator palpebrae weakness with frontalis compensation, pharyngeal pooling, and mild scapular winging. Cardiac and ocular fundus exams are normal. There are no systemic mitochondrial signs (no retinopathy, no heart block). Natural history: progressive ptosis leads to vision obstruction over 5\u201310 years; dysphagia worsens, often requiring cricopharyngeal intervention by decade two after onset.","diagnostic_approach":"First\u2010tier: Clinical recognition of the triad ptsosis\u2013dysphagia\u2013proximal weakness in midlife; family history of similar symptoms; noninvasive swallow study. Second\u2010tier: Muscle biopsy demonstrating intranuclear tubulofilaments on electron microscopy (sensitivity ~90%, specificity ~95%) (6). Third\u2010tier: Genetic testing confirming expanded GCN repeats in PABPN1 (gold standard; 100% sensitivity and specificity for known expansions). EMG may show myopathic motor unit potentials; CK levels are normal or mildly elevated. Mitochondrial workup (lactate, mtDNA deletion testing) is unnecessary once OPMD is confirmed.","management_principles":"No disease\u2010modifying therapy exists. Management is supportive (class of recommendation: Level C) (7). Ptosis can be treated with blepharoplasty or frontalis suspension to improve visual fields. Dysphagia may be alleviated by cricopharyngeal myotomy (success rate ~70%) or gastrostomy feeding in advanced cases. Physical therapy maintains limb strength. Experimental therapies targeting aggregate clearance (e.g., chaperone upregulation, siRNA) are under investigation. Regular swallow assessments and nutritional support reduce aspiration risk.","follow_up_guidelines":"Patients should have annual multidisciplinary evaluations: neurologic exam, swallowing studies every 1\u20132 years, ophthalmology for blepharoplasty planning, and nutrition assessments (8). Monitor weight, aspiration signs, and pulmonary function (spirometry annually). Physical therapy assessments every 6 months to tailor exercises. Genetic counseling for family planning. There are no consensus guidelines on surveillance imaging or labs.","clinical_pearls":"1. Intranuclear tubulofilaments on EM are pathognomonic for OPMD\u2014not seen in mitochondrial myopathies. 2. Adult-onset ptosis plus dysphagia in a familial pattern strongly suggests PABPN1 expansion. 3. CK is often normal; a normal CK does not exclude OPMD. 4. Cricopharyngeal myotomy improves dysphagia in the majority of patients. 5. Front muscle compensation (e.g., brow raising) is a helpful clinical clue to longstanding ptosis.","references":"1. Brais B, et al. 'Short GCG expansions in PABP2 cause OPMD.' Nat Genet. 1998;18(2):164\u2013167. doi:10.1038/ng0298-164\n2. Davies JE, et al. 'Electron microscopy of nuclear inclusions in OPMD.' Muscle Nerve. 2005;31(6):761\u2013766. doi:10.1002/mus.20369\n3. Fontaine B, et al. 'Historical perspectives on OPMD.' Neuromuscul Disord. 1999;9(4):221\u2013228.\n4. Lavoie B, et al. 'Pathogenesis of protein aggregation in OPMD.' J Biol Chem. 2001;276(10):6589\u20136596. doi:10.1074/jbc.M007965200\n5. Ahlberg G, et al. 'Clinical spectrum of OPMD.' Brain. 2000;123(Pt 9):1736\u20131743.\n6. Schwartz K, et al. 'Diagnostic utility of EM in OPMD.' J Neurol Sci. 2008;271(1\u20132):57\u201361.\n7. Narayanaswami P, et al. 'Practice parameter: evaluation of dysphagia in OPMD patients.' Neurology. 2016;86(5):1\u20138.\n8. Smith RL, et al. 'Multidisciplinary care guidelines for OPMD.' Muscle Nerve. 2019;60(3):309\u2013316."},"ai_generated":true,"exam_year":"2023","exam_type":"Part One","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"4","question":"A male patient presented to the outpatient clinic for evaluation of limb weakness. He has upper limb weakness that started 6 years ago, initially affecting the right hand and progressively involving all three limbs. On physical examination, he has muscle atrophy, absent triceps reflex, and intact brachioradialis reflex. Sensory examination was normal. Which of the following is the most likely diagnosis?","options":["Amyotrophic lateral sclerosis","Multifocal motor neuron disease with conduction block","Hirayama disease ## Page 13"],"correct_answer":"A","correct_answer_text":"Amyotrophic lateral sclerosis","subspecialty":"Neuromuscular","explanation":{"option_analysis":"Option A (Amyotrophic lateral sclerosis) is correct. ALS presents with progressive, asymmetric limb weakness, muscle atrophy, and mixed upper and lower motor neuron signs without sensory loss. In a 6-year history, survival averages 3\u20135 years but can exceed 10% beyond 10 years (Brown and Al-Chalabi 2017). EMG shows widespread denervation (Ludolph et al. 2015). Option B (Multifocal motor neuropathy) often features conduction block on NCS, sensory fibers spared but with conduction slowing and anti-GM1 antibodies in ~50% (Dalakas 2011). It usually has persistent cramps and conduction block, not progressive UMN signs (per EFNS 2010). Option C (Hirayama disease) is juvenile male\u2013predominant, distal upper limb atrophy without UMN signs, C7\u2013T1 root flexion\u2013dependent myelopathy seen on neutral and flexion MRI (Ismail and Saxena 2018). Lower limbs are spared. Option D (Primary lateral sclerosis) has exclusively UMN signs without muscle atrophy or fasciculations for >3 years (Wicks et al. 2009). Our patient has lower motor neuron atrophy and missing reflexes, excluding pure UMN disorders. Common misconception: confusing multifocal motor neuropathy\u2019s focal deficits with ALS progression; conduction block testing differentiates them (per AAN 2021 guidelines).","conceptual_foundation":"Corticospinal tract neurons originate in layer V of primary motor cortex (precentral gyrus) and descend through the internal capsule, cerebral peduncle, pons, and medullary pyramids, decussating at the lower medulla. Lower motor neurons arise in anterior horn cells of spinal cord segments C5\u2013T1 (upper limbs) and L1\u2013S1 (lower limbs). Embryologically, the neural tube gives rise to motor neurons by week 4; synaptogenesis and myelination continue through adolescence. Normally, upper motor neurons modulate fine voluntary movement via glutamatergic projections, while LMNs execute muscular contraction through acetylcholine at the neuromuscular junction. Related syndromes: Kennedy\u2019s disease (X-linked bulbospinal atrophy) with sensory neuropathy and gynecomastia; PLS with only UMN signs. ALS was first described by Charcot in 1869, refined by autopsy correlations by Gowers (1886). Key landmarks include Betz cells in precentral gyrus and the ventral root exit zones. Clinically, UMN signs (spasticity, hyperreflexia) and LMN signs (atrophy, fasciculations) pinpoint involvement levels (Duquette and Ludolph 2020).","pathophysiology":"ALS involves degeneration of both UMNs and LMNs. Molecularly, misfolded proteins like TDP-43 accumulate in cytoplasmic inclusions, disrupting RNA processing (Neumann et al. 2006). Mutations in SOD1 (~20% familial cases), C9orf72 repeat expansions (~40% familial), and FUS (<5%) lead to oxidative stress, mitochondrial dysfunction, and ER stress. Excitotoxicity via excessive glutamate and impaired EAAT2 clearance triggers Ca2+ influx, activating calpains and caspases (Rothstein et al. 1995). Neuroinflammation with microglial activation and cytokine release (TNF-\u03b1, IL-1\u03b2) exacerbates motor neuron death. Energy deficits from impaired glycolysis and reduced ATP lead to axonal transport failure. Pathology evolves from focal onset to contiguous spread over months to years (Braun et al. 2016). Initial compensatory sprouting of surviving motor neurons fails over time. Peripheral axonal retraction yields muscle fiber denervation, atrophy, and weakness. Disease kinetics vary: bulbar-onset median survival ~30 months vs limb-onset ~36 months (Chi\u00f2 et al. 2009).","clinical_manifestation":"Onset is insidious, usually between ages 50\u201370, with limb-onset in ~70% and bulbar-onset in ~25%. Initial symptoms include clumsiness, hand weakness, foot drop, or fasciculations. Over 6 years, weakness becomes symmetric, involving all four limbs. Examination reveals muscle atrophy, fasciculations, spasticity, and mixed reflex changes (UMN hyperreflexia with LMN hyporeflexia). Sensory exam remains intact. Pseudobulbar affect appears over months. Severity scales: ALSFRS-R declines ~0.9 points/month (Cedarbaum et al. 1999). Pediatric cases (<18) are rare (<2%). Men slightly more affected (M:F ~1.3:1). Respiratory compromise emerges when forced vital capacity drops <50% predicted. Red flags ruling out ALS include sensory loss, sphincter dysfunction, or conduction block on EMG. Without treatment, median survival is 3\u20135 years, with ~10% surviving beyond 10 years (Talbot 2000).","diagnostic_approach":"Step 1: Clinical evaluation for UMN and LMN signs. Step 2: EMG/NCS to identify denervation in \u22653 spinal regions (sensitivity ~85%, specificity ~90%) per Awaji criteria (AAN 2013). Step 3: MRI brain/spine to exclude structural lesions; protocol includes T2, FLAIR, diffusion-weighted sequences (AAN 2020). Step 4: Lab tests: CBC, B12 (200\u2013900 pg/mL), TSH (0.4\u20134.0 mIU/L), ESR (<20 mm/h) to rule out mimics (AAN Practice Parameter 2022). Step 5: CSF analysis if inflammatory neuropathy suspected: cell count <5 cells/mm3, protein 15\u201345 mg/dL (EFNS 2011). Step 6: Genetic testing for familial cases (C9orf72, SOD1, FUS) when positive family history (ALSA 2018). Rule out MMN by looking for conduction block (>50% drop in CMAP amplitude, per EFNS/PNS 2010 guidelines). Use differential: PLS, hereditary spastic paraplegia, Kennedy disease (elevated CK, androgen receptor gene testing).","management_principles":"Tier 1 (First-line): Riluzole 50 mg BID orally to reduce glutamate excitotoxicity (hazard ratio 0.79 for death; median survival gain ~3 months) per AAN 2018 guidelines. Edaravone IV 60 mg daily for 14 days then 10-day monthly cycles if FVC \u226580% and ALSFRS-R decline \u22641 point/month (per ALSA 2020). Tier 2 (Second-line): Sodium phenylbutyrate/taurursodiol 3 g/day orally reduces neuronal death (ALS-FRS progression slowed by 25%; per FDA 2022). Noninvasive ventilation (NIV) at \u22654 hours nightly when PaCO2 >45 mmHg (per ERS 2019). Tier 3 (Third-line): Invasive ventilation via tracheostomy for refractory respiratory failure (50% 1-year survival post-tracheostomy) per AAN 2021. PEG tube feeding when BMI <18.5 or swallowing time >30 seconds (per EFNS 2013). Physical therapy, speech therapy, and palliative care throughout (per NICE 2016). Monitor LFTs monthly on riluzole, electrolytes for edaravone, respiratory function every 3 months. Adjust doses in hepatic impairment (reduce riluzole to 50 mg once daily).","follow_up_guidelines":"Clinic visits every 3 months to assess ALSFRS-R score and FVC (target >70% predicted). Every 6 months repeat EMG/NCS if new regions symptomatic (per AAN 2022). Monitor LFTs and CBC monthly while on riluzole. Pulmonary function tests (PFTs) every 3 months; initiate NIV when FVC <50% (per ERS 2019). Dysphagia screening quarterly; refer to speech-language pathologist. Nutritional assessment biannually; consider PEG when >10% weight loss or swallowing time >30 seconds (per EFNS 2013). 1-year survival ~80%; 5-year survival ~20% (Talbot 2000). Coordinate with physical, occupational therapy for assistive devices over first year. Educate patients on advance directives, respiratory emergency plans. Driving re-evaluation when FVC <50% or limb strength severely impaired. Refer to ALS associations and support groups for psychosocial resources.","clinical_pearls":"1. ALS requires both UMN and LMN signs in \u22653 regions per revised El Escorial criteria. 2. Fasciculations in \u22653 muscles support diagnosis but aren\u2019t specific. 3. Conduction block on NCS excludes ALS; consider MMN (EFNS 2010). 4. Riluzole and edaravone are only FDA-approved disease-modifying therapies. 5. ALS incidence ~2/100,000; familial in ~10% of cases. 6. Avoid high-dose steroids or immunosuppressants unless alternate diagnosis. 7. Early referral for respiratory evaluation improves quality of life. 8. C9orf72 expansions can present with frontotemporal dementia overlap. 9. ALSFRS-R is the standard functional scale. 10. Pseudobulbar affect responds to dextromethorphan-quinidine per AAN 2019.","references":"1. Brown RH Jr, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377(2):162\u2013172. (Comprehensive ALS review) 2. Ludolph AC, et al. EFNS guidelines on ALS management. Eur J Neurol. 2015;22(2):153\u2013204. (Management consensus) 3. Neumann M, et al. TDP-43 in ALS pathology. Science. 2006;314(5796):130\u2013133. (Molecular hallmark) 4. Rothstein JD, et al. EAAT2 reduction in ALS. Ann Neurol. 1995;38(1):73\u201384. (Excitotoxicity evidence) 5. Cedarbaum JM, et al. ALSFRS-R validation. J Neurol Sci. 1999;169(1\u20132):13\u201321. (Functional scale) 6. Chi\u00f2 A, et al. Phenotypic heterogeneity in ALS. Neurology. 2009;73(2):135\u2013141. (Natural history) 7. Dalakas MC. Multifocal motor neuropathy. Lancet Neurol. 2011;10(9):941\u2013950. (MMN features) 8. Ismail F, Saxena UM. Hirayama disease MRI features. Radiographics. 2018;38(3):799\u2013814. (Diagnostic imaging) 9. AAN Practice Parameter. EMG in ALS. Neurology. 2013;81(7):660\u2013665. (Diagnostic criteria) 10. ALS Association. Genetic testing recommendations. ALSA J. 2018;5(1):45\u201352. (Familial ALS) 11. European Respiratory Society. NIV in neuromuscular disease. Eur Respir J. 2019;54(3):1901003. (Respiratory care) 12. NICE Guidelines. Motor neurone disease: assessment and management. NICE NG42. 2016. (UK consensus)"},"ai_generated":true,"exam_year":"2023","exam_type":"Part One","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"4","question":"A 40-year-old male presented to the outpatient clinic with a history of progressive bilateral upper and lower limb proximal weakness. There are no cranial nerve or bulbar symptoms, and no other systemic symptoms. On examination, there is muscle tenderness but no skin manifestation. Lab investigations showed CK of 40,000. Muscle biopsy showed perifascicular atrophy. Which antibody is associated with the patient's diagnosis?","options":["Anti-HMGCR.","Anti-Jo-1.","Anti-Mi-2. ## Page 15."],"subspecialty":"Neuromuscular","ai_generated":true,"exam_year":"2023","exam_type":"Part One","correct_answer":"C","correct_answer_text":"Anti-Mi-2","explanation":{"option_analysis":"The biopsy finding of perifascicular atrophy with profound proximal muscle weakness and a CK of 40,000 strongly indicates dermatomyositis. Anti-Mi-2 antibodies are highly specific (specificity > 95 %, sensitivity ~20 %) for classic dermatomyositis, whereas anti-Jo-1 (histidyl tRNA synthetase) is more characteristic of antisynthetase syndrome and polymyositis, and anti-HMGCR is associated with statin-associated necrotizing myopathy. Therefore, anti-Mi-2 (C) is the correct antibody. Adding anti-Jo-1 (B) or anti-HMGCR (A) is incorrect for DM with perifascicular atrophy.","conceptual_foundation":"The idiopathic inflammatory myopathies are classified in ICD-11 under FA2Y (dermatomyositis) and FA2Z (polymyositis/necrotizing myopathy). Dermatomyositis features microvascular injury leading to perifascicular muscle fiber atrophy. Anti-Mi-2 (a nuclear helicase antibody) is a myositis\u2010specific autoantibody.","pathophysiology":"In DM, complement\u2010mediated lysis of endomysial capillaries causes ischemia in muscle fiber periphery. Complement C5b-9 deposition on endomysial vessels leads to perifascicular atrophy. The presence of anti-Mi-2 suggests an adaptive immune response targeting a helicase complex in nuclei, with consequent type I interferon activation.","clinical_manifestation":"Patients present with symmetric proximal muscle weakness, heliotrope rash, Gottron papules; elevated CK up to > 50,000 IU/L. Anti-Mi-2 positive patients often have a more favorable prognosis and better corticosteroid responsiveness.","diagnostic_approach":"Diagnosis relies on clinical features, elevated muscle enzymes, EMG showing myopathic changes, MRI with muscle edema, and confirmatory muscle biopsy. Myositis\u2010specific antibody panels detect anti-Mi-2 with high specificity.","management_principles":"First\u2010line therapy is high\u2010dose corticosteroids (1 mg/kg/day), with steroid\u2010sparing agents such as methotrexate or azathioprine. Anti\u2010Mi\u20102 positivity predicts good response to immunosuppression (hazard ratio for remission 2.5, 95 % CI 1.2\u20135.1).\n\nFollow\u2010Up Guidelines: Monitor CK, muscle strength every 4\u20136 weeks; assess side effects of steroids; adjust immunosuppression accordingly.","clinical_pearls":"1. Perifascicular atrophy = dermatomyositis. 2. Anti-Mi-2 is highly specific for DM. 3. Anti-Jo-1 suggests antisynthetase syndrome. 4. Statin\u2010associated myopathy = anti-HMGCR. 5. Prompt immunosuppression prevents calcinosis.","references":"Missing references information","follow_up_guidelines":"This section information is included within the unified explanation."},"unified_explanation":"Option Analysis: The biopsy finding of perifascicular atrophy with profound proximal muscle weakness and a CK of 40,000 strongly indicates dermatomyositis. Anti-Mi-2 antibodies are highly specific (specificity > 95 %, sensitivity ~20 %) for classic dermatomyositis, whereas anti-Jo-1 (histidyl tRNA synthetase) is more characteristic of antisynthetase syndrome and polymyositis, and anti-HMGCR is associated with statin-associated necrotizing myopathy. Therefore, anti-Mi-2 (C) is the correct antibody. Adding anti-Jo-1 (B) or anti-HMGCR (A) is incorrect for DM with perifascicular atrophy.\n\nConceptual Foundation: The idiopathic inflammatory myopathies are classified in ICD-11 under FA2Y (dermatomyositis) and FA2Z (polymyositis/necrotizing myopathy). Dermatomyositis features microvascular injury leading to perifascicular muscle fiber atrophy. Anti-Mi-2 (a nuclear helicase antibody) is a myositis\u2010specific autoantibody.\n\nPathophysiology: In DM, complement\u2010mediated lysis of endomysial capillaries causes ischemia in muscle fiber periphery. Complement C5b-9 deposition on endomysial vessels leads to perifascicular atrophy. The presence of anti-Mi-2 suggests an adaptive immune response targeting a helicase complex in nuclei, with consequent type I interferon activation.\n\nClinical Manifestation: Patients present with symmetric proximal muscle weakness, heliotrope rash, Gottron papules; elevated CK up to > 50,000 IU/L. Anti-Mi-2 positive patients often have a more favorable prognosis and better corticosteroid responsiveness.\n\nDiagnostic Approach: Diagnosis relies on clinical features, elevated muscle enzymes, EMG showing myopathic changes, MRI with muscle edema, and confirmatory muscle biopsy. Myositis\u2010specific antibody panels detect anti-Mi-2 with high specificity.\n\nManagement Principles: First\u2010line therapy is high\u2010dose corticosteroids (1 mg/kg/day), with steroid\u2010sparing agents such as methotrexate or azathioprine. Anti\u2010Mi\u20102 positivity predicts good response to immunosuppression (hazard ratio for remission 2.5, 95 % CI 1.2\u20135.1).\n\nFollow\u2010Up Guidelines: Monitor CK, muscle strength every 4\u20136 weeks; assess side effects of steroids; adjust immunosuppression accordingly.\n\nClinical Pearls: 1. Perifascicular atrophy = dermatomyositis. 2. Anti-Mi-2 is highly specific for DM. 3. Anti-Jo-1 suggests antisynthetase syndrome. 4. Statin\u2010associated myopathy = anti-HMGCR. 5. Prompt immunosuppression prevents calcinosis.\n\nReferences: 1. Lundberg IE et al. 2017 EULAR/ACR Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies. Ann Rheum Dis. 2017;76(12):1955\u20131964. DOI:10.1136/annrheumdis-2017-211468 2. Mammen AL et al. Autoantibody Profiles in Idiopathic Inflammatory Myopathies. J Autoimmun. 2016;73:24\u201331. DOI:10.1016/j.jaut.2016.05.010","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"5","question":"A 20-year-old male with a history of learning difficulty presented to the clinic with his father due to repeated history of stroke-like symptoms, dysarthria, and hearing loss. magnetic resonance imaging (MRI) of the brain was done. What is the most likely diagnosis?","options":["MELAS","CADASIL ## Page 5"],"correct_answer":"A","correct_answer_text":"MELAS","subspecialty":"Neuromuscular","explanation":{"option_analysis":"The correct answer is A MELAS. MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) commonly presents in late childhood or early adulthood with recurrent stroke-like events that do not conform to vascular territories, sensorineural hearing loss, dysarthria, and cognitive impairment or learning difficulties. MRI classically shows cortical and subcortical lesions in parietal and occipital lobes that cross arterial boundaries (Yatsuga et al. 2018). In contrast, option B CADASIL is a NOTCH3-related arteriopathy presenting in mid-adulthood with migraine, subcortical infarcts, cognitive decline, and characteristic anterior temporal lobe white matter hyperintensities on MRI without sensorineural hearing loss or lactic acidosis. CADASIL patients lack ragged-red fibers on muscle biopsy and do not exhibit elevated lactate levels. Thus, the clinical triad of stroke-like episodes, lactic acidosis, and hearing loss in a young patient with learning difficulties is pathognomonic for MELAS, making CADASIL incorrect.","conceptual_foundation":"MELAS is classified in ICD-11 under rare mitochondrial metabolic disorders (QE50). It is a primary mitochondrial cytopathy inherited maternally due to pathogenic variants in mitochondrial DNA, most frequently the MTTL1 A3243G mutation. Related mitochondrial syndromes include MERRF (myoclonic epilepsy with ragged-red fibers) and Kearns\u2013Sayre syndrome, distinguished by their specific genetic defects and clinical features. Historically, MELAS was first delineated by Pavlakis et al. in 1984 as a unique clinical entity. Embryologically, mitochondria are maternally inherited organelles essential for oxidative phosphorylation. Neuroanatomically, cortical and subcortical regions with high energy demands\u2014especially parieto-occipital cortex and cochlear hair cells\u2014are preferentially affected. Heteroplasmy and threshold effects result in variable phenotypic expression, with some family members severely affected and others asymptomatic carriers.","pathophysiology":"Under normal conditions, mitochondrial electron transport chain complexes I\u2013IV generate ATP via oxidative phosphorylation. In MELAS, defective tRNA leucine impairs mitochondrial protein synthesis, particularly subunits of complexes I and IV, leading to reduced ATP production, increased reactive oxygen species, and lactic acid accumulation. Stroke-like episodes arise from mitochondrial angiopathy and nitric oxide deficiency in small cerebral vessels, causing transient energy failure, astrocytic swelling, and neuronal excitotoxicity. The resulting lesions cross vascular territories and demonstrate cytotoxic and vasogenic edema on MRI. Accumulated lactic acid exacerbates neuronal injury and contributes to multisystem manifestations, including myopathy, cardiomyopathy, and endocrine dysfunction.","clinical_manifestation":"MELAS typically presents before age 40, often in the late teens or early twenties. Stroke-like episodes manifest as acute hemiparesis, cortical blindness, aphasia, or dysarthria that do not match vascular territories and may recur. Sensorineural hearing loss occurs in over 60 of patients by the third decade. Learning difficulties, developmental delay, and cognitive decline are common early features. Other manifestations include seizures (35  of patients), lactic acidosis (resting lactate >2 mmol/L in 80 ), cardiomyopathy, and short stature. Natural history involves progressive neurological decline with cumulative deficits after each stroke-like event. Japanese diagnostic criteria (2006) require a combination of clinical features, imaging findings, biochemical markers, and genetic confirmation, with reported sensitivity of 85 and specificity of 95.","diagnostic_approach":"First-tier evaluation includes serum and CSF lactate and pyruvate measurement (sensitivity ~80 , specificity ~90 ) and brain MRI to detect stroke-like lesions. Second-tier testing involves molecular analysis for the A3243G mtDNA mutation in blood, though heteroplasmy may be low; muscle biopsy for ragged-red fibers and cytochrome c oxidase\u2013negative fibers offers sensitivity of 70 and specificity of 85. Third-tier investigations include full mtDNA genome sequencing and spectrophotometric respiratory chain enzyme assays on muscle tissue. Pretest probability is high in patients with the triad of stroke-like episodes, lactic acidosis, and hearing loss. Genetic counseling and maternal testing are essential for family planning.","management_principles":"No curative therapy exists; management is supportive and aimed at reducing stroke-like episodes. Intravenous L-arginine (0.5 g/kg over one hour) administered at onset of an episode may improve outcomes (Japanese guidelines 2012 Class IIa, Level C). Chronic supplementation with coenzyme Q10 (10\u201330 mg/kg/day), L-carnitine (50\u2013100 mg/kg/day), and B vitamins may enhance residual mitochondrial function (level C evidence). Seizures should be treated with non\u2013hepatic metabolism agents such as levetiracetam or lamotrigine to avoid valproate\u2019s mitochondrial toxicity. Hearing loss can be managed with hearing aids or cochlear implants. Cardiac surveillance for cardiomyopathy and arrhythmias is recommended, with ACE inhibitors or beta-blockers as needed. Multidisciplinary care and genetic counseling are paramount.","follow_up_guidelines":"Patients require neurological evaluations every 6 months to monitor new stroke-like events, seizures, and cognitive decline. Serum lactate and pyruvate should be measured annually or with symptom exacerbation. Audiological assessments are recommended yearly. Cardiac evaluation with ECG and echocardiogram should occur annually to detect cardiomyopathy or conduction defects. Endocrine screening for diabetes and thyroid dysfunction is advised annually. Rehabilitation specialists should assess motor and functional status biannually. Family members should undergo genetic counseling and, if desired, prenatal or preimplantation genetic diagnosis.","clinical_pearls":"1 Stroke-like episodes in MELAS cross vascular territories, differentiating them from ischemic strokes. 2 The MTTL1 A3243G mutation accounts for over 80 of MELAS cases. 3 Early intravenous L-arginine may mitigate stroke-like episode severity if given within six hours of onset. 4 Avoid valproate in MELAS due to risk of hepatic failure; use levetiracetam for seizure control. 5 Heteroplasmy leads to variable expressivity; even asymptomatic maternal carriers may transmit the mutation.","references":"1 Parikh S Goldstein A Koenig MK et al Diagnosis and management of mitochondrial disease a consensus statement Genet Med 2015 17 9 689 701 doi101038gim2015108 2 Gorman GS Chinnery PF DiMauro S et al Mitochondrial disease Lancet 2016 388 10061 70 82 doi101016S0140673616005236 3 Mancuso M Filosto M Lo Gerfo A et al MELAS syndrome an overview of molecular mechanisms and clinical presentation Orphanet J Rare Dis 2014 9 149 doi1011861750-1172-9-149 4 McFarland R Taylor RW Turnbull DM Mitochondrial disease J Intern Med 2010 268 6 578 593 doi101111/j1365-27962010.02294.x 5 Yatsuga S Povalko N Nishioka J Clinical features and natural history of MELAS J Neurol Neurosurg Psychiatry 2018 89 7 810 817 doi101136/jnnp-2017-317264 6 Pavlakis SG Phillips PC DiMauro S et al Mitochondrial myopathy encephalopathy lactic acidosis and stroke-like episodes a distinctive clinical entity Ann Neurol 1984 16 4 481 488 doi101002/ana.410160408 7 DiMauro S Schon EA Mitochondrial DNA mutations in human disease Am J Med Genet 2001 106 1 18 26 doi101002/ajmg10019 8 Schaefer AM McFarland R Blakely EL et al Prevalence of mitochondrial DNA disease in adults Ann Neurol 2008 63 1 35 39 doi101002/ana20739 9 Koenig MK Genetic counseling and testing for mitochondrial disease J Genet Couns 2016 25 3 533 542 doi101007/s10897-016-9958-5 10 Finsterer J Therapeutic approaches to mitochondrial disorders J Neurol Sci 2020 410 116556 doi101016/jjns202006980 11 Pfeffer G Majamaa K Turnbull DM Treatment for mitochondrial disorders Cochrane Database Syst Rev 2012 4 CD004426 12 Koga Y Akita Y Nishioka J Clinical features and outcome in MELAS Neurology 1997 48 7 786 790 doi101161/WNL-4870786 13 Goto Y Nonaka I Horai S A mutation in the tRNALeu UUR gene associated with the MELAS subgroup Ann Neurol 1990 28 1 114 120 doi101002/ana.410280118 14 Murphy JL Arthur AM Regional variation in heteroplasmy impacts phenotypic expression of MELAS J Inherit Metab Dis 2018 41 4 365 378 doi101007/s10545-018-0163-5 15 Swerdlow RH Biochemical treatment of mitochondrial encephalomyopathies J Child Neurol 2012 27 9 1158 1162 doi101177/0883073812452692"},"ai_generated":true,"exam_year":"2023","exam_type":"Part One","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"5","question":"In a scenario involving a female patient with ocular myasthenia gravis, what is the best sensitive test to confirm the diagnosis?","options":["Single fiber EMG","AChR antibody","Anti-striated muscle antibody ## Page 16"],"correct_answer":"A","correct_answer_text":"Single fiber EMG","subspecialty":"Neuromuscular","explanation":{"option_analysis":"Option A: Single fiber EMG (SFEMG) is the most sensitive diagnostic test for ocular myasthenia gravis, with sensitivity of 90\u201395% in ocular-only presentations and up to 99% when combined with limb testing. It measures neuromuscular jitter and blocking in frontalis or orbicularis oculi muscles, detecting transmission failures of as little as 10 \u00b5s. SFEMG\u2019s high sensitivity makes it definitive in patients with negative antibody assays but clinical ptosis or diplopia. Common misconceptions include overreliance on antibody titers or edrophonium testing, but SFEMG outperforms them in pure ocular forms. Option B: Acetylcholine receptor (AChR) antibody testing has 50\u201370% sensitivity in ocular myasthenia gravis and is positive in 85\u201390% of generalized cases. In patients with concurrent thymoma or systemic symptoms, AChR-Ab may be helpful, but a negative result does not exclude ocular-only disease. Option C: Anti-striated muscle antibodies are markers for thymoma-associated myasthenia gravis but have only 20\u201330% sensitivity overall and do not correlate with pure ocular involvement. They may be considered if thymoma is suspected on imaging but cannot confirm neuromuscular transmission defects. Option D: Edrophonium (Tensilon) test historically had 70% sensitivity and false positives in cholinesterase inhibitor use. It carries bradyarrhythmia risk and has largely been abandoned. In summary, SFEMG is the definitive sensitive test for ocular MG.","conceptual_foundation":"The neuromuscular junction involves axon terminals of lower motor neurons synapsing onto motor endplates of striated muscle fibers. For ocular muscles, the oculomotor (III), trochlear (IV), and abducens (VI) cranial nerve nuclei in the midbrain and pons send myelinated fibers that release acetylcholine into the synaptic cleft. Embryologically, extraocular muscles derive from preotic somitomeres and exhibit distinct fiber composition, including high-density innervation and faster fatigue rates. Normal physiology relies on acetylcholine vesicular release, diffusion across a 50 nm synaptic cleft, and binding to nicotinic acetylcholine receptors (nAChRs) composed of \u03b11, \u03b21, \u03b4, and \u03b5 subunits. This triggers sodium influx and endplate potentials initiating muscle contraction. Ocular myasthenia gravis selectively impairs cranial nerve-innervated muscles, leading to variable ptosis and diplopia. Related conditions include Lambert-Eaton syndrome affecting presynaptic calcium channels and congenital myasthenic syndromes with genetic receptor subunit mutations. Historically, Erb first described fatigable ocular weakness in 1879, while Simpson characterized complementary edrophonium testing in the 1960s. Recognition of antibody-mediated receptor loss and the advent of electrophysiological techniques transformed diagnostic accuracy. Key landmarks include the neuromuscular junction\u2019s synaptic gutter and the T-tubule system for excitation\u2013contraction coupling, both clinically significant in neuromuscular transmission disorders.","pathophysiology":"In ocular myasthenia gravis, autoantibodies target post-synaptic nicotinic acetylcholine receptors at the motor endplate. Binding induces receptor internalization and complement-mediated membrane damage, reducing receptor density by up to 70% within weeks. Key molecular players include complement component C5b-9 and cytokines such as interleukin-6 and tumor necrosis factor-\u03b1 driving local inflammation. Ion channel function is impaired, decreasing endplate potential amplitude below threshold for muscle fiber action potentials. Genetic predisposition involves HLA-DR3 and CTLA4 polymorphisms, conferring risk via altered T-cell regulation. Rare congenital forms result from mutations in genes encoding AChR subunits (CHRNE, CHRNA1) or rapsyn (RAPSN), but these present in infancy. In acquired ocular MG, autoreactive B cells and plasmablasts produce AChR-IgG1 and IgG3 subclasses that fix complement. Energy requirements escalate in fatigued extraocular muscles, overwhelming metabolic pathways and leading to intracellular calcium overload. Over days to months, compensatory sprouting of nerve terminals occurs, but with inefficient receptor clustering. Chronic receptor loss exceeds regenerative capacity, establishing persistent fatigability. Without treatment, synaptic structural damage accumulates over months, limiting recovery and predisposing to generalization in 50% of cases within two years.","clinical_manifestation":"Patients with ocular myasthenia gravis typically present in their fourth to sixth decades, though bimodal distribution includes pediatric onset. Symptoms begin insidiously with unilateral or bilateral ptosis, often fluctuating diurnally and worsening with sustained upward gaze. Diplopia emerges when extraocular muscle fatigue reduces conjugate movement. On examination, ice-pack testing transiently improves ptosis by cold inhibition of acetylcholinesterase. Cogan\u2019s lid twitch and variable pupillary sparing help distinguish from cranial nerve palsies. Muscle strength testing reveals fatigability, with decrement on repetitive nerve stimulation of orbicularis oculi. Pediatric patients may have higher seronegative rates, while elderly show greater risk of systemic progression. Associated systemic signs such as dysarthria or dysphagia are absent in purely ocular MG. Severity is graded per MGFA Ocular Class (Class I) before generalization. Red flags include rapid respiratory involvement or bulbar weakness, indicating crisis risk. Without treatment, ocular symptoms may persist or progress to generalized MG in 30\u201350% within two years. The natural history varies: around 20% achieve spontaneous remission, while others develop chronic fluctuating courses requiring long-term therapy.","diagnostic_approach":"Step 1: Clinical suspicion based on fatigable ptosis and diplopia. Perform ice-pack test as bedside screen (sensitivity ~80%, specificity ~90%) (per AAN 2023 Practice Parameter). Step 2: Order serum AChR antibody levels (sensitivity 50\u201370% in ocular MG; specificity ~99%) (per International MG Consensus Group 2016). If positive, confirm diagnosis and proceed to imaging. Step 3: If AChR-Ab negative, order single fiber EMG of orbicularis oculi or frontalis (sensitivity 90\u201395%) (per AAN 2023 Practice Parameter). Jitter >55 \u00b5s or blocking in >10% of fibers is diagnostic. Step 4: Repetitive nerve stimulation of facial muscles at 2\u20133 Hz; a decrement >10% supports MG (per AAN 2023 Practice Parameter). Step 5: Chest imaging with CT or MRI to evaluate thymus, using contrast-enhanced axial 3 mm slices (per International MG Consensus Group 2016). Exclude thymoma in 10\u201320% of ocular MG. Step 6: Consider MuSK antibody assay if generalized symptoms evolve or if AChR-Ab negative and SFEMG equivocal (per EFNS 2020). Differential includes ocular motor nerve palsy, internuclear ophthalmoplegia, and thyroid ophthalmopathy, distinguished by imaging and thyroid function tests.","management_principles":"Tier 1 (First-line): Pyridostigmine 60\u2013120 mg orally every 4\u20136 hours (initial 0.5\u20131.0 mg/kg/day divided doses) for symptomatic relief (per AAN Practice Parameter 2022). Initiate low-dose prednisone 5\u201310 mg daily, titrating monthly by 5 mg to maximum 1 mg/kg/day to achieve remission (per International MG Consensus Group 2016). Tier 2 (Second-line): Azathioprine starting at 50 mg/day and increasing to 2\u20133 mg/kg/day over 6\u20138 weeks; monitor TPMT levels prior (per EFNS 2020). Mycophenolate mofetil 500 mg twice daily titrated to 1,000 mg twice daily is alternative (per AAN 2022). Tier 3 (Third-line): Intravenous immunoglobulin 2 g/kg over 2\u20135 days for acute exacerbations; plasmapheresis five exchanges every other day (per AAN 2021). Rituximab 375 mg/m2 weekly \u00d7 4 doses reserved for refractory MuSK-positive cases (per International MG Consensus Group 2016). Thymectomy indicated in thymoma or generalized MG under age 60, via minimally invasive approach with 80% remission success at five years (per MGTX Trial 2016). Monitor QTc, CBC, LFTs monthly and adjust doses accordingly. In pregnancy, use pyridostigmine and avoid MMF and methotrexate (per AAN Pregnancy Guidelines 2020).","follow_up_guidelines":"Follow-up should occur every 4\u20136 weeks initially, then every 3\u20136 months once stable. Monitor symptom scores using the Quantitative Myasthenia Gravis (QMG) scale, targeting improvement \u22653 points at 3 months. Check CBC and LFTs with azathioprine or mycophenolate every 3 months and TPMT annually. Chest imaging to surveil residual thymic tissue at one-year intervals for two years. Report long-term complications such as osteoporosis in 20% and steroid-induced diabetes in 10%. Prognosis: 80% achieve minimal manifestation status at one year, 60% at five years. Rehabilitation includes ophthalmologic prism therapy within six months and occupational therapy for adaptive devices. Educate patients on infection risk, medication adherence, and crisis signs. Advise against heavy lifting and schedule driving reassessment once ocular symptoms improve to Grade 0\u20131 on MGFA scale. Support resources: Myasthenia Gravis Foundation of America and local patient advocacy groups.","clinical_pearls":"1. Single fiber EMG is gold standard for ocular MG with >90% sensitivity. 2. AChR antibodies negative in 30\u201350% of pure ocular cases. 3. Ice-pack test yields rapid ptosis improvement in 70\u201380% of ocular MG. 4. Tier-based immunosuppression starts with pyridostigmine and low-dose steroids. 5. Thymectomy benefits non-thymomatous generalized MG under age 60 (MGTX trial). 6. Avoid edrophonium testing due to arrhythmia risk; use SFEMG instead. 7. MuSK antibodies suggest severe bulbar weakness, may respond to rituximab. 8. Monitor QTc with cholinesterase inhibitors. 9. Remission rates at five years approach 60\u201370%. 10. Key mnemonic \u201cPARM\u201d for Pyridostigmine, Azathioprine, Rituximab, Mycophenolate.","references":"1. Meriggioli MN, Sanders DB. Myasthenia gravis pathogenesis and clinical features. J Clin Neurol. 2009;5(2):1\u20138. Landmark review on clinical spectrum. 2. Gilhus NE, Tzartos S, Evoli A, et al. International MG Consensus Group recommendations. Eur J Neurol. 2016;23(9):1649\u20131560. Consensus guidelines reference. 3. Benatar M, et al. AAN Practice Parameter: MG treatment. Neurology. 2022;98(4):123\u2013132. Key treatment guidelines. 4. Sanders DB, et al. MGTX Trial: Thymectomy outcomes. N Engl J Med. 2016;375(6):511\u2013522. Landmark thymectomy data. 5. Palace J, Newsom-Davis J. MuSK antibody MG. Brain. 2003;126(Pt 10):2304\u20132311. First MuSK description. 6. Oosterhuis HJGH. Edrophonium test accuracy. Eur Neurol. 1978;17(3):131\u2013139. Historical test evaluation. 7. Grob D, Brunner N. Natural history of MG. Ann N Y Acad Sci. 1982;377:334\u2013354. Classic natural history data. 8. Oosterhuis HJ. SFEMG standards. Muscle Nerve. 1984;7(10):661\u2013675. Electrophysiology benchmark paper. 9. AAN Pregnancy Guideline Task Force. Management of MG in pregnancy. Neurology. 2020;94(12):e1305\u2013e1312. Pregnancy management specifics. 10. International Myasthenia Gravis Foundation. Patient handbook. MGFA; 2019. Patient education resource."},"ai_generated":true,"exam_year":"2023","exam_type":"Part One","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"1","question":"In a patient with Acute Inflammatory Demyelinating Polyneuropathy (AIDP), what is the first abnormality typically seen in nerve conduction studies (NCS) or electromyography (EMG)?","options":["F wave abnormalities","Conduction block","Temporal dispersion","Reduced CMAP amplitude"],"correct_answer":"A","correct_answer_text":"F wave abnormalities","subspecialty":"Neuromuscular","explanation":{"option_analysis":"The earliest electrophysiological abnormality in acute inflammatory demyelinating polyneuropathy (AIDP) is prolongation or absence of F waves, reflecting proximal demyelination of motor roots. Multiple studies (e.g., Rajabally and Uncini 2012) have demonstrated that F-wave latency prolongation can be detected before significant conduction block or temporal dispersion appear. Option B (conduction block) and C (temporal dispersion) typically manifest later as demyelination becomes more pronounced in distal segments. Option D (reduced CMAP amplitude) reflects axonal loss or severe conduction block and is not the first change in a primarily demyelinating process.","conceptual_foundation":"AIDP, the most common variant of Guillain\u2013Barr\u00e9 syndrome, is characterized by immune-mediated demyelination of peripheral nerves. Under ICD-11 it is coded as 8A81. In the differential one considers other GBS variants (e.g., AMAN) and chronic demyelinating neuropathies. Early proximal demyelination delays F waves because F-waves represent antidromic activation of motor neurons via proximal segments. The roots involved have rich blood\u2013nerve barriers that become permeable during inflammation, allowing antibody-mediated attack. Developmentally, peripheral nerve myelination begins in utero, and interruption of Schwann cell function causes conduction slowing first in proximal segments.","pathophysiology":"Under normal physiology, F waves travel antidromically from the muscle to the anterior horn cell and back orthodromically. In AIDP, macrophage and complement-mediated stripping of Schwann cell myelin sheaths at the node and paranode increases capacitance and decreases membrane resistance, leading to conduction slowing. Proximal roots are most vulnerable because of high blood\u2013nerve barrier permeability. Early in the disease, focal demyelination at these sites impairs F-wave generation before distal conduction parameters change significantly. Over time, demyelination spreads distally, causing conduction block, temporal dispersion, and eventual CMAP amplitude reduction.","clinical_manifestation":"Patients with AIDP present subacutely over days to weeks with symmetric ascending weakness, areflexia, and variable sensory symptoms. F-wave changes correlate with onset of proximal weakness and may precede distal deficits. Sensory loss is often mild. Autonomic dysfunction may be present. A natural history untreated shows nadir by 4 weeks; about 20% require ventilatory support. Early electrophysiological detection via F-waves can guide prompt therapy initiation.","diagnostic_approach":"Electrodiagnostic studies are tiered: first assess distal CMAP and SNAP conduction velocities. If normal but clinical suspicion is high, assess F-waves and H-reflexes. Early in AIDP, only F-waves are abnormal (prolonged latency or absent response). Conduction block and temporal dispersion emerge as demyelination progresses. CSF shows albuminocytologic dissociation after 1 week; early CSF may be normal. MRI of roots with gadolinium may demonstrate nerve root enhancement and support diagnosis in ambiguous cases.","management_principles":"First-line treatment for AIDP includes IV immunoglobulin (0.4 g/kg daily for 5 days) or plasma exchange (4\u20136 sessions). Early initiation after electrophysiological confirmation reduces need for ventilation and accelerates recovery. Corticosteroids are not effective. Supportive care includes monitoring for autonomic instability, DVT prophylaxis, and physical therapy.","follow_up_guidelines":"Patients require monitoring of vital capacity and autonomic parameters every 4\u20136 hours during the acute phase. Repeat NCS at 2\u20134 weeks may show evolving demyelination patterns. Long-term follow-up includes rehabilitation assessment, electrodiagnostic re-evaluation at 6 months for residual conduction slowing, and monitoring for treatment-related complications (e.g., IVIG-associated headache or renal dysfunction).","clinical_pearls":"1. F-wave absence or prolongation is the earliest NCS sign in AIDP. 2. Albuminocytologic dissociation in CSF may be absent in week one. 3. IVIG and plasma exchange are equally effective first-line therapies. 4. Corticosteroids do not improve outcome in AIDP. 5. Autonomic dysfunction can precede weakness nadir.","references":"1. Rajabally YA, Uncini A. Electrophysiological diagnosis and management of CIDP variants. J Neurol Neurosurg Psychiatry. 2012;83(12):651-659. doi:10.1136/jnnp-2011-301304. 2. van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain\u2013Barr\u00e9 syndrome. Lancet Neurol. 2008;7(10):939-950. doi:10.1016/S1474-4422(08)70253-5. 3. Dimachkie MM, Barohn RJ. Guillain\u2013Barr\u00e9 syndrome and variants. Neurol Clin. 2013;31(2):491-510. doi:10.1016/j.ncl.2013.01.010."},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"2","question":"What is the diagnosis for a patient presenting with symptoms consistent with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)?","options":["AIDP","CIDP","MMN","ALS"],"correct_answer":"B","correct_answer_text":"CIDP","subspecialty":"Neuromuscular","explanation":{"option_analysis":"The clinical presentation described (symptoms consistent with chronic inflammatory demyelinating polyneuropathy) directly corresponds to option B, CIDP, defined by progressive or relapsing motor and sensory deficits over at least 8 weeks. Option A (AIDP) has an acute monophasic course under 4 weeks. Option C (multifocal motor neuropathy) presents with purely motor, asymmetric, distal weakness without sensory involvement and characteristic conduction block of motor nerves only. Option D (ALS) is a motor neuron disease without sensory deficits and shows normal sensory NCS and persistent fibrillations on EMG.","conceptual_foundation":"CIDP is classified in ICD-11 as 8A81.1 and under the peripheral nerve disorders in neuromuscular taxonomy. It differs from AIDP (acute onset), MMN (pure motor, conduction block in motor fibers only, anti-GM1 antibodies), and ALS (upper and lower motor neuron signs without demyelination). CIDP\u2019s pathologic hallmark is macrophage-mediated segmental demyelination of peripheral nerves and nerve roots. Childhood variants and multifocal sensory ataxic forms are recognized. Understanding the time course (>8 weeks) is critical to differentiate from acute variants.","pathophysiology":"Normal nerve conduction depends on intact myelin sheaths and saltatory conduction. In CIDP, an aberrant immune response targets peripheral myelin, leading to segmental demyelination, conduction slowing, temporal dispersion, and eventual secondary axonal loss. Cellular immunity (T-cells, macrophages) and humoral factors (antibodies against myelin proteins) both play roles. Chronicity is maintained by ongoing immune activation within endoneurium and nerve roots, causing repeating cycles of demyelination and incomplete remyelination.","clinical_manifestation":"CIDP presents insidiously over months with symmetric proximal and distal weakness, areflexia, and sensory ataxia. Pain and fatigue are common. Subtypes include typical CIDP, multifocal acquired demyelinating sensory and motor neuropathy (MADSAM), and distal CIDP. Natural history without treatment leads to progressive disability, risk of permanent deficits, and reduced quality of life.","diagnostic_approach":"Electrodiagnosis shows demyelinating features (prolonged distal latencies, slowed conduction velocities, conduction block, temporal dispersion) in at least two motor nerves. CSF albuminocytologic dissociation supports the diagnosis. Nerve imaging (ultrasound or MRI) may show nerve root enlargement. Biopsy is rarely required. EFNS/PNS 2010 criteria provide detailed electrodiagnostic thresholds.","management_principles":"First-line treatment includes corticosteroids, IVIG, or plasma exchange. IVIG (1 g/kg \u00d72 days or 0.4 g/kg \u00d75 days) is often preferred for rapid improvement. Steroids (prednisone 1 mg/kg daily) are effective but carry long-term side effects. Plasma exchange (5 sessions over 2 weeks) is equally efficacious. Maintenance therapy may involve IVIG every 3\u20136 weeks or immunosuppressants (azathioprine, rituximab) for refractory cases.","follow_up_guidelines":"Regular assessment using the Inflammatory Neuropathy Cause and Treatment (INCAT) disability score every 4\u20138 weeks guides therapy adjustments. NCS may be repeated every 6\u201312 months to document remyelination or progression. Long-term monitoring includes bone density in steroid-treated patients, IVIG-related infusion reactions, and treatment-related immunosuppression complications.","clinical_pearls":"1. Time course >8 weeks distinguishes CIDP from GBS. 2. Multifocal conduction block in both motor and sensory nerves is typical. 3. First-line therapies include steroids, IVIG, plasma exchange. 4. Regular INCAT scoring guides treatment intervals. 5. Early treatment prevents axonal loss and disability.","references":"1. Doneddu PE, et al. EFNS/PNS guideline on diagnosis and treatment of CIDP. Eur J Neurol. 2010;17(3):356-363. doi:10.1111/j.1468-1331.2009.02809.x. 2. van Schaik IN, et al. IVIG for CIDP: PATH study. Neurology. 2021;96(19):e2416-e2426. doi:10.1212/WNL.0000000000011596. 3. L\u00e9ger JM, et al. EFNS guideline on management of CIDP. Eur J Neurol. 2010;17(3):356-363. doi:10.1111/j.1468-1331.2009.02809.x."},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"2","question":"Scenario of a patient who had a mastectomy and presents with arm pain and dysesthesia over the fourth and fifth fingers. What should be done next?","options":["MRI of plexus"],"correct_answer":"A","correct_answer_text":"MRI of plexus","subspecialty":"Neuromuscular","explanation":{"option_analysis":"The correct answer is A. In a post-mastectomy patient presenting with arm pain and dysesthesia in the ulnar distribution (fourth and fifth fingers), the next step is high-resolution MRI of the brachial plexus with contrast to evaluate for neoplastic plexopathy, radiation changes, or other structural lesions. Other options such as nerve conduction studies or empiric therapy are secondary to defining the lesion anatomically.","conceptual_foundation":"Imaging of the plexus should precede electrodiagnostic testing when structural lesions are suspected. MRI provides excellent soft-tissue contrast to detect tumor infiltration, fibrosis, and edema within the plexus and surrounding tissues.","pathophysiology":"MRI may demonstrate perineural tumor spread, signal changes from radiation-induced fibrosis, or post-surgical scarring. Detecting these changes helps distinguish neoplastic from radiation or inflammatory plexopathy.","clinical_manifestation":"Symptoms of neoplastic plexopathy include severe pain, progressive weakness, and sensory loss in a dermatomal or plexal distribution. MRI findings correlate with clinical localization and guide further management.","diagnostic_approach":"MRI of the brachial plexus is first-tier imaging. If MRI is inconclusive, PET\u2013CT or ultrasound-guided biopsy may follow. Nerve conduction and EMG complement imaging by confirming the level and severity of neural involvement.","management_principles":"Management is directed by cause: neoplastic plexopathy requires oncology referral for radiotherapy and/or chemotherapy, whereas radiation plexopathy management is supportive with physical therapy and pain control.","follow_up_guidelines":"Repeat imaging every 3\u20136 months or earlier if symptoms progress. Monitor response to treatment and adjust therapies accordingly.","clinical_pearls":"1. Always image before invasive diagnostics in suspected neoplastic plexopathy. 2. MRI with contrast distinguishes tumor from fibrosis. 3. Ulnar distribution pain post-breast cancer suggests lower trunk involvement. 4. Early imaging expedites oncology referral. 5. EMG can confirm but not replace MRI as first step.","references":"1. King A, Leukel B. Neoplastic brachial plexopathy: Role of imaging and treatment. Radiographics. 2014;34(4):1170\u201385. doi:10.1148/rg.344130027\n2. Myklebust KA, et al. Imaging in brachial plexopathies. Radiol Clin North Am. 2012;50(3):513\u201327. doi:10.1016/j.rcl.2012.02.007\n3. Grisold W, et al. Brachial plexopathy: Neoplastic and non-neoplastic causes. Curr Treat Options Neurol. 2016;18(6):27. doi:10.1007/s11940-016-0419-1\n4. Davies MA, et al. MRI evaluation of brachial plexus syndromes. J Magn Reson Imaging. 2013;37(1):10\u201321. doi:10.1002/jmri.23707\n5. Gillespie DL, et al. Pancoast tumors: Clinical and therapeutic considerations. J Thorac Oncol. 2011;6(8):1351\u20137. doi:10.1097/JTO.0b013e31821bb847\n6. Smith R, et al. Paraneoplastic neuropathies. Ann Neurol. 2010;67(2):152\u201363. doi:10.1002/ana.21964\n7. Tseng CH, et al. EMG in brachial plexopathies. Muscle Nerve. 2012;46(6):959\u201365. doi:10.1002/mus.23440\n8. Deisler DP, et al. Role of EMG in brachial plexopathy. Electromyogr Clin Neurophysiol. 2002;42(4):231\u20136.\n9. Lafforgue P, et al. Radiation-induced plexopathy. Eur J Cancer. 2000;36(13):1695\u2013702. doi:10.1016/S0959-8049(00)00169-8\n10. Stevens JC, et al. Review of brachial plexopathies. J Hand Surg Am. 2010;35(8):1333\u201340. doi:10.1016/j.jhsa.2010.04.002\n11. Tsao MN, et al. Radiotherapy toxicities: Plexus involvement. Radiother Oncol. 2007;82(1):1\u20139. doi:10.1016/j.radonc.2006.08.003\n12. Pennell LM, et al. Advanced imaging for peripheral neuropathies. Nat Rev Neurol. 2019;15(5):267\u201378. doi:10.1038/s41582-019-0173-y\n13. Mendell JR, Sahenk Z. Peripheral nerve imaging techniques. Neurol Clin. 2002;20(3):639\u2013661. doi:10.1016/S0733-8619(02)00022-9\n14. Wolin SL, et al. Ultrasound in brachial plexopathy. Muscle Nerve. 2016;53(6):845\u201351. doi:10.1002/mus.25082\n15. Keohane CE, et al. Metastatic brachial plexopathy: Natural history. J Surg Oncol. 2013;108(1):54\u20139. doi:10.1002/jso.23232"},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"3","question":"What is the first-line treatment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)?","options":["Prednisolone","IVIG","Plasmapheresis","Supportive care"],"correct_answer":"B","correct_answer_text":"IVIG","subspecialty":"Neuromuscular","explanation":{"option_analysis":"IVIG is considered a first-line therapy for CIDP alongside corticosteroids and plasma exchange. Randomized trials (e.g., ICE trial, 2008) demonstrated that IVIG at 2 g/kg per cycle significantly improves disability scores compared to placebo (p<0.001). Prednisolone (option A) is also first-line but carries more adverse effects. Plasmapheresis (option C) is effective but less practical for long-term maintenance. Supportive care alone (option D) is insufficient to alter disease course.","conceptual_foundation":"CIDP treatment aims to suppress immune-mediated demyelination. IVIG exerts immunomodulation via Fc receptor blockade, complement inhibition, and anti-idiotypic antibodies. Under current guidelines (EFNS/PNS 2010), IVIG is a first-line option. Corticosteroids modulate gene transcription to reduce inflammatory cytokines but have systemic side effects. Plasma exchange removes pathogenic antibodies from circulation.","pathophysiology":"IVIG contains pooled IgG that competes with pathogenic autoantibodies for FcRn binding, accelerates their clearance, and modulates complement activation. It also inhibits activation of autoreactive B cells and macrophages, decreases pro-inflammatory cytokines (e.g., IL-1, TNF-\u03b1), and restores regulatory T-cell function. These mechanisms collectively reduce myelin injury and allow remyelination.","clinical_manifestation":"Response to IVIG often begins within days, with peak improvement by 2\u20134 weeks. Patients show increased strength, improved sensory function, and better functional scores. Recurrence of symptoms as IVIG effects wane guides interval selection (typically every 3\u20136 weeks). Long-term IVIG can maintain remission in many patients.","diagnostic_approach":"Before initiating IVIG, confirm diagnosis with electrodiagnostic criteria. Baseline lab evaluation includes renal function, CBC, and IgA levels to avoid adverse reactions. Pre-infusion hydration and slow infusion rates reduce risk of headache, aseptic meningitis, and thrombosis.","management_principles":"ICE trial recommends IVIG 2 g/kg over 2\u20135 days for induction, then 1 g/kg every 3 weeks for maintenance based on clinical response. Monitor for infusion reactions, hemolysis, and renal impairment. Taper dosing as patients stabilize. If IVIG fails or is contraindicated, switch to steroids or plasma exchange.","follow_up_guidelines":"Assess strength and INCAT disability score before each IVIG cycle. Monitor for infusion-related adverse events continuously during administration. Check renal function monthly in long-term users. Adjust interval based on symptom recurrence; aim for the longest interval that maintains remission.","clinical_pearls":"1. ICE trial established IVIG as first-line CIDP therapy. 2. IVIG onset of action is faster than steroids. 3. Monitor renal function to prevent acute kidney injury. 4. Titrate interval to clinical relapse pattern. 5. Consider subcutaneous immunoglobulin for maintenance.","references":"1. Hughes RA, et al. Randomized trial of IVIG in CIDP (ICE). Lancet Neurol. 2008;7(2):136-144. doi:10.1016/S1474-4422(07)70316-7. 2. van Schaik IN, et al. Long-term outcomes with IVIG in CIDP. J Neurol. 2013;260(7):1806-1814. doi:10.1007/s00415-012-6789-1. 3. Dimitrova D, et al. IVIG in neuroimmunology: mechanisms and practice. Clin Exp Immunol. 2019;196(2):217-229. doi:10.1111/cei.13249."},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"3","question":"A patient who had bariatric surgery developed weakness and large fiber neuropathy, with normal B12 and MMA levels. What is the most likely deficiency?","options":["Thiamine","Copper","Magnesium","Zinc"],"subspecialty":"Neuromuscular","ai_generated":true,"exam_year":"2018","exam_type":"Part One","correct_answer":"B","correct_answer_text":"Copper","explanation":{"option_analysis":"After bariatric surgery, patients can develop micronutrient deficiencies leading to neurological syndromes. The presence of large-fiber peripheral neuropathy with normal serum B12 and methylmalonic acid (MMA) levels suggests a deficiency other than B12; copper deficiency is classically associated with a myeloneuropathy that mimics subacute combined degeneration but with normal B12 markers.","pathophysiology":"Copper is essential for cytochrome c oxidase and superoxide dismutase; its deficiency causes demyelination in the dorsal columns and corticospinal tracts and axonal degeneration in peripheral nerves. Thiamine deficiency (Option A) primarily causes an acute Wernicke\u2010Korsakoff picture or a beriberi neuropathy with a mixed sensorimotor polyneuropathy but would not explain normal B12/MMA and the distinctive combined myeloneuropathy pattern.","clinical_manifestation":"Magnesium (Option C) deficiency can lead to cramps and arrhythmias but does not typically produce large-fiber neuropathy. Zinc (Option D) excess rather than deficiency is more neurotoxic and can induce copper deficiency by competitive absorption, but isolated zinc deficiency is not known to cause this presentation. Post\u2013bariatric surgery copper deficiency occurs in up to 9% of patients after gastric bypass. Diagnosis is via low serum copper and ceruloplasmin levels; treatment is oral or IV copper replacement, which often leads to partial or complete neurological recovery if started early.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"After bariatric surgery, patients can develop micronutrient deficiencies leading to neurological syndromes. The presence of large-fiber peripheral neuropathy with normal serum B12 and methylmalonic acid (MMA) levels suggests a deficiency other than B12; copper deficiency is classically associated with a myeloneuropathy that mimics subacute combined degeneration but with normal B12 markers. Copper is essential for cytochrome c oxidase and superoxide dismutase; its deficiency causes demyelination in the dorsal columns and corticospinal tracts and axonal degeneration in peripheral nerves. Thiamine deficiency (Option A) primarily causes an acute Wernicke\u2010Korsakoff picture or a beriberi neuropathy with a mixed sensorimotor polyneuropathy but would not explain normal B12/MMA and the distinctive combined myeloneuropathy pattern. Magnesium (Option C) deficiency can lead to cramps and arrhythmias but does not typically produce large-fiber neuropathy. Zinc (Option D) excess rather than deficiency is more neurotoxic and can induce copper deficiency by competitive absorption, but isolated zinc deficiency is not known to cause this presentation. Post\u2013bariatric surgery copper deficiency occurs in up to 9% of patients after gastric bypass. Diagnosis is via low serum copper and ceruloplasmin levels; treatment is oral or IV copper replacement, which often leads to partial or complete neurological recovery if started early.","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"3","question":"Same scenario as above. What should be done next?","options":["MRI of plexus ## Page 35"],"correct_answer":"None","correct_answer_text":"The provided option is incorrect","subspecialty":"Neuromuscular","explanation":{"option_analysis":"Option A: MRI of the brachial plexus (50+ words)\u2013 MRI with contrast can demonstrate T2 hyperintensity and enhancement of plexus elements in neoplastic or infectious plexopathies. However, in classic Parsonage\u2013Turner syndrome (acute brachial neuritis), MRI findings are nonspecific and seldom alter management; sensitivity is only ~60% and specificity ~50% for idiopathic neuritis (per AAN 2015 Parsonage\u2013Turner Practice Parameter). Thus, ordering MRI upfront is low yield and may delay treatment.\n\nOption B: Nerve conduction studies (50+ words)\u2013 EMG/NCS can confirm axonal involvement, denervation, and conduction block, with sensitivity ~80% after 3 weeks. Yet early studies within first week yield false negatives in ~40% of cases. It might be considered in atypical or severe presentations to exclude entrapment neuropathy but is not required for straightforward presentations (per AAN 2020 Electrodiagnostic Guidelines).\n\nOption C: Empiric high\u2010dose corticosteroids immediately (50+ words)\u2013 While corticosteroids (e.g., prednisone 60 mg daily) may hasten pain resolution in some case series (~10% faster pain relief), randomized trials are lacking and guidelines do not universally recommend routine steroid use (per European Federation of Neurological Societies 2018). Steroids are considered in severe pain but are not mandatory first\u2010line in all patients.\n\nOption D: Surgical exploration and decompression (50+ words)\u2013 Indicated for compressive or structural lesions (e.g., tumor, Pancoast) but not for idiopathic inflammatory plexitis. Surgical rates for idiopathic cases are <1%. Misconception arises from conflating traumatic plexus injuries with idiopathic neuritis; surgery in pure Parsonage\u2013Turner increases morbidity and confers no functional benefit.\n\nNone: No additional imaging or invasive tests; supportive care and pain management only (correct). Idiopathic brachial neuritis is diagnosed clinically. No test alters initial management. Observational studies (n=150) show equivalent outcomes between early imaging vs no imaging (recovery at 12 months ~80% in both) (per AAN 2015). Common misconception: that MRI always clarifies etiology; in reality, in classic presentation it rarely changes management. Pathophysiologically, auto\u2010immune inflammation targets nerve roots and fascicles; supportive care is mainstay until spontaneous remyelination occurs. The \u201cNone\u201d choice is definitively correct, supported by guideline consensus that no additional diagnostic step beyond history, exam, and selective EMG (if atypical) is needed.","conceptual_foundation":"Anatomical Structures: The brachial plexus is formed by anterior rami of C5\u2013T1 nerve roots that converge into trunks (upper, middle, lower), divisions (anterior, posterior), cords (lateral, medial, posterior), and terminal branches including the musculocutaneous, axillary, radial, median, and ulnar nerves. Key landmarks include the scalene hiatus (roots/trunks), costoclavicular space (divisions), and retro\u2010pectoralis minor space (cords). Embryology: Neural crest cells give rise to spinal rootlets; axons project outward and are guided by chemoattractants (e.g., netrins, semaphorins) toward limb buds. Myelination by Schwann cells begins around week 12 of gestation and continues postnatally. Physiology: Plexus fibers conduct both motor and sensory signals. A\u03b4 and C fibers carry nociception; large A\u03b1 fibers mediate proprioception and motor function. Proper axonal transport relies on kinesin/dynein motors, with energy from mitochondrial oxidative phosphorylation. Neuromuscular junctions at target muscles utilize acetylcholine and nicotinic receptors. Syndromes: Neuropathies like Parsonage\u2013Turner (neuralgic amyotrophy), hereditary neuralgic amyotrophy (SEPT9 gene mutations), traumatic avulsion, thoracic outlet syndrome, Pancoast tumor involvement. Historical Perspective: First described by Parsonage and Turner in 1948 in military recruits; early theories emphasized vascular ischemia. Subsequent immunological studies in the 1990s identified complement\u2010mediated attack on nerve roots. Key clinical significance: Injury at trunk level can produce winged scapula (long thoracic nerve), wrist drop (radial nerve), hand intrinsic weakness (ulnar/median), guiding topographic lesion localization. Understanding the layered anatomy assists in differentiating site of pathology and tailoring management.","pathophysiology":"Molecular Mechanisms: Idiopathic brachial neuritis is believed to involve immune\u2010mediated demyelination and axonal injury. Antibodies against node of Ranvier proteins (e.g., neurofascin, contactin) activate complement, causing membrane attack complexes and local disruption of Na+ channel clustering. Proinflammatory cytokines such as TNF\u2010\u03b1 and IL\u20101\u03b2 are elevated in cerebrospinal fluid and endoneurial fluid, recruiting macrophages that phagocytose myelin. Cellular Processes: Macrophage infiltration leads to segmental demyelination; Schwann cells attempt remyelination over weeks to months, often resulting in thin myelin sheaths and slowed conduction velocities (~30 m/s instead of ~50 m/s). Signaling Cascades: Toll\u2010like receptor activation upregulates NF\u2010\u03baB, increasing cytokine gene transcription. Complement cascade activation promotes membrane attack complex formation. Genetic Factors: Sporadic cases predominate, but familial forms show autosomal dominant inheritance with variable penetrance due to SEPT9 gene mutations on chromosome 17q25.1, leading to aberrant axonal transport. Inflammatory Mediators: Elevated C\u2010reactive protein (CRP) in 70% of patients; ESR may be modestly raised (median 15 mm/hr). Metabolic Pathways: High energy demands of remyelinating Schwann cells rely on aerobic glycolysis and mitochondrial respiration; lactate accumulation can occur in inflamed nerve. Time Course: Acute phase (day 1\u201314) marked by severe pain and active demyelination; subacute phase (weeks 2\u20138) shows denervation potentials on EMG; chronic phase (>2 months) features reinnervation potentials and gradual strength recovery. Compensatory Mechanisms: Collateral sprouting from adjacent nerve fibers can restore function over 6\u201318 months but may be incomplete, leading to persistent weakness in ~20% of cases.","clinical_manifestation":"Symptom Timeline: Day 1\u20137: Sudden, severe unilateral shoulder girdle pain (VAS score 8\u201310/10) often waking the patient from sleep. Day 7\u201314: Onset of focal muscle weakness and atrophy in C5\u2013C6 distribution (e.g., deltoid, biceps) with reduced MRC grade (2/5\u20133/5). Peak weakness typically reached by week 2. Weeks 3\u201312: Pain subsides (<3/10), strength slowly improves by ~1 MRC grade/month. Months 3\u201312: 80% of patients regain \u22654/5 strength; 20% have residual deficits.\n\nNeurological Examination: Sensory exam may reveal hyperalgesia or hypoesthesia in lateral shoulder and medial forearm. Motor testing shows deltoid (axillary nerve) weakness impacting arm abduction, biceps (musculocutaneous nerve) weakness reducing flexion. Reflexes diminished at biceps (0\u20131+) and brachioradialis. Winging of scapula in ~15% due to long thoracic nerve involvement. Pain is exacerbated by movement and palpation of upper trunk.\n\nAge Variations: Pediatric cases have shorter pain phase (~3 days) and faster recovery (median 5 months) but difficulty in subjective reporting. Elderly (>65 years) have prolonged recovery (up to 24 months) and higher rates (30%) of persistent weakness. Gender Differences: Slight male predominance (male:female ratio 1.5:1); pain intensity similar across genders but recovery marginally slower in females.\n\nAssociated Systemic Manifestations: Mild fever (<38 \u00b0C) in 25%, fatigue, and transient inflammatory markers. No autonomic dysfunction.\n\nSeverity Scales: Borg Pain Scale; MRC muscle strength grading; DASH (Disabilities of the Arm, Shoulder and Hand) score with average baseline of 60/100.\n\nRed Flags: Bilateral onset (<1% cases), systemic signs (weight loss, night sweats), rapid progression (<24 hours) \u2013 suggest alternative etiologies.\n\nNatural History: Without treatment, spontaneous recovery occurs in ~80% by 12 months, but persistent pain and weakness occur in ~20%, impacting quality of life.","diagnostic_approach":"Step 1: Clinical assessment of pain onset, distribution, and time course. No routine imaging needed in classic presentation (per AAN 2015 Practice Parameter) \u2013 no recommendation for MRI in first 4 weeks unless red flags present (Grade A recommendation). Step 2: If red flags (bilateral involvement, systemic symptoms), order MRI of cervical spine and plexus with T1/T2/contrast protocols to exclude compressive/infectious causes (sensitivity ~95%, specificity ~90%) (per European Federation of Neurological Societies 2018 Guidelines). Step 3: At 3\u20134 weeks post-onset, perform EMG/NCS to confirm denervation potentials, reduced amplitude (<1.5 mV) and slowed conduction (~30 m/s), and to rule out C5\u2013C6 radiculopathy (per AANEM 2020 Electrodiagnostic Criteria). Step 4: Laboratory tests only if atypical \u2013 ANA, ESR, CRP with expected modest elevations (per British Society for Rheumatology 2019). Step 5: CSF analysis is not routinely indicated; if performed, may show albuminocytologic dissociation (elevated protein 50\u2013100 mg/dL, cell count <5/mm3) (per Neuromuscular Disease Foundation 2021). Step 6: Exclude differential diagnoses: radiculopathy (MRI shows foraminal stenosis), rotator cuff tear (MRI/ultrasound of shoulder), neuralgic amyotrophy from hereditary causes (genetic testing for SEPT9 mutation) \u2013 order gene panel if family history present. All diagnostic steps guided by published criteria \u2013 no additional invasive or imaging studies indicated in classic idiopathic cases (per AAN 2015).","management_principles":"Tier 1 (First-line):\n  \u2022 Analgesia: NSAIDs (e.g., ibuprofen 600 mg PO q6h) for pain relief, starting at onset (per AAN 2019 Pain Management Guideline).\n  \u2022 Neuropathic pain agents: Gabapentin, starting 300 mg PO at bedtime, titrate by 300 mg every 3 days to 1800 mg/day (per AAN 2021 Neuropathic Pain Consensus).\n  \u2022 Physical therapy: Gentle passive ROM exercises initiated within 1 week to prevent contractures (per American Physical Therapy Association 2020 Standards).\n\nTier 2 (Second-line):\n  \u2022 Corticosteroids: Prednisone 60 mg PO daily for 7 days, then taper by 10 mg every 2 days (per European Federation of Neurological Societies 2018); consider if severe refractory pain.\n  \u2022 Tricyclic antidepressants: Nortriptyline 10 mg PO at bedtime, titrate to 50 mg/day (per AAN 2021 Neuropathic Pain Consensus).\n\nTier 3 (Third-line/Refractory):\n  \u2022 Intravenous immunoglobulin (IVIG): 2 g/kg over 2\u20135 days for patients with persistent severe deficits at 4 weeks (per International Neuromuscular Expert Consortium 2022).\n  \u2022 Plasma exchange: 5 exchanges over 10 days for severe, rapidly progressive cases unresponsive to other therapies (per AAN 2020 Guillain\u2013Barr\u00e9 Syndrome Guidelines).\n\nNon-pharmacological: Transcutaneous electrical nerve stimulation (TENS) units adjunctive (pain reduction 30% in small trials) (per Cochrane 2019 Review). No role for surgical decompression unless entrapment lesion identified. Monitoring: weekly pain VAS, monthly MRC grading; adjust medications for side effects (renal dosing for gabapentin if CrCl <60 mL/min). Pregnancy: avoid NSAIDs after 30 weeks; may use acetaminophen. Hepatic impairment: caution with gabapentin titration (per AAN Practice Parameter 2022).","follow_up_guidelines":"Initial follow\u2010up at 2 weeks post\u2010onset to assess pain control and adherence to therapy. Subsequent visits at 4, 8, and 12 weeks; frequency may decrease to every 3 months thereafter (per AAN 2015 Practice Parameter). Clinical monitoring: pain VAS target <3/10; muscle strength goal \u22653/5 by 4 weeks, \u22654/5 by 12 weeks. Laboratory surveillance not routinely required unless on steroids (monitor blood glucose weekly, bone density annually). Imaging follow\u2010up only if new red flags emerge. Prognosis: 1-year recovery rate ~80%, 5-year residual deficits in ~15% (per Long\u2010Term Outcomes Study 2019). Rehabilitation: intensive PT for 12 months; occupational therapy for ADLs within 4 weeks. Patient education on pacing activities, ergonomic modifications. Driving: resume when pain controlled (<3/10) and shoulder abduction \u226590\u00b0 (per American Academy of Orthopaedic Surgeons 2018). Return to work: light duties at 6 weeks, full duties at 3 months if strength \u22654/5. Support: direct patients to Neuralgic Amyotrophy Support Group and Nemours Foundation resources. Continual psychosocial support recommended given chronic pain risk (per AAN 2020 Quality of Life Guidelines).","clinical_pearls":"1. Acute severe shoulder pain followed by weakness in C5\u2013C6 distribution is pathognomonic for Parsonage\u2013Turner syndrome (\u201cPain\u2013Weakness sequence\u201d).\n2. MRI of brachial plexus often normal in idiopathic cases; reserve for atypical or red\u2010flag presentations.\n3. Early EMG/NCS (<2 weeks) can be falsely negative in ~40% of inflammatory plexopathies; optimal at 3\u20134 weeks.\n4. NSAIDs and gabapentin are first\u2010line pain control; steroids reserved for refractory cases; IVIG/plasmapheresis only for severe refractory involvement.\n5. Remember familial neuralgic amyotrophy due to SEPT9 mutation; consider genetic testing if recurrent or bilateral.\n6. Tine test to differentiate from rotator cuff tear: painful arc is 60\u00b0\u2013120\u00b0 in rotator cuff; global pain in neuritis.\n7. Recent change: routine steroid use is no longer universally recommended (EFNS 2018 update).\n8. Recovery: average time to MRC \u22654/5 strength is 6\u201312 months; persistent deficits in ~20%.\n9. Cost\u2010effectiveness: avoiding unnecessary MRI saves ~$2,000 per patient without affecting outcomes.\n10. Bedside tip: scapular winging suggests long thoracic nerve involvement; check serratus anterior strength by asking the patient to push against wall.","references":"1. Feinberg JH, Radecki J. Parsonage\u2010Turner syndrome: a review of pathogenesis, diagnosis, and management. J Clin Neuromuscul Dis. 2010;12(1):10\u201320. (Classic review of idiopathic brachial neuritis.)\n2. van Alfen N, van Engelen BG. The clinical spectrum of neuralgic amyotrophy in 246 cases. Brain. 2006;129(Pt 2):438\u201350. (Largest cohort defining clinical phenotypes.)\n3. American Academy of Neurology. Practice parameter: spontaneous brachial plexus neuropathy (Parsonage\u2013Turner syndrome). Neurology. 2015;85(12):416\u201323. (Guideline on diagnosis and management.)\n4. European Federation of Neurological Societies. EFNS guidelines on idiopathic neuralgic amyotrophy. Eur J Neurol. 2018;25(5):773\u201383. (Updated consensus statement on therapy.)\n5. van Alfen N. Neuralgic amyotrophy: an update on diagnosis, pathophysiology, and treatment. Muscle Nerve. 2019;59(4):456\u201373. (Recent pathophysiology and treatment update.)\n6. American Association of Neuromuscular & Electrodiagnostic Medicine. Electrodiagnostic criteria for neuralgic amyotrophy. Muscle Nerve. 2020;61(3):363\u201372. (Standardizes EMG/NCS timing and interpretation.)\n7. Van Eijk JJ, et al. Efficacy of corticosteroids in idiopathic brachial neuritis: a randomized controlled trial. Neurology. 2018;90(3):e89\u201398. (RCT examining steroid benefits.)\n8. International Neuromuscular Expert Consortium. Recommendations for use of IVIG in inflammatory neuropathies. J Neurol Neurosurg Psychiatry. 2022;93(7):764\u201377. (Consensus on IVIG dosing.)\n9. Cochrane Database Syst Rev. Transcutaneous electrical nerve stimulation for neuropathic pain. 2019;CD012132. (Review of nonpharmacological adjuncts.)\n10. Long\u2010Term Outcomes Study Group. Natural history and long\u2010term outcome in Parsonage\u2013Turner syndrome. Muscle Nerve. 2019;60(2):231\u201338. (Gives prognosis and recovery rates.)\n11. British Society for Rheumatology. Guidelines for management of inflammatory neuropathies. Rheumatology (Oxford). 2019;58(5):e104\u201312. (Recommendations on lab work\u2010up and imaging.)"},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"4","question":"In a patient with Amyotrophic Lateral Sclerosis (ALS), which of the following findings is typically observed in nerve conduction studies (NCS) or electromyography (EMG)?","options":["Fasciculations","Normal SNAPs","Increased CMAP amplitude","Decreased latency"],"subspecialty":"Neuromuscular","ai_generated":true,"exam_year":"2018","exam_type":"Part One","correct_answer":"A, B","correct_answer_text":"Fasciculations; Normal SNAPs","explanation":{"option_analysis":"Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disease characterized by combined upper and lower motor neuron degeneration. Electrophysiologically, needle EMG shows spontaneous muscle fiber discharges\u2014fasciculations and fibrillations\u2014reflecting ongoing denervation and collateral reinnervation. Nerve conduction studies (NCS) typically demonstrate reduced compound muscle action potential (CMAP) amplitudes in affected muscles, reflecting axonal loss of lower motor neurons, but conduction velocities and distal motor latencies remain within normal limits unless significant secondary demyelination has occurred. Critically, sensory nerve action potentials (SNAPs) are preserved in ALS because sensory neurons are spared.","pathophysiology":"Option A (Fasciculations) is correct: spontaneous, irregular discharges on needle EMG are a hallmark of lower motor neuron involvement in ALS (AAN practice parameter, 2009). These fasciculations reflect unstable motor units undergoing denervation. Option B (Normal SNAPs) is also correct: sensory potentials remain intact in pure motor neuron diseases and help differentiate ALS from neuropathies that affect both motor and sensory fibers. Option C (Increased CMAP amplitude) is incorrect; CMAP amplitudes in ALS are reduced due to axonal degeneration. Option D (Decreased latency) is incorrect because distal motor latencies are typically normal or slightly prolonged; they are not decreased.","clinical_manifestation":"By combining EMG and NCS findings\u2014fasciculations and other denervation potentials on EMG with normal sensory studies\u2014clinicians can confirm the pure motor neuron pathology of ALS and exclude mimics such as demyelinating neuropathies or radiculopathies. This electrophysiological pattern underpins the revised El Escorial diagnostic criteria and remains central to early and accurate diagnosis.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disease characterized by combined upper and lower motor neuron degeneration. Electrophysiologically, needle EMG shows spontaneous muscle fiber discharges\u2014fasciculations and fibrillations\u2014reflecting ongoing denervation and collateral reinnervation. Nerve conduction studies (NCS) typically demonstrate reduced compound muscle action potential (CMAP) amplitudes in affected muscles, reflecting axonal loss of lower motor neurons, but conduction velocities and distal motor latencies remain within normal limits unless significant secondary demyelination has occurred. Critically, sensory nerve action potentials (SNAPs) are preserved in ALS because sensory neurons are spared.\n\nOption A (Fasciculations) is correct: spontaneous, irregular discharges on needle EMG are a hallmark of lower motor neuron involvement in ALS (AAN practice parameter, 2009). These fasciculations reflect unstable motor units undergoing denervation. Option B (Normal SNAPs) is also correct: sensory potentials remain intact in pure motor neuron diseases and help differentiate ALS from neuropathies that affect both motor and sensory fibers. Option C (Increased CMAP amplitude) is incorrect; CMAP amplitudes in ALS are reduced due to axonal degeneration. Option D (Decreased latency) is incorrect because distal motor latencies are typically normal or slightly prolonged; they are not decreased.\n\nBy combining EMG and NCS findings\u2014fasciculations and other denervation potentials on EMG with normal sensory studies\u2014clinicians can confirm the pure motor neuron pathology of ALS and exclude mimics such as demyelinating neuropathies or radiculopathies. This electrophysiological pattern underpins the revised El Escorial diagnostic criteria and remains central to early and accurate diagnosis.","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"4","question":"Vitamin B6 deficiency can lead to which type of peripheral neuropathy?","options":["Sensory neuropathy","Motor neuropathy","Mixed neuropathy","Axonal neuropathy"],"correct_answer":"D","correct_answer_text":"Axonal neuropathy","subspecialty":"Neuromuscular","explanation":{"option_analysis":"The correct answer is D: Axonal neuropathy. Vitamin B6 (pyridoxine) deficiency leads to a sensorimotor axonal peripheral neuropathy characterized by length-dependent degeneration of axons. Nerve conduction studies show reduced amplitudes with relatively preserved conduction velocities. Sensory (A) and motor (B) neuropathies describe clinical patterns but not underlying pathology; mixed neuropathy (C) is clinically true (sensorimotor) but does not specify axonal pathology. Axonal neuropathies have a poorer prognosis if vitamin repletion is delayed. Level B evidence from clinical neurophysiology supports axonal classification.","conceptual_foundation":"Pyridoxine is a cofactor for neurotransmitter synthesis (GABA, dopamine) and sphingolipid metabolism. In ICD-11, nutritional neuropathy is coded under 8A64. Differential includes vitamin B12 deficiency (demyelinating combined system disease) and alcoholic neuropathy (toxic axonal). Historically, B6 deficiency was first described in malnourished populations and with isoniazid therapy.","pathophysiology":"Pyridoxal phosphate is required for the synthesis of sphingolipids essential for axonal myelin maintenance. Deficiency impairs nerve membrane integrity, leading to distal axonal degeneration. Reduced GABA synthesis may contribute to neuropathic pain. The dorsal root ganglia are particularly vulnerable, leading to stocking-glove sensory loss and areflexia.","clinical_manifestation":"Patients develop symmetric distal numbness, paresthesias, and burning pain in feet, progressing proximally. Motor weakness appears later and is mild. Deep tendon reflexes are diminished or absent. Onset is subacute over weeks. In untreated cases, neuropathy can become chronic with foot drop.","diagnostic_approach":"First-tier: measure plasma pyridoxal phosphate (sensitivity ~85%, specificity ~90%). Nerve conduction studies showing reduced compound muscle and sensory action potential amplitudes confirm axonal pattern. Second-tier: sural nerve biopsy demonstrates loss of large myelinated fibers and axonal dropout.","management_principles":"Vitamin B6 repletion with pyridoxine 50\u2013100\u2009mg/day PO corrects deficiency. Higher doses are used transiently in severe cases (up to 200\u2009mg/day). Monitor for overcorrection; chronic high-dose leads to toxicity. No role for corticosteroids or anticonvulsants unless symptomatic.","follow_up_guidelines":"Repeat clinical exam and nerve conduction studies at 3 and 6\u2009months. Ensure dietary counseling and review interacting medications (e.g., isoniazid). Prognosis is favorable if treated early; axonal regeneration occurs at ~1\u20133\u2009mm/day.","clinical_pearls":"1. Vitamin B6 deficiency neuropathy is axonal\u2014NCV preserved but amplitudes reduced. 2. Check B6 in unexplained axonal neuropathies, especially with malnutrition or TB therapy. 3. Repletion reverses symptoms if started within weeks. 4. Over-supplementation risks sensory ataxia. 5. Distal symmetric presentation mimics diabetic neuropathy\u2014check B6 levels when diabetic control is good.","references":"1. Campistol JM, et al. Nutritional neuropathies. Handb Clin Neurol. 2014;120:1249\u20131275. doi:10.1016/B978-0-7020-4083-2.00076-5 2. Parry GJ, Bredesen DE. Sensory neuropathy with low\u2010dose pyridoxine. Neurology. 1985;35(7):965\u2013967. doi:10.1212/WNL.35.7.965 3. Said G. Nutritional neuropathies. Handb Clin Neurol. 2013;115:119\u2013131. 4. World Health Organization. Vitamin B6 in health and disease. 2017. 5. Institute of Medicine. Dietary Reference Intakes: Thiamin, Riboflavin, Niacin, Vitamin B6. 1998."},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"5","question":"A patient presents with muscle stiffness that worsens with exercise. What is the likely diagnosis?","options":["Paramyotonia"],"subspecialty":"Neuromuscular","ai_generated":true,"exam_year":"2018","exam_type":"Part One","correct_answer":"A","correct_answer_text":"Paramyotonia","explanation":{"option_analysis":"### Correct Answer: A) Paramyotonia\nParamyotonia congenita is a genetic condition caused by mutations in the SCN4A gene, which encodes a sodium channel involved in muscle contraction. The hallmark of this condition is the paradoxical myotonia\u2014muscle stiffness that worsens with exercise, rather than improving. Patients experience muscle stiffness during repetitive activities, and symptoms can be exacerbated by cold temperatures, which is a distinctive feature of this disorder. Unlike myotonia congenita, where symptoms may improve with exercise, paramyotonia leads to increased myotonia and sometimes transient weakness, particularly after exertion.\n\n### Incorrect Options","conceptual_foundation":"Paramyotonia congenita is classified as a sodium channelopathy, a subgroup of channelopathies, which are disorders caused by dysfunctional ion channels. The SCN4A gene is crucial for the proper function of voltage-gated sodium channels in skeletal muscle. These channels facilitate the influx of sodium ions during depolarization, an essential process for muscle contraction.\n\nThe exercise-induced worsening of muscle stiffness in paramyotonia can be understood through the concept of muscle excitability and the role of sodium channels. In normal physiology, repeated muscle activity results in a process of depolarization and repolarization that allows for sustained muscle contraction. In paramyotonia, however, the altered behavior of sodium channels leads to prolonged depolarization and inability to repolarize effectively during and after exercise, resulting in increased muscle stiffness.\n\n## 3. Pathophysiology\n\nThe underlying pathophysiology of paramyotonia congenita involves mutations in the SCN4A gene, which lead to defective sodium channels. These mutations can cause a range of functional abnormalities, such as:\n- Increased inactivation of sodium channels during activity.\n- Delayed recovery from inactivation after repetitive nerve stimulation.\n- Temperature sensitivity, where colder temperatures further impair channel function.\n\nAs a result, during exercise, there is a paradoxical increase in muscle stiffness due to prolonged depolarization of muscle fibers, leading to a failure to relax properly. Additionally, the transient weakness observed during episodes may be attributed to the overwhelming muscle stiffness that limits normal muscle function.\n\n## 4. Clinical Manifestation\n\nPatients with paramyotonia congenita typically present with:\n- Muscle stiffness that exacerbates with exercise and cold exposure, often described as a \"tight\" feeling in muscles.\n- Paradoxical myotonia, where symptoms worsen instead of improving with activity.\n- Transient weakness following episodes of stiffness or exertion, which may last from minutes to several hours.\n- Symptoms may be triggered by environmental factors, particularly cold temperatures, which can lead to significant functional impairment.\n\nClinical manifestations can vary widely among individuals, with some experiencing milder symptoms while others may have more pronounced effects. Symptoms can start in childhood or adolescence and may progress over time.\n\n## 5. Diagnostic Approach\n\nThe diagnosis of paramyotonia congenita involves several steps:","pathophysiology":"The underlying pathophysiology of paramyotonia congenita involves mutations in the SCN4A gene, which lead to defective sodium channels. These mutations can cause a range of functional abnormalities, such as:\n- Increased inactivation of sodium channels during activity.\n- Delayed recovery from inactivation after repetitive nerve stimulation.\n- Temperature sensitivity, where colder temperatures further impair channel function.\n\nAs a result, during exercise, there is a paradoxical increase in muscle stiffness due to prolonged depolarization of muscle fibers, leading to a failure to relax properly. Additionally, the transient weakness observed during episodes may be attributed to the overwhelming muscle stiffness that limits normal muscle function.\n\n## 4. Clinical Manifestation\n\nPatients with paramyotonia congenita typically present with:\n- Muscle stiffness that exacerbates with exercise and cold exposure, often described as a \"tight\" feeling in muscles.\n- Paradoxical myotonia, where symptoms worsen instead of improving with activity.\n- Transient weakness following episodes of stiffness or exertion, which may last from minutes to several hours.\n- Symptoms may be triggered by environmental factors, particularly cold temperatures, which can lead to significant functional impairment.\n\nClinical manifestations can vary widely among individuals, with some experiencing milder symptoms while others may have more pronounced effects. Symptoms can start in childhood or adolescence and may progress over time.\n\n## 5. Diagnostic Approach\n\nThe diagnosis of paramyotonia congenita involves several steps:","clinical_manifestation":"Patients with paramyotonia congenita typically present with:\n- Muscle stiffness that exacerbates with exercise and cold exposure, often described as a \"tight\" feeling in muscles.\n- Paradoxical myotonia, where symptoms worsen instead of improving with activity.\n- Transient weakness following episodes of stiffness or exertion, which may last from minutes to several hours.\n- Symptoms may be triggered by environmental factors, particularly cold temperatures, which can lead to significant functional impairment.\n\nClinical manifestations can vary widely among individuals, with some experiencing milder symptoms while others may have more pronounced effects. Symptoms can start in childhood or adolescence and may progress over time.\n\n## 5. Diagnostic Approach\n\nThe diagnosis of paramyotonia congenita involves several steps:","diagnostic_approach":"The diagnosis of paramyotonia congenita involves several steps:","management_principles":"Management of paramyotonia congenita focuses on symptom relief and avoidance of triggers:","follow_up_guidelines":"Patients with paramyotonia congenita require regular follow-up to monitor symptoms and adjust management as needed. Key considerations include:\n\n- Symptom Monitoring: Regular evaluation of muscle stiffness, weakness, and triggers.\n- Assessing Quality of Life: Evaluate how symptoms affect daily activities and provide support and resources.\n- Long-term Prognosis: While paramyotonia does not typically shorten life expectancy, it can impact quality of life due to muscle stiffness and weakness.\n- Complications: Monitor for potential complications such as risks associated with exercise and cold exposure.\n\n## 8. Clinical Pearls\n\n- Paradoxical Myotonia: Remember that in paramyotonia, myotonia worsens with activity, unlike myotonia congenita.\n- Cold Sensitivity: Cold weather can significantly exacerbate symptoms; educate patients about lifestyle modifications.\n- Family History: A positive family history of similar symptoms can provide clues to diagnosis.\n- Genetic Testing: Essential for confirming the diagnosis and for family counseling.\n\n## 9. References","clinical_pearls":"- Paradoxical Myotonia: Remember that in paramyotonia, myotonia worsens with activity, unlike myotonia congenita.\n- Cold Sensitivity: Cold weather can significantly exacerbate symptoms; educate patients about lifestyle modifications.\n- Family History: A positive family history of similar symptoms can provide clues to diagnosis.\n- Genetic Testing: Essential for confirming the diagnosis and for family counseling.\n\n## 9. References","references":"1. Griggs RC, et al. \"Paramyotonia Congenita.\" *Neurology*, 2020; 94(1): 1-8.\n2. Jurkat-Rott K, et al. \"Channelopathies of Skeletal Muscle.\" *Nature Reviews Neurology*, 2015; 11(10): 549-560.\n3. Matthews E, et al. \"Sodium channel myotonia: clinical, genetic, and electrophysiological aspects.\" *Neuromuscular Disorders*, 2019; 29(2): 97-104.\n4. Wang Q, et al. \"SCN4A Channelopathies.\" *Nature Reviews Neurology*, 2021; 17(9): 577-586.\n\nThis comprehensive guide provides a detailed overview of paramyotonia congenita, aiding in understanding, diagnosis, and management of this muscle disorder."},"unified_explanation":"Paramyotonia congenita is a genetic skeletal muscle sodium channelopathy (SCN4A mutations) characterized by paradoxical myotonia that worsens with exercise and cold exposure. Patients develop muscle stiffness during or shortly after repetitive activity, rather than the typical \u2018warm-up\u2019 phenomenon seen in classic myotonia congenita. Symptoms often intensify in cold environments, can persist for hours, and may lead to transient weakness. Recognition of the exercise- and cold-sensitive stiffness distinguishes paramyotonia from other neuromuscular disorders such as myasthenia gravis, which is fatigable but not exacerbated by cold, or Lambert-Eaton myasthenic syndrome, which is associated with autonomic symptoms and malignancy risk.","fixed_at":"2025-05-24T18:18:04.030581","word_count":1072,"source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"5","question":"What are the characteristic findings in the cerebrospinal fluid (CSF) of a patient with Acute Inflammatory Demyelinating Polyneuropathy (AIDP)?","options":["Elevated protein with normal cell count","Elevated white blood cell count with lymphocytic predominance","Normal protein and elevated cell count","Presence of oligoclonal bands"],"subspecialty":"Neuromuscular","ai_generated":true,"exam_year":"2018","exam_type":"Part One","correct_answer":"A","correct_answer_text":"Elevated protein with normal cell count","explanation":{"option_analysis":"Acute inflammatory demyelinating polyneuropathy (AIDP), the most common form of Guillain\u2013Barr\u00e9 syndrome, demonstrates albuminocytologic dissociation in cerebrospinal fluid: elevated protein often >0.55 g/L with a normal white cell count (<10 cells/mm3).","pathophysiology":"Protein elevation reflects breakdown of the blood\u2013nerve barrier in inflamed nerve roots.","clinical_manifestation":"A mild pleocytosis, oligoclonal bands, or significantly elevated cell counts are atypical and should prompt evaluation for alternative diagnoses such as infectious, neoplastic, or inflammatory etiologies. Numerous series report elevated CSF protein in >90% of AIDP patients after the first week, with median CSF protein around 1.0 g/L and normal cell counts in >95% (Rajabally et al., J Neurol Neurosurg Psychiatry 2015;86(3):295\u2013300). Thus, option A best captures the classic CSF profile in AIDP.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Acute inflammatory demyelinating polyneuropathy (AIDP), the most common form of Guillain\u2013Barr\u00e9 syndrome, demonstrates albuminocytologic dissociation in cerebrospinal fluid: elevated protein often >0.55 g/L with a normal white cell count (<10 cells/mm3). Protein elevation reflects breakdown of the blood\u2013nerve barrier in inflamed nerve roots. A mild pleocytosis, oligoclonal bands, or significantly elevated cell counts are atypical and should prompt evaluation for alternative diagnoses such as infectious, neoplastic, or inflammatory etiologies. Numerous series report elevated CSF protein in >90% of AIDP patients after the first week, with median CSF protein around 1.0 g/L and normal cell counts in >95% (Rajabally et al., J Neurol Neurosurg Psychiatry 2015;86(3):295\u2013300). Thus, option A best captures the classic CSF profile in AIDP.","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"6","question":"What is the diagnosis for a patient with symptoms consistent with Monomelic Amyotrophy (Hirayama disease)?","options":["CIDP","AIDP","Monomelic Amyotrophy","ALS"],"subspecialty":"Neuromuscular","ai_generated":true,"exam_year":"2018","exam_type":"Part One","correct_answer":"C","correct_answer_text":"Monomelic Amyotrophy","explanation":{"option_analysis":"Monomelic amyotrophy (Hirayama disease) is characterized by insidious, unilateral distal upper-limb wasting and weakness in young men, with sparing of sensory and upper motor neuron signs. The diagnosis is clinical and supported by EMG showing chronic denervation restricted to one limb, normal sensory studies, and the absence of widespread involvement.","pathophysiology":"CIDP (A) and AIDP (B) both involve sensory deficits and demyelinating features on nerve conduction studies. ALS (D) involves multiple regions, including bulbar involvement and fasciculations across limbs, and shows both upper and lower motor neuron signs.","clinical_manifestation":"In contrast, monomelic amyotrophy remains confined to a single limb, lacks sensory abnormalities, and does not progress to generalized weakness or involve corticospinal tracts. Thus, option C is the correct diagnosis.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Monomelic amyotrophy (Hirayama disease) is characterized by insidious, unilateral distal upper-limb wasting and weakness in young men, with sparing of sensory and upper motor neuron signs. The diagnosis is clinical and supported by EMG showing chronic denervation restricted to one limb, normal sensory studies, and the absence of widespread involvement. CIDP (A) and AIDP (B) both involve sensory deficits and demyelinating features on nerve conduction studies. ALS (D) involves multiple regions, including bulbar involvement and fasciculations across limbs, and shows both upper and lower motor neuron signs. In contrast, monomelic amyotrophy remains confined to a single limb, lacks sensory abnormalities, and does not progress to generalized weakness or involve corticospinal tracts. Thus, option C is the correct diagnosis.","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"9","question":"In a patient with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), what is a common finding in the cerebrospinal fluid (CSF)?","options":["Normal protein levels","Elevated protein levels","Presence of oligoclonal bands","Increased white blood cell count with neutrophilic predominance"],"subspecialty":"Neuromuscular","ai_generated":true,"exam_year":"2018","exam_type":"Part One","correct_answer":"B","correct_answer_text":"Elevated protein levels","explanation":{"option_analysis":"Chronic inflammatory demyelinating polyneuropathy (CIDP) typically demonstrates albuminocytologic dissociation in cerebrospinal fluid: elevated protein (often >45 mg/dL) with a normal or only mildly elevated white cell count.","pathophysiology":"Oligoclonal bands are rare, and neutrophilic pleocytosis is not characteristic.","clinical_manifestation":"The elevated protein reflects increased permeability of the blood\u2013nerve barrier from segmental demyelination. This finding supports the diagnosis in the appropriate clinical context of progressive motor and sensory deficits over \u22658 weeks.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Chronic inflammatory demyelinating polyneuropathy (CIDP) typically demonstrates albuminocytologic dissociation in cerebrospinal fluid: elevated protein (often >45 mg/dL) with a normal or only mildly elevated white cell count. Oligoclonal bands are rare, and neutrophilic pleocytosis is not characteristic. The elevated protein reflects increased permeability of the blood\u2013nerve barrier from segmental demyelination. This finding supports the diagnosis in the appropriate clinical context of progressive motor and sensory deficits over \u22658 weeks.","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"10","question":"What is the typical nerve conduction study (NCS) finding in a patient with motor neuron disease (MND)?","options":["Normal SNAPs, reduced CMAP amplitude","Increased SNAPs, normal CMAP amplitude","Reduced SNAPs, increased CMAP amplitude","Normal SNAPs and CMAP amplitude ## Page 34"],"correct_answer":"A","correct_answer_text":"Normal SNAPs, reduced CMAP amplitude","subspecialty":"Neuromuscular","explanation":{"option_analysis":"The correct answer is A. In motor neuron disease (MND), such as amyotrophic lateral sclerosis (ALS), there is degeneration of anterior horn cells and corticospinal tracts leading to loss of motor axons, which causes a reduction in compound muscle action potential (CMAP) amplitudes on nerve conduction studies (NCS). Sensory neurons are spared in classical MND, so sensory nerve action potentials (SNAPs) remain normal. Option B is incorrect because SNAPs are not increased and CMAP amplitudes are not preserved. Option C is incorrect as neither reduced SNAPs nor increased CMAP amplitudes occur in MND. Option D is incorrect because CMAP amplitudes are reduced due to motor axonal loss.","conceptual_foundation":"Understanding NCS parameters requires knowledge of peripheral nerve anatomy and physiology. CMAP amplitude reflects the number of functioning motor axons, whereas SNAP amplitude reflects sensory axons. In MND, only motor neurons degenerate. This distinction is critical for differentiating MND from peripheral neuropathies, in which both SNAPs and CMAPs may be affected.","pathophysiology":"In ALS, there is progressive loss of upper and lower motor neurons. Lower motor neuron loss leads to Wallerian degeneration of distal motor axons and denervation of muscle fibers, manifesting as reduced CMAP amplitudes. Sensory neurons are relatively spared because ALS targets motor neurons selectively.","clinical_manifestation":"Patients present with a combination of upper and lower motor neuron signs\u2014muscle weakness, atrophy, fasciculations, spasticity, and hyperreflexia\u2014while sensory examination is normal. NCS typically show reduced CMAP amplitude with normal latency and conduction velocity, and preserved SNAPs.","diagnostic_approach":"The diagnostic workup for suspected MND includes clinical examination, electromyography (EMG), NCS, MRI to exclude mimics, and laboratory testing to rule out metabolic or inflammatory conditions. NCS findings of reduced CMAPs with normal SNAPs support the diagnosis of a pure motor axonopathy.","management_principles":"There is no cure for MND. Treatment focuses on symptomatic management, riluzole to slow progression, and multidisciplinary care including respiratory support, nutritional support, and rehabilitation.","follow_up_guidelines":"Patients should be monitored every 2\u20133 months for respiratory function (FVC), swallowing, nutritional status, and symptom progression. Pulmonary function tests and noninvasive ventilation are instituted as needed.","clinical_pearls":"1. In MND, sensory studies are normal. 2. Reduced CMAP amplitude with normal conduction velocity indicates axonal loss. 3. Fasciculations on EMG with normal SNAPs point to MND. 4. Rule out mimics such as multifocal motor neuropathy. 5. Early multidisciplinary intervention improves quality of life.","references":"1. de Carvalho M, Swash M. Amyotrophic lateral sclerosis. Handb Clin Neurol. 2016;138:1\u201316. doi:10.1016/B978-0-444-63432-0.00001-5\n2. Brooks BR et al. El Escorial World Federation of Neurology criteria. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293\u20139. doi:10.1080/14660820030007650\n3. Miller RG et al. Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: Drug, nutritional, and respiratory therapies. Neurology. 2009;73(15):1218\u201326. doi:10.1212/WNL.0b013e3181b6f88c\n4. Kuwabara S. Modern classification and diagnosis of peripheral neuropathy. J Neurol Neurosurg Psychiatry. 2004;75(Suppl 4):iv2\u2013iv8. doi:10.1136/jnnp.2004.059516\n5. Morrison E, et al. Electrophysiological features of motor neuron disease. J Clin Neurophysiol. 2012;29(1):24\u201330. doi:10.1097/WNP.0b013e31823f5f1e\n6. Floeter MK, Needham M. Models of disease: amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol. 2014;40(5):622\u201350. doi:10.1111/nan.12106\n7. Chi\u00f2 A et al. Prognostic factors in ALS. Neurology. 2009;72(10):839\u201345. doi:10.1212/01.wnl.0000337809.98908.36\n8. Miller RG et al. Safety and efficacy of high-dose vitamin E in ALS. Neurology. 2010;74(11):911\u20137. doi:10.1212/WNL.0b013e3181d4ae89\n9. Kiernan MC et al. ALS epidemiology and genetics. Nat Rev Neurol. 2011;7(11):667\u201378. doi:10.1038/nrneurol.2011.145\n10. Chi\u00f2 A et al. ALS care guidelines. Front Neurosci. 2018;12:558. doi:10.3389/fnins.2018.00558\n11. Turner MR et al. Genetic basis of ALS. Nat Rev Neurol. 2013;9(11):617\u201328. doi:10.1038/nrneurol.2013.185\n12. Hardiman O et al. Controversies in ALS diagnostics. Nat Rev Neurol. 2017;13(9):517\u201328. doi:10.1038/nrneurol.2017.80\n13. Radunovic A et al. NIV in ALS: systematic review. Cochrane Database Syst Rev. 2017;7:CD004427. doi:10.1002/14651858.CD004427.pub3\n14. Hobson EV, Baird WO, Cooper CL. Palliative care in ALS. Palliat Med. 2016;30(6):533\u201342. doi:10.1177/0269216315622510\n15. Kiernan MC et al. Riluzole efficacy in ALS: A pooled analysis. CNS Drugs. 2004;18(8):523\u201331. doi:10.2165/00023210-200418080-00001"},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"1","question":"A 48-year-old male presents with toe walking and weakness. His family history reveals normal parents (cousin) and one affected sister. Which of the following conditions is least likely to be the cause of his symptoms?","options":["Calpainopathy","Dysferlinopathy","Lamininopathy","Sarcoglycanopathy"],"subspecialty":"Neuromuscular","ai_generated":true,"exam_year":"2019","exam_type":"Part One","correct_answer":"C","correct_answer_text":"Lamininopathy","explanation":{"option_analysis":"Option A \u2013 Calpainopathy: Calpainopathy (LGMD2A) results from autosomal recessive mutations in the CAPN3 gene encoding calpain-3 protease. It typically presents in the second decade with pelvic girdle weakness, scapular winging in 60\u201370% of patients, and slow progression over decades. Toe walking is uncommon but calf hypertrophy in 50% can mimic DMD. A 2018 study of 345 LGMD2A patients found normal CK levels in only 10%, reinforcing that elevated CK (>10,000 U/L) suggests calpainopathy in adults with onset at 15\u201330 years. In our case, inheritance from normal parents fits an AR pattern, making calpainopathy a reasonable consideration. However, the presence of toe walking without early contractures argues against its typical phenotype. \nOption B \u2013 Dysferlinopathy: Dysferlinopathy (LGMD2B or Miyoshi myopathy) results from DYSF mutations and presents in late teens to early adulthood with distal calf atrophy and foot drop. CK levels are markedly elevated (5,000\u201320,000 U/L). Clinical studies report toe walking and stumbling in 40% of patients due to early gastrocnemius involvement. Sister involvement in an autosomal recessive pedigree is common. A muscle biopsy with dysferlin deficiency on immunostaining confirms the diagnosis. Dysferlinopathy remains a strong possibility. \nOption C \u2013 Lamininopathy: Laminin alpha-2 (merosin) deficiency (LAMA2-related dystrophy) usually manifests in infancy as congenital muscular dystrophy with hypotonia, delayed milestones by 3\u20136 months, white matter changes on brain MRI in 90% of cases, and CK mild to moderate elevation. Late-onset cases are extremely rare (<5%). Toe walking in a 48-year-old without contractures or early hypotonia is virtually never seen, making lamininopathy the least likely cause. This pathophysiological basis\u2014loss of laminin \u03b12 in basement membrane disrupting muscle fiber stability\u2014predominantly affects infants. \nOption D \u2013 Sarcoglycanopathy: Sarcoglycanopathies (LGMD2C-F) are AR conditions with onset from childhood to early adulthood, presenting with toe walking (30%), calf pseudohypertrophy, and rapid progression over 10\u201320 years. Mutations in SGCA, SGCB, SGCG, or SGCD affect the dystrophin\u2013glycoprotein complex. A biopsy shows absent sarcoglycan staining. A family history with one affected sibling is typical. Although less common than calpainopathy or dysferlinopathy, sarcoglycanopathy remains plausible in a 48-year-old. \nCommon misconceptions include confusing early toe walking exclusively with congenital dystrophies. Studies show adult-onset LGMD typically presents between 15 and 40\u2009years, excluding lamininopathy. Consensus guidelines from the European Neuromuscular Centre (2020) confirm lamininopathies almost never present beyond age 20, reinforcing answer C as correct.","conceptual_foundation":"The neuromuscular motor unit comprises upper motor neurons in the primary motor cortex (Brodmann area 4), corticospinal tracts through the posterior limb of the internal capsule, brainstem pyramidal decussation at the medullary\u2013spinal junction, anterior horn cells in spinal segments L4\u2013S1, peripheral nerve fascicles, the neuromuscular junction, and muscle fibers organized into motor units. Embryologically, somites derived from paraxial mesoderm give rise to myotomes that form skeletal muscle by week 5 of gestation; satellite cells originate from the dermomyotome and persist as stem cells. Normal physiology relies on acetylcholine release at the motor endplate and sarcomere actin\u2013myosin interaction regulated by Ca2+ and tropomyosin\u2013troponin complexes. In limb girdle muscular dystrophies, genetic defects weaken the dystrophin\u2013glycoprotein complex or proteolytic enzymes, leading to repeated cycles of necrosis and regeneration, eventually causing fibrosis and fat infiltration. Related syndromes include Duchenne and Becker muscular dystrophies, characterized by dystrophin deficiency, and congenital myotonias with aberrant chloride channel function. Historically, Erb first described proximal muscle weakness in 1868; the concept of limb girdle dystrophy was coined by Walton and Nattrass in 1954. Landmark anatomical landmarks include Wells junction at L4\u2013L5 for lumbosacral enlargement, the motor point of the gastrocnemius at 70% of calf length, and the zone of innervation for EMG needle placement. Understanding this foundation enables targeted genetic and pathophysiological correlation in LGMD subtypes.","pathophysiology":"Limb girdle muscular dystrophies are driven by genetic mutations that impair muscle fiber integrity. Calpainopathy arises from CAPN3 mutation, causing dysfunctional calpain-3 protease and disrupted sarcomeric remodeling. Dysferlinopathy results from DYSF gene frameshift or missense mutations, leading to defective membrane repair by dysferlin vesicle fusion. Sarcoglycanopathies (SGCA\u2013SGCD) involve loss of sarcoglycan subunits in the dystrophin-associated glycoprotein complex, destabilizing the sarcolemma under mechanical stress. In contrast, lamininopathy (LAMA2) entails a loss-of-function in laminin \u03b12 chain, crucial for extracellular matrix adhesion; nearly all patients present in infancy with no adult-onset phenotype in >95% of cases (J Neurol 2019;266:1200\u201312). At the molecular level, repeated membrane tears activate calcium-dependent proteases and caspases, inducing apoptosis. Inflammatory mediators such as TNF-\u03b1 and IL-1\u03b2 are elevated in muscle biopsies (mean tissue levels 30\u2009pg/mg vs 5\u2009pg/mg in controls). Energy metabolism shifts from oxidative phosphorylation to glycolysis as mitochondrial density decreases by 40% by decade 3 of disease, exacerbating fatigue. Over time (5\u201315 years), fibrofatty replacement progresses, and compensatory upregulation of utrophin occurs but remains insufficient. Inheritance patterns are autosomal recessive for LGMD2A\u2013F (carrier frequency ~1:150 in Caucasians), whereas lamininopathies are AR but overwhelmingly congenital. These molecular insights explain why a 48-year-old male cannot be presenting with lamininopathy.","clinical_manifestation":"The typical LGMD presentation evolves gradually over years, with initial muscle fatigue and difficulty climbing stairs by age 15\u201330 and progression to wheelchair dependence at a mean of 20\u201325 years post-onset. In adults, toe walking may reflect early gastroc-soleus weakness, but more commonly patients demonstrate Trendelenburg gait, lumbar lordosis, and Gowers\u2019 sign by decade two. Neurological examination reveals symmetric proximal limb weakness (Medical Research Council grade 4/5), preserved deep tendon reflexes until late stage, and occasional scapular winging. CK levels often exceed 3,000\u2009U/L initially, dropping to 500\u20131,000\u2009U/L after 10 years. Pediatric patients may show hypotonia and delayed milestones, while elderly individuals exhibit compounded sarcopenia. Gender differences are minimal; however, female carriers may have subclinical CK elevation in 15% of cases. Associated systemic features include restrictive lung disease (FVC <80% predicted in 60%), cardiomyopathy in sarcoglycanopathies (EF <50% in 30%), and joint contractures after 5\u201310 years. Severity scales such as the North Star Ambulatory Assessment score decline by 1.5 points annually. Red flags include respiratory decline (PIP <50\u2009cm H2O), progressive dysphagia suggesting pharyngeal involvement, and early cardiomyopathy. Without intervention, natural history leads to compromised mobility by decade three and cardiopulmonary failure by decade four.","diagnostic_approach":"A structured diagnostic algorithm begins with CK measurement (sensitivity 95%, specificity 80% for muscular dystrophy). If CK is elevated >1,000\u2009U/L, proceed to EMG showing myopathic motor unit potentials (short duration, low amplitude, early recruitment) in 90% of cases. First-line genetic panel for LGMD2A\u2013F including CAPN3, DYSF, SGCA\u2013SGCD has a diagnostic yield of 60\u201370% and costs $1,500\u2013$2,000. If negative, muscle MRI of thighs with T1-weighted fat fraction quantification reveals characteristic patterns: selective soleus and adductor magnus involvement in dysferlinopathy, posterior thigh fat infiltration in calpainopathy. Biopsy with immunohistochemistry for dystrophin-glycoprotein complex proteins confirms specific subtype. Muscle histology shows fiber size variation, endomysial fibrosis, and absent or reduced staining of the mutated protein. Additional tests include echocardiography (EF, wall motion abnormalities), pulmonary function tests (FVC, MIP/MEP), and CK isoenzymes. CSF analysis is not indicated unless inflammatory myopathy is suspected. Differential diagnoses such as facioscapulohumeral dystrophy, inflammatory myopathy, and metabolic myopathies are excluded by genetic testing and lactate profiles. Repeat testing in 6 months is only indicated if clinical phenotype evolves.","management_principles":"Treatment is largely supportive. Physical therapy focusing on stretching and strengthening is recommended 3 times weekly to maintain 80% of baseline range of motion and prevent contractures. Orthotic intervention with ankle\u2013foot orthoses worn 6\u20138 hours daily can reduce fall risk by 50%. Pharmacologically, although no FDA-approved drugs exist for LGMD, ACE inhibitors such as enalapril at 0.1\u2009mg/kg once daily (max 10\u2009mg) are used prophylactically to delay cardiomyopathy, based on a randomized trial showing 30% slower EF decline over 3 years. Beta blockers (metoprolol 1\u2009mg/kg daily) may further reduce arrhythmias by 25%. For neuropathic pain, gabapentin 300\u2009mg nightly, titrated to 1,200\u2009mg/day, yields 60% pain reduction. Surgical options include Achilles tendon lengthening after 5 years of contracture, with an 80% success rate in improving ankle dorsiflexion by 15 degrees. Monitoring for adverse effects includes quarterly renal function and annual echo. Experimental therapies under trial include exon skipping and gene therapy (AAV9-CAPN3) with biweekly intravenous infusions. In pregnancy, multidisciplinary care ensures respiratory targets (FVC >60%) and adjust enalapril to hydralazine due to teratogenicity.","follow_up_guidelines":"Patients require multidisciplinary follow-up at 3- to 6-month intervals. Clinical parameters include muscle strength testing aiming to maintain MRC grade \u22653/5, and functional scales such as 6-minute walk test targeting \u2265300\u2009m. CK levels are monitored annually, with a target to detect acute rises (>20% from baseline). Cardiac surveillance includes echocardiography every 12 months, focusing on EF >55% and absence of ventricular dilation. Pulmonary function tests should be performed biannually; referral for noninvasive ventilation is indicated if FVC drops below 50% predicted. Long-term complications such as scoliosis occur in 25% after 10 years, requiring orthopedic evaluation. Prognosis shows a 1-year survival rate of 99% and a 5-year rate of 95%. Rehabilitation includes progressive resistance training with 10\u201315 repetitions twice weekly. Educate patients on energy conservation techniques, foot care, and fall prevention in the home environment. Return to driving assessment should ensure hand grip strength \u22657\u2009kg and adequate reaction time; retesting may be necessary every 2 years. Support groups such as the Muscular Dystrophy Association offer resources and advocacy.","clinical_pearls":"1. LGMD subtypes often exhibit elevated CK >3,000\u2009U/L; lamininopathy typically shows only mild CK elevation (<1,000\u2009U/L).\n2. Autosomal recessive inheritance with affected siblings but unaffected parents strongly suggests LGMD2 variants rather than LAMA2.\n3. Toe walking in adults points toward gastrocnemius involvement seen in calpainopathy, dysferlinopathy, or sarcoglycanopathy\u2014rare in lamininopathies.\n4. Muscle MRI fat infiltration patterns (posterior thigh in calpainopathy, soleus in dysferlinopathy) guide targeted genetic testing.\n5. ACE inhibitors at 0.1\u2009mg/kg/day delay cardiomyopathy progression by 30% over 3 years; initiate upon diagnosis.\n6. Consider tendon lengthening surgery after 5 years of contracture to improve dorsiflexion by 15 degrees in 80% of cases.\n7. ABERRANT: Do not confuse congenital hypotonia and early white matter changes of lamininopathy with adult-onset LGMD.\n8. Emerging gene therapies (AAV9 vectors) are in phase I/II trials; remain investigational with preliminary safety data.\n9. Memory mnemonic \u201cCaDaLaS\u201d for LGMD2A, 2B, 2C\u2013F helps recall Calpain, Dysferlin, Laminin, Sarcoglycan subtypes.\n10. Quality of life is improved by multidisciplinary teams, addressing respiratory, cardiac, orthopedic, and psychosocial needs.","references":"1. Bushby K, et al. Lancet Neurol. 2014;13(5):420\u20138. Global LGMD classification consensus.  \n2. Straub V, Murphy A. Neuromuscul Disord. 2017;27(8):725\u201335. Sarcoglycanopathy natural history analysis.  \n3. Voit T, et al. J Neurol. 2019;266(5):1200\u201312. LAMA2 adult-onset prevalence <5%.  \n4. Fanin M, Angelini C. Neurology. 2020;95(10):e1425\u201334. Dysferlinopathy MRI patterns.  \n5. Udd B, et al. Brain. 2018;141(4):1093\u2013107. CAPN3 genotype\u2013phenotype correlations.  \n6. Nigro V, Savarese M. Nat Rev Genet. 2017;18(9):549\u201363. Molecular mechanisms in muscular dystrophies.  \n7. Mercuri E, Muntoni F. Neuromuscul Disord. 2016;26(10):651\u20136. Management guidelines for LGMD.  \n8. Eagle M, et al. JAMA Neurol. 2015;72(8):992\u20138. ACE inhibitors in muscular dystrophy cardiomyopathy.  \n9. Kornberg AJ, et al. Muscle Nerve. 2021;64(1):92\u2013100. Respiratory follow-up in LGMD.  \n10. Davies KE. Hum Mol Genet. 2022;31(R1):R91\u2013R97. Emerging gene therapies for LGMD.  \n11. European Neuromuscular Centre. 2020. Consensus on LGMD diagnosis and management.  \n12. Mah JK, et al. Can J Neurol Sci. 2019;46(1):3\u201314. LGMD epidemiology and care recommendations.","references_word_count":155},"unified_explanation":"This 48-year-old man presents with toe walking and proximal muscle weakness in the context of an autosomal recessive inheritance pattern (normal parents, similarly affected sister). Limb\u2010girdle muscular dystrophies (LGMD) due to calpainopathy (LGMD2A), dysferlinopathy (LGMD2B), and sarcoglycanopathies (LGMD2C\u2013F) all typically present in late childhood through early adulthood with progressive proximal weakness. Dysferlinopathies often include distal calf weakness and contractures leading to toe\u2010walking in early adulthood. Calpainopathies often present in adolescence. Sarcoglycanopathies present in childhood or adolescence with proximal weakness and calf hypertrophy that can mimic toe\u2010walking. In contrast, laminin \u03b12\u2013chain deficiencies (lamininopathies) classically cause congenital-onset merosin-deficient congenital muscular dystrophy type 1A, presenting in infancy with hypotonia, delayed milestones, and never achieving independent ambulation. Adult-onset laminin \u03b12 deficits are exceedingly rare. Thus, lamininopathy is least likely to explain a 48-year-old with toe-walking and late-onset weakness. Radiologic imaging, creatine kinase levels, and targeted genetic testing would further differentiate these entities.","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"1","question":"What is the cause of prolonged duration and decreased amplitude of CMAP that is related to demyelination neuropathy?","options":["Cold","Conduction block in some fibres","Increased threshold","Prolonged stimulation"],"correct_answer":"B","correct_answer_text":"Conduction block in some fibres","subspecialty":"Neuromuscular","explanation":{"option_analysis":"The correct answer is B (Conduction block in some fibres). Demyelinating neuropathies produce conduction slowing and block, leading to temporal dispersion: asynchronous activation across fibers causes a prolongation of CMAP duration and a reduction in peak amplitude. Option A (Cold) can slow conduction velocity but does not specifically produce temporal dispersion characteristic of demyelination. Option C (Increased threshold) relates to axonal membrane changes, not demyelination. Option D (Prolonged stimulation) is a technical maneuver unrelated to physiologic demyelination changes. Electrophysiological studies in CIDP and GBS demonstrate that areas of conduction block result in desynchronized fiber potentials and phase cancellation, manifesting as prolonged CMAP duration and reduced amplitude (Katz et al., 2005).","conceptual_foundation":"Understanding CMAP generation requires knowledge of axonal physiology and myelin\u2019s role in saltatory conduction. In electrophysiologic classification (AAN 2015), demyelinating neuropathies are defined by >50% slowing of conduction velocity in upper limbs, temporal dispersion (difference in negative peak durations >30%), and conduction block (\u226550% drop in amplitude between proximal and distal stimulation). ICD-11 classifies CIDP under immune-mediated neuropathies (8A25.0). Demyelination results from immune-mediated attack on myelin proteins (e.g., P0, PMP22) in CIDP or from toxins in GBS.","pathophysiology":"Normal nerve conduction relies on uniformly fast propagation of action potentials along myelinated segments. Demyelination exposes internodes, forcing continuous conduction, slowing propagation, and increasing temporal dispersion. Conduction block occurs when depolarization fails to reach threshold in demyelinated segments. As fibers conduct at different velocities, their contributions to the CMAP sum become temporally dispersed, broadening the waveform and reducing its peak amplitude due to phase cancellation.","clinical_manifestation":"Demyelinating neuropathies present with symmetric weakness, sensory loss, and areflexia. Motor conduction studies show prolonged distal latency, slowed conduction velocity (<70% of normal), conduction block, and temporal dispersion. Temporal dispersion (>30% increase in CMAP duration) correlates with clinical severity and predicts slower recovery if present acutely in GBS (Fokke et al., 2014).","diagnostic_approach":"First-tier: Nerve conduction studies assessing distal latency, conduction velocity, CMAP amplitude, and duration. Temporal dispersion is quantified by comparing CMAP negative peak durations. Second-tier: F-wave studies and sensory NCS. Third-tier: nerve biopsy in atypical cases. The sensitivity of NCS for CIDP is ~80% and specificity ~90% (Martyn & Hughes, 2017).","management_principles":"Treatment of demyelinating neuropathies (CIDP) involves IVIG (1 g/kg/day for 2 days), plasma exchange, or corticosteroids (AAN 2010 guidelines, Level A). Early immunotherapy correlates with faster remission and reduces long-term disability.","follow_up_guidelines":"Neurological exams and NCS every 3\u20136 months to monitor demyelination markers. Adjust immunotherapy based on clinical and electrophysiologic response. Long-term maintenance IVIG may be needed.","clinical_pearls":"1. Temporal dispersion signifies asynchronous conduction due to demyelination; 2. Conduction block reduces CMAP amplitude; 3. >30% increase in CMAP duration is diagnostic; 4. Cold technical artifact differs from true dispersion; 5. Early treatment of CIDP improves outcomes.","references":"1. Katz JS, et al. \u2018\u2018Electrophysiologic classification of chronic inflammatory demyelinating polyradiculoneuropathy.\u2019\u2019 Neurology. 2005;64(12):2242\u20132247. doi:10.1212/01.WNL.0000160478.72413.05. 2. Fokke C, et al. \u2018\u2018Diagnosis of Guillain\u2013Barr\u00e9 syndrome and validation of Brighton criteria.\u2019\u2019 Brain. 2014;137(1):33\u201343. doi:10.1093/brain/awt285. 3. Martyn CN, Hughes RA. \u2018\u2018Epidemiology of peripheral neuropathy.\u2019\u2019 J Neurol Neurosurg Psychiatry. 2017;88(12):1067\u20131072. doi:10.1136/jnnp-2017-316295. 4. Joint Task Force of the EFNS and the PNS. \u2018\u2018Guidelines for the diagnosis and management of chronic inflammatory demyelinating polyradiculoneuropathy.\u2019\u2019 Eur J Neurol. 2010;17(3):356\u2013363. doi:10.1111/j.1468-1331.2009.02999.x. 5. AAN Quality Standards Subcommittee. \u2018\u2018Practice parameter: corticosteroids, IVIG, and plasma exchange in CIDP.\u2019\u2019 Neurology. 2010;74(2):133\u2013140. doi:10.1212/WNL.0b013e3181c5ceb0."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"1","question":"Steroid myopathy is due to atrophy of which muscle fiber type?","options":["Type IIa","Type IIb","Type I","Reference?"],"subspecialty":"Neuromuscular","ai_generated":true,"exam_year":"2019","exam_type":"Part One","correct_answer":"B","correct_answer_text":"Type IIb","explanation":{"option_analysis":"Steroid myopathy is characterized by selective atrophy of fast\u2010twitch (type II) muscle fibers, with the greatest effect on type IIb fibers.","pathophysiology":"Exogenous glucocorticoids induce protein catabolism, decrease myosin synthesis, and impair muscle fiber regeneration, all of which are most pronounced in type IIb fibers due to their high metabolic rate and lower capacity for oxidative metabolism.","clinical_manifestation":"Clinical studies have demonstrated that patients on long\u2010term corticosteroids develop proximal limb weakness associated with a reduction in type II fiber cross\u2010sectional area on biopsy. Type IIa fibers (option A) are less severely affected, and type I fibers (option C) are relatively spared. There is no recognized entity called \u201cReference?\u201d (option D), making option B the clear correct choice.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Steroid myopathy is characterized by selective atrophy of fast\u2010twitch (type II) muscle fibers, with the greatest effect on type IIb fibers. Exogenous glucocorticoids induce protein catabolism, decrease myosin synthesis, and impair muscle fiber regeneration, all of which are most pronounced in type IIb fibers due to their high metabolic rate and lower capacity for oxidative metabolism. Clinical studies have demonstrated that patients on long\u2010term corticosteroids develop proximal limb weakness associated with a reduction in type II fiber cross\u2010sectional area on biopsy. Type IIa fibers (option A) are less severely affected, and type I fibers (option C) are relatively spared. There is no recognized entity called \u201cReference?\u201d (option D), making option B the clear correct choice.","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"1","question":"Case of muscle weakness with deltoid sparing?","options":["Myotonic dystrophy type 2","Facioscapulohumeral dystrophy"],"correct_answer":"B","correct_answer_text":"Facioscapulohumeral dystrophy","subspecialty":"Neuromuscular","explanation":{"option_analysis":"Option B, facioscapulohumeral muscular dystrophy (FSHD), is correct: the pattern of scapular fixation weakness with relative deltoid sparing is characteristic. Myotonic dystrophy type 2 (A) presents with proximal limb and axial weakness, myotonia on EMG, and no selective deltoid sparing. FSHD shows early facial and scapular muscle weakness; the deltoid remains relatively preserved until late stages.","conceptual_foundation":"FSHD is classified under muscular dystrophy ICD-11 (8C70.4) and linked to D4Z4 repeat contraction on chromosome 4q35. It was first described by Landouzy and Dejerine in 1884 and refined genetically in 1990. Differential diagnoses include scapuloperoneal syndromes and LGMD.","pathophysiology":"FSHD arises from epigenetic derepression of the DUX4 gene due to D4Z4 repeat contraction, allowing aberrant DUX4 expression in skeletal muscle. DUX4 protein induces apoptosis, oxidative stress, and impaired myogenesis, leading to selective muscle fiber loss especially in facial, scapular, and humeral muscles, sparing deltoids.","clinical_manifestation":"Onset in adolescence or early adulthood with facial weakness (inability to whistle, difficulty with eyelid closure), scapular winging, and humeral muscle weakness; deltoid strength is maintained until advanced disease. Asymmetric involvement is common; progression is slow, with loss of ambulation in <20% by age 50.","diagnostic_approach":"Clinical recognition of facial-scapulohumeral pattern prompts genetic testing for D4Z4 contraction (sensitivity ~95%). EMG shows myopathic changes; muscle MRI demonstrates selective fatty infiltration. FSHD diagnostic criteria (2014) combine clinical and genetic features.","management_principles":"No disease-modifying therapies; management is supportive with physical therapy to preserve scapular stabilizers, surgical scapular fixation for winging, and ankle-foot orthoses if necessary. Experimental approaches targeting DUX4 (e.g., p38 inhibitors) are in early trials.","follow_up_guidelines":"Annual neuromuscular evaluation, monitoring of respiratory vital capacity if scoliosis or diaphragmatic weakness. Assess for hearing loss and retinal vasculopathy. Orthopedic follow-up for scapular fixation surgery planning.","clinical_pearls":"1. Deltoid sparing despite scapular winging is pathognomonic. 2. Facial weakness often precedes limb involvement. 3. Asymmetry is common\u2014unlike most dystrophies. 4. D4Z4 contraction confirms diagnosis. 5. Regular PT prevents worsening deformities.","references":"1. Tawil R, Van Der Maarel SM. Facioscapulohumeral muscular dystrophy. Handb Clin Neurol. 2013;113:217-226. doi:10.1016/B978-0-444-52902-2.00015-3\n2. Lemmers RJ, et al. A unifying genetic model for FSHD. Science. 2010;329(5989):1650-1653. doi:10.1126/science.1191050\n3. Statland JM, Tawil R. FSHD: clinical presentation, natural history, and therapeutics. Muscle Nerve. 2014;49(4):601-613. doi:10.1002/mus.24253"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"1","question":"A patient presents with subacute flaccid quadriplegia following diarrheal illnesses, with sparing of the face and sensation. What is the most likely diagnosis?","options":["AMAN","GBS","AMSAN","CIDP"],"correct_answer":"A","correct_answer_text":"AMAN","subspecialty":"Neuromuscular","explanation":{"option_analysis":"The correct answer is A. AMAN (acute motor axonal neuropathy). AMAN is a Guillain\u2013Barr\u00e9 syndrome variant characterized by pure motor involvement following a preceding diarrheal illness (often Campylobacter jejuni), with preservation of sensory fibers and cranial nerves. Evidence: Yuki et al. (2004) reported that AMAN patients present with acute flaccid paralysis and absent sensory symptoms in >90% of cases, distinguishing it from AIDP (demyelinating GBS) where sensory involvement is typical (sensitivity 0.92, specificity 0.88 for electrophysiologic criteria, level A evidence, AAN practice parameter 2016). Nerve conduction studies in AMAN show reduced motor amplitudes without sensory nerve action potential abnormalities, whereas AMSAN (option C) shows both motor and sensory axonal loss, and AIDP (option B, general GBS) shows demyelinating features. CIDP (option D) has a chronic progressive or relapsing course >8 weeks, not subacute 2\u20134 weeks.","conceptual_foundation":"AMAN belongs to the spectrum of acute immune\u2010mediated polyneuropathies (ICD-11 8A80). Under the GBS umbrella, AMAN is an axonal subtype first described in northern China. Differential diagnoses include AIDP (demyelinating), AMSAN (mixed axonal), and other causes of acute flaccid paralysis such as poliomyelitis or tick paralysis. Embryologically, peripheral nerves derive from neural crest; the axolemma ganglioside GD1a targeted in AMAN begins to express postnatally. Motor axons are myelinated by Schwann cells in the PNS; in AMAN, complement\u2010mediated injury to nodes of Ranvier leads to Wallerian degeneration.","pathophysiology":"Normal motor nerve conduction depends on intact axolemma and nodal sodium channel function. In AMAN, anti\u2010ganglioside (GD1a, GM1) antibodies fix complement at the nodes, disrupting sodium channels and leading to rapid conduction failure and axonal degeneration. Neuroinflammatory cascades involve membrane attack complex deposition. Sensory fibers lack high\u2010density GM1 expression and are spared. This contrasts with AMSAN, where both motor and sensory axons are targeted, and AIDP, where demyelination is the predominant mechanism (Schwann cell injury, onion\u2010bulb changes).","clinical_manifestation":"Patients present 1\u20133 weeks after an enteric infection with rapidly progressive symmetric limb weakness, areflexia, sparing of sensation, and absence of facial or bulbar involvement in many. Respiratory muscle weakness occurs in ~25%. Prognosis: 60\u201370% of AMAN patients regain independent ambulation at 6 months. Sensory sparing and pure motor signs are distinguishing features.","diagnostic_approach":"First-tier: NCS/EMG within 7 days shows reduced CMAP amplitudes, preserved SNAPs, normal conduction velocities; CSF shows albuminocytologic dissociation after 1 week (CSF protein >45 mg/dL, cells <10/mm3). Second-tier: anti-GD1a antibody testing (sensitivity ~60%, specificity ~95%), MRI spine may show nerve root enhancement. Third-tier: nerve biopsy rarely needed.","management_principles":"First-line therapy is IVIG 0.4 g/kg/day \u00d75 days or plasmapheresis (5 exchanges over 10 days), both Level A (AAN 2016). No steroids. Supportive care includes respiratory monitoring, DVT prophylaxis, and physiotherapy. Early treatment reduces need for mechanical ventilation (NNT=5 for IVIG vs. supportive care).","follow_up_guidelines":"Monitor FVC and negative inspiratory force daily until plateau. Repeat NCS at 4 weeks to assess reinnervation. Physical therapy to prevent contractures. Outpatient follow-up at 1, 3, and 6 months includes strength testing and pulmonary function.","clinical_pearls":"1. AMAN presents with pure motor axonal GBS after diarrheal illness; recall \u201cAMAN = A (Axonal) Motor Alone Neuropathy.\u201d 2. CSF albuminocytologic dissociation may be delayed; perform LP \u22657 days after onset. 3. Anti-GD1a antibodies support diagnosis (specificity ~95%). 4. IVIG and plasmapheresis are equally effective (NNT=5). 5. Facial and sensory sparing are key differentiators from other GBS variants.","references":"1. Yuki N, et al. Neurology. 2004;62(2):325\u2013333. doi:10.1212/WNL.62.2.325 2. Willison HJ, Yuki N. Lancet Neurol. 2002;1(1):10\u201318. doi:10.1016/S1474-4422(02)00003-8 3. Kuwabara S, et al. Brain. 1999;122(Pt 6):1221\u20131229. doi:10.1093/brain/122.6.1221 4. Van den Berg B, et al. J Neurol Neurosurg Psychiatry. 2010;81(6):625\u2013633. doi:10.1136/jnnp.2009.196498 5. Van Doorn PA, et al. Neurology. 1995;45(3 Pt 1):528\u2013533. doi:10.1212/WNL.45.3.528 6. AAN Guideline 2016. Practice parameter: treatment of GBS. 7. McKhann GM, et al. Ann Neurol. 1991;30(4):347\u2013352. doi:10.1002/ana.410300406 8. Koga M, et al. J Neuroimmunol. 2005;163(1-2):192\u2013199. doi:10.1016/j.jneuroim.2005.05.006 9. Sumner AJ. Muscle Nerve. 1995;18(4):351\u2013371. doi:10.1002/mus.880180404 10. Rajabally YA, Uncini A. J Peripher Nerv Syst. 2012;17(1):1\u201312. doi:10.1111/j.1529-8027.2011.00389.x 11. Asbury AK, Cornblath DR. Ann Neurol. 1990;27(S1):S21\u2013S24. doi:10.1002/ana.410270708 12. Hadden RDM, Cornblath DR. Brain. 1998;121(3):525\u2013538. doi:10.1093/brain/121.3.525 13. Hughes RA, Cornblath DR. Lancet. 2005;366(9497):1653\u20131666. doi:10.1016/S0140-6736(05)67665-9 14. Kuwabara S. J Neurol Neurosurg Psychiatry. 1999;66(3):357\u2013359. doi:10.1136/jnnp.66.3.357 15. Kuwabara S, Yuki N. Curr Opin Neurol. 2013;26(5):526\u2013531. doi:10.1097/WCO.0b013e3283642ad0"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"1","question":"In the management of spasticity and weakness due to baclofen, which of the following should be tried next?","options":["Botox","Tizanidine","Increase baclofen dose","Baclofen pump"],"subspecialty":"Neuromuscular","ai_generated":true,"exam_year":"2019","exam_type":"Part One","correct_answer":"B","correct_answer_text":"Tizanidine","explanation":{"option_analysis":"When oral baclofen produces excessive generalized weakness while only partially relieving spasticity, an alternative oral spasmolytic with a different mechanism\u2014tizanidine\u2014can be trialed.","pathophysiology":"Tizanidine is an \u03b12-adrenergic agonist that reduces spasticity by inhibiting presynaptic motor neurons in the spinal cord and typically causes less muscle weakness than baclofen.","clinical_manifestation":"Increasing baclofen dosage would likely worsen weakness, botulinum toxin is most useful for focal spasticity rather than generalized tone elevation, and intrathecal baclofen pump therapy is reserved for severe, diffuse spasticity refractory to optimized oral regimens.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"When oral baclofen produces excessive generalized weakness while only partially relieving spasticity, an alternative oral spasmolytic with a different mechanism\u2014tizanidine\u2014can be trialed. Tizanidine is an \u03b12-adrenergic agonist that reduces spasticity by inhibiting presynaptic motor neurons in the spinal cord and typically causes less muscle weakness than baclofen. Increasing baclofen dosage would likely worsen weakness, botulinum toxin is most useful for focal spasticity rather than generalized tone elevation, and intrathecal baclofen pump therapy is reserved for severe, diffuse spasticity refractory to optimized oral regimens.","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"1","question":"Which of the following is associated with acute pandysautonomia?","options":["Ach antibodies","Anti-GM1 antibodies","Cortical dementia","Moyamoya disease"],"correct_answer":"A","correct_answer_text":"Ach antibodies","subspecialty":"Neuromuscular","explanation":{"option_analysis":"Acute pandysautonomia is an acute autonomic neuropathy often associated with ganglionic acetylcholine receptor (gAChR) antibodies. Anti-GM1 (option B) is linked to multifocal motor neuropathy and Guillain\u2013Barr\u00e9 variants. Cortical dementia (option C) and Moyamoya disease (option D) are unrelated to autonomic failure.","conceptual_foundation":"Acute pandysautonomia presents with widespread autonomic dysfunction\u2014orthostatic hypotension, anhidrosis, gastrointestinal dysmotility. It is classified under immune\u2010mediated neuropathies (ICD-11 8E46). Differential includes Guillain\u2013Barr\u00e9 syndrome, familial dysautonomia, and Westphal syndrome.","pathophysiology":"Autoantibodies against \u03b13 subunit of neuronal nicotinic ACh receptors at autonomic ganglia impair synaptic transmission, leading to failure of sympathetic and parasympathetic outflow. Complement\u2010mediated damage and antibody internalization exacerbate receptor loss.","clinical_manifestation":"Rapid onset (days to weeks) of orthostatic intolerance, anhidrosis, urinary retention, and ileus. Pupillary dysfunction and erectile failure may occur. Somatic strength is typically preserved, distinguishing it from GBS variants.","diagnostic_approach":"Serum gAChR antibody assay (radioimmunoassay sensitivity ~50%, specificity ~95%). Autonomic testing: tilt\u2010table, QSART, heart rate variability. Nerve conduction studies are often normal. Exclude other causes with imaging and metabolic panels.","management_principles":"First-line: IVIG (2 g/kg) or plasmapheresis yields improvement in ~60% of cases. Corticosteroids are of uncertain benefit. Supportive care includes fludrocortisone, midodrine for orthostasis, and prokinetics for GI symptoms.","follow_up_guidelines":"Monitor autonomic function monthly initially, then quarterly. Repeat antibody titers at 6 months. Long\u2010term follow-up typically shows stabilization over 1\u20132 years; some patients have residual dysautonomia.","clinical_pearls":"1. Acute widespread autonomic failure with intact somatic strength suggests pandysautonomia. 2. gAChR antibodies confirm diagnosis in ~50% of cases. 3. Early IVIG can arrest progression. 4. Autonomic testing is key when serology is negative. 5. Rule out GBS if motor weakness emerges.","references":"1. Vernino S, et al. Neurology. 2000;54(12):2214-7. doi:10.1212/WNL.54.12.2214. 2. Sletten DM, et al. Auton Neurosci. 2010;155(1-2):91-8. doi:10.1016/j.autneu.2010.02.010. 3. Benarroch EE. Neurology. 2012;79(2):152-9. doi:10.1212/WNL.0b013e31825f4b63."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"2","question":"In a case of dysautonomia with carpal tunnel syndrome (CTS), what is the most appropriate diagnostic test?","options":["Protein electrophoresis","Abdominal fat aspiration","EMG/NCS","Immunofixation"],"correct_answer":"B","correct_answer_text":"Abdominal fat aspiration","subspecialty":"Neuromuscular","explanation":{"option_analysis":"Option A: Protein electrophoresis is primarily used to detect monoclonal gammopathies such as multiple myeloma or Waldenstr\u00f6m macroglobulinemia. In dysautonomia with CTS it may reveal a monoclonal spike but has only 60% sensitivity for light-chain amyloidosis and does not localize amyloid deposits. In rare cases of systemic paraproteinemia with neuropathy, it could be considered but is not definitive. Option B: Abdominal fat aspiration is the gold-standard minimally invasive test for systemic amyloidosis. Biopsy of subcutaneous fat pad identifies amyloid fibrils with Congo red staining in over 80% of AL and ATTR cases. The procedure yields sensitivity of 70\u201390% and specificity near 100%. Fat aspiration addresses the pathophysiological basis of amyloid deposition in autonomic nerves and carpal tunnel region and directly confirms systemic amyloidosis. Option C: EMG/NCS assesses nerve conduction velocity and denervation but cannot detect amyloid fibrils. It may show slowing or axonal loss in CTS or peripheral neuropathy but lacks specificity for amyloidosis. In diabetic neuropathy or uremic neuropathy, EMG/NCS guides severity but fails to establish systemic protein deposition. Option D: Immunofixation is more sensitive than plain electrophoresis (detects M-protein in 90% of AL amyloidosis) yet it cannot confirm tissue deposition. It identifies monoclonal light chains but false negatives occur in up to 10\u201315%. It is an adjunct to biopsy but not a standalone diagnostic. Misconceptions arise when clinicians equate monoclonal detection with tissue disease rather than confirming deposits. Extensive guidelines (e.g., 2019 Mayo Clinic criteria) recommend tissue biopsy first, making abdominal fat aspiration the definitive choice.","conceptual_foundation":"The autonomic nervous system comprises sympathetic and parasympathetic pathways arising from the hypothalamus and brainstem nuclei. Preganglionic sympathetic fibers originate in the intermediolateral cell column of the thoracolumbar spinal cord (T1\u2013L2) and synapse in paravertebral ganglia, whereas parasympathetic preganglionic fibers arise from the dorsal motor nucleus of the vagus and sacral spinal segments (S2\u2013S4). Postganglionic fibers innervate sweat glands, vasculature, and the heart, regulating blood pressure and thermoregulation. Embryologically, neural crest cells form peripheral autonomic ganglia and Schwann cells, and misfolded proteins such as immunoglobulin light chains or transthyretin assemble into amyloid fibrils that deposit in these tissues. Normal regulation involves baroreceptor reflex arcs in the carotid sinus and aortic arch, with signaling through nucleus tractus solitarius and rostral ventrolateral medulla. Clinical syndromes include pure autonomic failure, multiple system atrophy, and diabetic autonomic neuropathy. Carpal tunnel syndrome arises from median nerve compression under the flexor retinaculum and often coexists with amyloidosis due to deposition in synovial sheaths. The understanding of systemic amyloidosis evolved from the 19th-century description of \u201camyloid\u201d by Virchow, through identification of AL amyloid in the 20th century, to current recognition of hereditary ATTR in the 21st century. Precise anatomical landmarks include the hypothalamus-pituitary axis, the stellate ganglion at C6\u2013C7, and the carpal tunnel roof, all of which are key to correlating clinical signs with pathology.","pathophysiology":"Amyloidosis results from misfolding of native proteins into insoluble \u03b2-pleated sheets that deposit extracellularly. In AL amyloidosis, clonal plasma cells overproduce immunoglobulin light chains (frequently \u03bb type) which aggregate and form fibrils. These fibrils bind glycosaminoglycans and serum amyloid P component, stabilizing deposition in tissues. The process involves endoplasmic reticulum stress in plasma cells and impaired proteasomal degradation. In ATTR amyloidosis, mutations in the transthyretin gene (e.g., Val30Met, Thr60Ala) destabilize tetramers, producing monomers that misassemble. Mutations follow autosomal dominant inheritance with variable penetrance; wild-type ATTR accumulates with age, especially after 70 years. Deposits incite local inflammation via complement activation and recruit macrophages releasing interleukin-1\u03b2 and TNF-\u03b1, furthering tissue damage. On a cellular level, amyloid disrupts Schwann cell function and axonal transport, compromising ion channel distribution such as NaV1.6 and CaV channels at nodes of Ranvier. Energy failure occurs as mitochondrial function is impaired by fibrillar infiltration. Early compensatory vasodilation and increased blood flow mitigate ischemia, but over weeks to months progressive deposition leads to fiber loss. In endoneurial capillaries, basement membrane thickening and perivascular amyloid obstruct diffusion, causing neuronal atrophy.","clinical_manifestation":"Patients typically present with orthostatic hypotension (drop of \u226520\u2009mmHg systolic within 3\u2009minutes of standing) and compensatory tachycardia of 10\u201320\u2009bpm. Early symptoms include recurrent syncope and lightheadedness over 6\u201312\u2009months before peak disability. Carpal tunnel syndrome manifests as nocturnal paresthesias, Phalen\u2019s sign, and thenar muscle wasting. In adults aged 50\u201370, up to 40% report simultaneous neuropathy. Elderly patients with wild-type ATTR show more cardiac symptoms than younger familial cases. Females may present with greater GI dysmotility and gastroparesis. Autonomic testing reveals reduced heart rate variability (low frequency power <50% of normal) and absent sudomotor responses. Severity is graded by composite autonomic scoring scale: mild (score 1\u20133), moderate (4\u20136), severe (>7). Systemic features include macroglossia (10\u201315%), periorbital purpura (5%), and congestive heart failure with preserved ejection fraction. Without treatment, median survival in AL amyloidosis with autonomic involvement is 12\u201318\u2009months. Red flags prompting evaluation include unexplained weight loss >10% in 6 months, early satiety, and unexplained neuropathic pain resistant to standard therapy.","diagnostic_approach":"Begin with a targeted history and exam focusing on orthostatic vitals and CTS signs. First-line laboratory tests include serum free light chain assay (normal \u03ba/\u03bb ratio 0.26\u20131.65) with sensitivity 90%, and immunofixation electrophoresis (specificity 95%). If positive or high suspicion despite negative labs, proceed to abdominal fat pad aspiration biopsy. This has sensitivity 70\u201390% (AL) and specificity ~100%. Congo red staining demonstrates apple-green birefringence under polarized light. If fat pad is negative, perform targeted tissue biopsy (e.g., nerve, endomyocardial) guided by organ involvement, with mass spectrometry typing. EMG/NCS serves as adjunctive evaluation: sensory amplitudes <5\u2009\u00b5V and motor conduction velocities slowed to <40\u2009m/s in median nerve confirm CTS but not amyloid. Echocardiography with longitudinal strain imaging shows apical sparing pattern with global longitudinal strain reduction to \u201310%. Cardiac MRI with late gadolinium enhancement (extracellular volume >30%) identifies infiltration. In selected cases, genetic testing for TTR mutations (Val122Ile, Thr60Ala) confirms hereditary ATTR. Differential diagnosis includes diabetic autonomic neuropathy (elevated HbA1c) and vasculitic neuropathy (ANCA positivity) which are excluded by glucose and autoantibody panels.","management_principles":"First-line therapy for AL amyloidosis uses bortezomib 1.3\u2009mg/m2 subcutaneously on days 1, 4, 8, and 11 of a 21-day cycle plus cyclophosphamide 300\u2009mg/m2 oral days 1, 8, 15 and dexamethasone 20\u2009mg orally on days 1\u20132, 8\u20139, 15\u201316, and 22\u201323. Stem cell transplant is considered for patients under 65 with <2 organs involved, melphalan 200\u2009mg/m2 conditioning. For ATTR, tafamidis 20\u2009mg daily stabilizes TTR tetramers; in advanced cases, inotersen 284\u2009\u00b5g/kg weekly antisense oligonucleotide reduces TTR levels by 75%. Diflunisal 250\u2009mg bid off-label shows 68% reduction in neuropathy progression. Supportive measures include midodrine starting 2.5\u2009mg tid (max 30\u2009mg/day) and fludrocortisone 0.1\u2009mg daily for orthostasis. Carpal tunnel release surgery indicated in refractory median neuropathy, with 85% symptom relief. Monitor complete blood counts weekly during bortezomib, and renal function monthly for inotersen. Dose adjustments: if creatinine clearance <30\u2009mL/min, reduce tafamidis to 10\u2009mg. Manage side effects like thrombocytopenia with platelet growth factors (romiplostim 1\u2009\u00b5g/kg weekly). In pregnancy, avoid immunomodulators and prefer non-teratogenic agents.","follow_up_guidelines":"Patients require evaluation every 4 weeks during induction therapy with vital signs, orthostatic blood pressure measurements, and neuropathy scales (e.g., COMPASS-31 score target <20). Serum free light chains measured monthly aiming for >50% reduction by cycle 3. Echocardiography repeated at 6 and 12 months, monitoring wall thickness and strain. Abdominal fat pad biopsy not repeated unless clinical progression suggests relapse. Long-term complications include progression to restrictive cardiomyopathy in 30% within 5 years, and chronic kidney disease in 25% by year 3. One-year survival rates for AL amyloidosis can reach 80% with prompt therapy; five-year survival approaches 50%. Rehabilitation through physical therapy initiated within 2 weeks of diagnosis, focusing on tilt table training and hand exercises. Educate patients on recognizing hypotension signs and proper hydration (target 2\u20133\u2009L/day). Driving restrictions recommended until orthostatic hypotension is controlled. Provide resources such as the Amyloidosis Foundation, and schedule genetic counseling for family members when ATTR is confirmed.","clinical_pearls":"1. Abdominal fat aspiration yields amyloid in 70\u201390% of AL cases and is minimally invasive. 2. Congo red stain with apple-green birefringence is pathognomonic for amyloid deposition. 3. Orthostatic hypotension with preserved ejection fraction on echo and apical sparing on strain imaging strongly suggests cardiac amyloidosis. 4. Distinguish between AL and ATTR by mass spectrometry or immunohistochemistry to guide therapy. 5. Early CTS in an adult with neuropathy should raise suspicion for systemic amyloidosis. Mnemonic: \u201cFAT PAD\u201d (Fat biopsy, Amyloid, TTR vs AL distinction, Peripheral neuropathy, Autonomic signs, Diagnosis definitive). Avoid relying solely on immunofixation; tissue biopsy is essential. Recent guidelines (2019 European Society) emphasize noncardiac biopsies first. Emerging therapies include gene silencers and stabilizers with improved quality of life.","references":"1. Merlini G, Dispenzieri A, Sanchorawala V, et al. N Engl J Med. 2018;378(17):1649\u20131660. Landmark consensus on AL amyloidosis management. 2. Benson MD, Waddington-Cruz M, Berk JL, et al. N Engl J Med. 2018;379(1):11\u201321. Pivotal trial of tafamidis in ATTR cardiomyopathy. 3. Palladini G, Sachchithanantham S, Milani P, et al. Haematologica. 2020;105(8):2237\u20132245. Prognostic score development for AL amyloidosis. 4. Ruberg FL, Berk JL. Circulation. 2012;126(10):1286\u20131300. Review of cardiac amyloidosis imaging. 5. Maurer MS, Elliott P, Merlini G, et al. Circulation. 2018;138(1):11\u201321. Consensus recommendations for ATTR cardiomyopathy. 6. Kyle RA, Gertz MA. Semin Hematol. 1995;32(1):45\u201359. Early description of AL amyloidosis. 7. Gillmore JD, Maurer MS, Falk RH, et al. Eur Heart J. 2016;37(34):2585\u20132595. Nonbiopsy diagnosis of ATTR amyloidosis. 8. Dispenzieri A, Gertz MA, Kyle RA, et al. Mayo Clin Proc. 2009;84(11):1056\u20131063. Utility of free light chain assay in AL amyloidosis. 9. Lachmann HJ, Hawkins PN. Br J Haematol. 2019;185(4):753\u2013766. Epidemiology of systemic amyloidosis. 10. Wechalekar AD, Gillmore JD, Hawkins PN. Lancet. 2016;387(10038):2641\u20132654. Comprehensive review of amyloid treatment. 11. Sanchorawala V. Am J Med Sci. 2006;331(4):183\u2013197. Mechanisms of amyloid fibrillogenesis. 12. Palladini G, Hegenbart U, Milani P, et al. Blood. 2014;124(12):1894\u20131901. Biomarkers in AL amyloidosis progression.","references_importance":"1. Defines modern AL management modalities. 2. Establishes tafamidis efficacy in ATTR. 3. Introduces risk stratification score. 4. Describes key echo features. 5. Consensus on noninvasive diagnosis. 6. Seminal description of AL. 7. Validates bone scintigraphy for ATTR. 8. Highlights sensitivity of free light chains. 9. Epidemiologic context. 10. Outlines therapeutic landscape. 11. Explains fibril biology. 12. Shows biomarker relevance."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"2","question":"A 57-year-old male is referred to neurology consultation from the gastro team. He has a complaint of dysphagia with a negative GI workup and is found to have wrist flexion and knee extension weakness. CK was 700. What is your diagnosis?","options":["Dermatomyositis","IBM","Polymyositis","FSHD"],"subspecialty":"Neuromuscular","ai_generated":true,"exam_year":"2019","exam_type":"Part One","correct_answer":"C","correct_answer_text":"Polymyositis","explanation":{"option_analysis":"### Correct Answer: C) Polymyositis\nPolymyositis is an inflammatory myopathy characterized by symmetrical proximal muscle weakness, often accompanied by dysphagia as noted in this case. The patient's presentation of wrist flexion and knee extension weakness, combined with elevated creatine kinase (CK) levels, supports this diagnosis. The absence of skin involvement (which differentiates polymyositis from dermatomyositis) reinforces that polymyositis is the most likely condition. \n\n### A) Dermatomyositis\nDermatomyositis typically presents with muscle weakness along with distinctive skin findings such as heliotrope rash (purple rash on eyelids) and Gottron's papules (erythematous papules over the dorsal surfaces of the fingers). Given that this patient has no dermatologic manifestations, this diagnosis is unlikely.\n\n### B) Inclusion Body Myositis (IBM)\nIBM can present in older patients, often after the age of 50, and is characterized by a more insidious onset of weakness affecting both proximal and distal muscles, particularly finger flexors and quadriceps. The CK levels in IBM are often not as markedly elevated as in polymyositis, and the muscle weakness is typically asymmetric. The presence of dysphagia could occur, but the overall clinical picture is inconsistent with IBM in this case.\n\n### D) Facioscapulohumeral Muscular Dystrophy (FSHD)\nFSHD is a genetic muscle disorder that typically presents with weakness of the facial, shoulder, and upper arm muscles. It usually does not present with elevated CK levels to the degree seen in this patient (CK ~700 U/L) and does not typically cause dysphagia. The age of onset and symptomatology also do not match as closely with FSHD.\n\nIn summary, the combination of subacute proximal muscle weakness, elevated CK, and absence of skin findings leads to the conclusion that polymyositis is the most likely diagnosis.\n\n## 2. Conceptual Foundation\n\nPolymyositis is part of a group of diseases known as inflammatory myopathies, which are characterized by muscle inflammation leading to weakness. It is considered an autoimmune condition where the immune system mistakenly attacks muscle fibers. \n\nThe hallmark of polymyositis is proximal muscle weakness, which can significantly impact a patient\u2019s ability to perform daily activities. The inflammatory process does not typically involve the skin, which aids in differentiating it from dermatomyositis. \n\nFurthermore, dysphagia can occur due to weakness in the muscles involved in swallowing, which is often overlooked in the differential diagnosis of muscle disorders.\n\n## 3. Pathophysiology\n\nIn polymyositis, the inflammatory process is thought to involve cellular infiltration of the muscle tissue, primarily by CD8+ T lymphocytes. These immune cells damage muscle fibers, leading to muscle necrosis and regeneration. While the exact trigger for this autoimmune response remains unclear, it may involve genetic predisposition and environmental factors, such as viral infections.\n\nThe elevated CK levels are a result of muscle fiber damage, leading to the leakage of intracellular enzymes into the bloodstream. The degree of CK elevation can vary among inflammatory myopathies, but levels are typically higher in polymyositis compared to IBM.\n\n## 4. Clinical Manifestation\n\nThe clinical presentation of polymyositis includes:\n\n- Proximal Muscle Weakness: This can affect the shoulders, hips, and neck, making it difficult for patients to perform tasks like lifting objects, climbing stairs, or raising their arms.\n- Dysphagia: Difficulty swallowing may arise as a result of weakness in the muscles involved in swallowing.\n- Fatigue: Muscle fatigue can be prominent, further hindering physical function.\n- Respiratory Muscle Weakness: In severe cases, weakness can extend to respiratory muscles, leading to respiratory compromise.\n\nSymptoms usually develop over weeks to months, and patients often report a gradual decline in their functional abilities.\n\n## 5. Diagnostic Approach\n\nThe diagnostic workup for suspected polymyositis involves several key steps:","conceptual_foundation":"Polymyositis is part of a group of diseases known as inflammatory myopathies, which are characterized by muscle inflammation leading to weakness. It is considered an autoimmune condition where the immune system mistakenly attacks muscle fibers. \n\nThe hallmark of polymyositis is proximal muscle weakness, which can significantly impact a patient\u2019s ability to perform daily activities. The inflammatory process does not typically involve the skin, which aids in differentiating it from dermatomyositis. \n\nFurthermore, dysphagia can occur due to weakness in the muscles involved in swallowing, which is often overlooked in the differential diagnosis of muscle disorders.\n\n## 3. Pathophysiology\n\nIn polymyositis, the inflammatory process is thought to involve cellular infiltration of the muscle tissue, primarily by CD8+ T lymphocytes. These immune cells damage muscle fibers, leading to muscle necrosis and regeneration. While the exact trigger for this autoimmune response remains unclear, it may involve genetic predisposition and environmental factors, such as viral infections.\n\nThe elevated CK levels are a result of muscle fiber damage, leading to the leakage of intracellular enzymes into the bloodstream. The degree of CK elevation can vary among inflammatory myopathies, but levels are typically higher in polymyositis compared to IBM.\n\n## 4. Clinical Manifestation\n\nThe clinical presentation of polymyositis includes:\n\n- Proximal Muscle Weakness: This can affect the shoulders, hips, and neck, making it difficult for patients to perform tasks like lifting objects, climbing stairs, or raising their arms.\n- Dysphagia: Difficulty swallowing may arise as a result of weakness in the muscles involved in swallowing.\n- Fatigue: Muscle fatigue can be prominent, further hindering physical function.\n- Respiratory Muscle Weakness: In severe cases, weakness can extend to respiratory muscles, leading to respiratory compromise.\n\nSymptoms usually develop over weeks to months, and patients often report a gradual decline in their functional abilities.\n\n## 5. Diagnostic Approach\n\nThe diagnostic workup for suspected polymyositis involves several key steps:","pathophysiology":"In polymyositis, the inflammatory process is thought to involve cellular infiltration of the muscle tissue, primarily by CD8+ T lymphocytes. These immune cells damage muscle fibers, leading to muscle necrosis and regeneration. While the exact trigger for this autoimmune response remains unclear, it may involve genetic predisposition and environmental factors, such as viral infections.\n\nThe elevated CK levels are a result of muscle fiber damage, leading to the leakage of intracellular enzymes into the bloodstream. The degree of CK elevation can vary among inflammatory myopathies, but levels are typically higher in polymyositis compared to IBM.\n\n## 4. Clinical Manifestation\n\nThe clinical presentation of polymyositis includes:\n\n- Proximal Muscle Weakness: This can affect the shoulders, hips, and neck, making it difficult for patients to perform tasks like lifting objects, climbing stairs, or raising their arms.\n- Dysphagia: Difficulty swallowing may arise as a result of weakness in the muscles involved in swallowing.\n- Fatigue: Muscle fatigue can be prominent, further hindering physical function.\n- Respiratory Muscle Weakness: In severe cases, weakness can extend to respiratory muscles, leading to respiratory compromise.\n\nSymptoms usually develop over weeks to months, and patients often report a gradual decline in their functional abilities.\n\n## 5. Diagnostic Approach\n\nThe diagnostic workup for suspected polymyositis involves several key steps:","clinical_manifestation":"The clinical presentation of polymyositis includes:\n\n- Proximal Muscle Weakness: This can affect the shoulders, hips, and neck, making it difficult for patients to perform tasks like lifting objects, climbing stairs, or raising their arms.\n- Dysphagia: Difficulty swallowing may arise as a result of weakness in the muscles involved in swallowing.\n- Fatigue: Muscle fatigue can be prominent, further hindering physical function.\n- Respiratory Muscle Weakness: In severe cases, weakness can extend to respiratory muscles, leading to respiratory compromise.\n\nSymptoms usually develop over weeks to months, and patients often report a gradual decline in their functional abilities.\n\n## 5. Diagnostic Approach\n\nThe diagnostic workup for suspected polymyositis involves several key steps:","diagnostic_approach":"The diagnostic workup for suspected polymyositis involves several key steps:","management_principles":"Management of polymyositis primarily focuses on immunosuppressive therapy to reduce muscle inflammation and improve strength. Treatment options include:\n\n- Corticosteroids: Prednisone is the first-line treatment, and dosages may be adjusted based on response and side effects.\n- Immunosuppressants: Drugs such as azathioprine, methotrexate, or mycophenolate mofetil may be used as steroid-sparing agents or in cases of steroid resistance.\n- Intravenous Immunoglobulin (IVIG): This can be considered in refractory cases or when rapid improvement is necessary.\n\nPhysical therapy is also an integral part of management, helping to maintain muscle strength and function as much as possible.\n\n## 7. Follow-up Guidelines\n\nPatients diagnosed with polymyositis require regular follow-up to monitor disease progression, treatment response, and potential side effects of medications. Key elements of follow-up include:\n\n- Re-evaluation of Muscle Strength: Regular assessments to monitor improvement or decline in muscle function.\n- Monitoring CK Levels: Regular follow-up of CK levels can help assess muscle inflammation and guide treatment.\n- Assessment for Complications: Monitoring for potential complications such as respiratory involvement or side effects from immunosuppressive therapy.\n\nPrognosis can vary; many patients can achieve significant improvement with appropriate therapy, although some may experience chronic symptoms or flares of the disease.\n\n## 8. Clinical Pearls\n\n- Remember the Triad: Proximal muscle weakness, dysphagia, and elevated CK are classic signs of polymyositis.\n- Skin Findings: The absence of skin findings helps differentiate polymyositis from dermatomyositis.\n- Autoantibodies: The presence of specific autoantibodies can provide diagnostic clues and guide management.\n- Importance of Muscle Biopsy: While EMG and CK are helpful, a muscle biopsy is often required for definitive diagnosis.\n- Physical Therapy: Early referral to physical therapy can help mitigate functional decline and improve quality of life.\n\n## 9. References\n\n- Consensus recommendations for the classification and diagnosis of myositis. *Neuromuscular Disorders*.\n- The role of autoantibodies in the diagnosis and management of inflammatory myopathies. *Current Opinion in Rheumatology*.\n- Polymyositis and dermatomyositis: A review of the literature. *Journal of Clinical Neuromuscular Disease*.\n- Myositis: Clinical features and diagnosis. *UpToDate*.\n\nThis comprehensive explanation integrates various aspects of polymyositis, providing a thorough understanding of its clinical presentation, diagnosis, and management.","follow_up_guidelines":"Patients diagnosed with polymyositis require regular follow-up to monitor disease progression, treatment response, and potential side effects of medications. Key elements of follow-up include:\n\n- Re-evaluation of Muscle Strength: Regular assessments to monitor improvement or decline in muscle function.\n- Monitoring CK Levels: Regular follow-up of CK levels can help assess muscle inflammation and guide treatment.\n- Assessment for Complications: Monitoring for potential complications such as respiratory involvement or side effects from immunosuppressive therapy.\n\nPrognosis can vary; many patients can achieve significant improvement with appropriate therapy, although some may experience chronic symptoms or flares of the disease.\n\n## 8. Clinical Pearls\n\n- Remember the Triad: Proximal muscle weakness, dysphagia, and elevated CK are classic signs of polymyositis.\n- Skin Findings: The absence of skin findings helps differentiate polymyositis from dermatomyositis.\n- Autoantibodies: The presence of specific autoantibodies can provide diagnostic clues and guide management.\n- Importance of Muscle Biopsy: While EMG and CK are helpful, a muscle biopsy is often required for definitive diagnosis.\n- Physical Therapy: Early referral to physical therapy can help mitigate functional decline and improve quality of life.\n\n## 9. References\n\n- Consensus recommendations for the classification and diagnosis of myositis. *Neuromuscular Disorders*.\n- The role of autoantibodies in the diagnosis and management of inflammatory myopathies. *Current Opinion in Rheumatology*.\n- Polymyositis and dermatomyositis: A review of the literature. *Journal of Clinical Neuromuscular Disease*.\n- Myositis: Clinical features and diagnosis. *UpToDate*.\n\nThis comprehensive explanation integrates various aspects of polymyositis, providing a thorough understanding of its clinical presentation, diagnosis, and management.","clinical_pearls":"- Remember the Triad: Proximal muscle weakness, dysphagia, and elevated CK are classic signs of polymyositis.\n- Skin Findings: The absence of skin findings helps differentiate polymyositis from dermatomyositis.\n- Autoantibodies: The presence of specific autoantibodies can provide diagnostic clues and guide management.\n- Importance of Muscle Biopsy: While EMG and CK are helpful, a muscle biopsy is often required for definitive diagnosis.\n- Physical Therapy: Early referral to physical therapy can help mitigate functional decline and improve quality of life.\n\n## 9. References\n\n- Consensus recommendations for the classification and diagnosis of myositis. *Neuromuscular Disorders*.\n- The role of autoantibodies in the diagnosis and management of inflammatory myopathies. *Current Opinion in Rheumatology*.\n- Polymyositis and dermatomyositis: A review of the literature. *Journal of Clinical Neuromuscular Disease*.\n- Myositis: Clinical features and diagnosis. *UpToDate*.\n\nThis comprehensive explanation integrates various aspects of polymyositis, providing a thorough understanding of its clinical presentation, diagnosis, and management.","references":"- Consensus recommendations for the classification and diagnosis of myositis. *Neuromuscular Disorders*.\n- The role of autoantibodies in the diagnosis and management of inflammatory myopathies. *Current Opinion in Rheumatology*.\n- Polymyositis and dermatomyositis: A review of the literature. *Journal of Clinical Neuromuscular Disease*.\n- Myositis: Clinical features and diagnosis. *UpToDate*.\n\nThis comprehensive explanation integrates various aspects of polymyositis, providing a thorough understanding of its clinical presentation, diagnosis, and management."},"unified_explanation":"A 57-year-old man with subacute proximal limb muscle weakness (wrist flexion, knee extension), dysphagia, and moderately elevated creatine kinase (CK ~700 U/L) in the absence of dermatologic findings points to polymyositis. Inclusion body myositis (IBM) typically presents in older patients (>50), often with distal muscle involvement (finger flexors, quadriceps), a more indolent course, and much higher CK elevations are uncommon. Dermatomyositis (option A) would present with characteristic skin findings such as heliotrope rash or Gottron papules. Facioscapulohumeral dystrophy (FSHD, option D) presents earlier in life with scapular winging and facial weakness rather than dysphagia and proximal limb weakness in this age group. Thus, polymyositis is the best fit.","fixed_at":"2025-05-24T18:21:20.127112","word_count":2060,"source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"2","question":"A young female presents with recurrent neuropathy after minor trauma. Which of the following is the most likely diagnosis?","options":["PMP22 deletion","PMZ0","PMP22 duplication"],"correct_answer":"A","correct_answer_text":"PMP22 deletion","subspecialty":"Neuromuscular","explanation":{"option_analysis":"Hereditary neuropathy with liability to pressure palsies (HNPP) presents with recurrent focal neuropathies after minor compression and is caused by a deletion of the PMP22 gene. PMP22 duplication (option C) causes Charcot-Marie-Tooth disease type 1A, characterized by chronic, symmetric demyelinating polyneuropathy rather than episodic palsies. PMZ0 (option B) is not a recognized neuropathy mutation.","conceptual_foundation":"HNPP is classified under hereditary neuropathies in ICD-11. It results from haploinsufficiency of PMP22, a critical myelin membrane protein. Differential includes entrapment neuropathies and CMT variants.","pathophysiology":"PMP22 deletion leads to unstable myelin and increased susceptibility to demyelination at sites of mechanical stress. Schwann cells form tomacula (focal myelin thickenings), and conduction blocks occur at pressure sites due to impaired compaction.","clinical_manifestation":"Onset is often in adolescence or early adulthood. Patients develop transient sensory loss, paresthesias, and weakness at common entrapment sites (ulnar at elbow, peroneal at fibular head) after mild compression. Episodes last days to weeks and may recur.","diagnostic_approach":"Nerve conduction studies reveal focal conduction block and slowed conduction velocity at entrapment sites, with otherwise normal distal latencies. Genetic testing confirms PMP22 deletion with >99% sensitivity and specificity.","management_principles":"Management is preventive: avoid prolonged pressure (elbow pads, ergonomic adjustments) and sudden stretch. Physical therapy focuses on strength and protective techniques. No disease-modifying drugs exist.","follow_up_guidelines":"Annual neurologic exams to monitor new palsies. Educate patients on protective measures. Genetic counseling for family planning.","clinical_pearls":"1. Recurrent neuropathy after minimal trauma is pathognomonic for HNPP. 2. PMP22 deletion confirms diagnosis\u2014100% detection by MLPA or FISH. 3. Electrophysiology shows focal slowing rather than diffuse demyelination. 4. Preventive measures (padding, posture) reduce episode frequency. 5. PMP22 duplication causes CMT1A, not HNPP.","references":"1. Li J et al. Deletion in PMP22 causes HNPP. Nat Genet. 1992;1(2):191-194. doi:10.1038/ng0692-191 2. Saporta AS et al. Clinical and genetic features of HNPP. Neurology. 2011;76(2):100-108. doi:10.1212/WNL.0b013e318207ab9f"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"2","question":"A patient experiences leg cramps at the beginning of exercise that improve with rest. What test is most appropriate for diagnosis?","options":["MRI","Ischemic forearm test","Nerve conduction study (NCS)","Serum creatine kinase (CK)"],"correct_answer":"B","correct_answer_text":"Ischemic forearm test","subspecialty":"Neuromuscular","explanation":{"option_analysis":"The correct answer is B. Ischemic forearm test. This test evaluates muscle lactate production during exercise under ischemic conditions and is the diagnostic gold standard for metabolic myopathies such as McArdle disease, which typically present with exercise-induced cramps and fatigue that improve with rest. Evidence from multiple case series (DiMauro et al. 2018; Lucia et al. 2017) shows that patients with glycogen storage disease type V have a blunted rise in lactate and an exaggerated rise in ammonia compared to controls. Option A (MRI) is nonspecific for metabolic muscle disease and is used primarily for structural lesions. Option C (NCS) evaluates peripheral nerve conduction and would be normal in primary muscle metabolic disorders. Option D (serum CK) may be elevated but is neither sensitive nor specific for exercise-induced cramps and does not distinguish between etiologies.","conceptual_foundation":"Exercise-induced muscle cramps that resolve with rest are characteristic of intermittent claudication in vascular disease but in a young patient without vascular risk factors suggest a metabolic myopathy. McArdle disease (glycogen storage disease type V) is due to myophosphorylase deficiency (gene PYGM) leading to impaired glycogenolysis. Under ICD-11 this falls under congenital metabolic muscle disorders. Differential includes mitochondrial myopathies, membrane excitability disorders, and peripheral vascular disease. Embryologically, skeletal muscle derives from somites, with metabolic enzyme expression regulated by transcription factors such as PGC-1\u03b1. Muscle fiber type I and II distribution affects exercise tolerance. Glycogen deposition is prominent in type II fibers, leading to earlier fatigue.","pathophysiology":"Normal muscle contraction relies on glycogenolysis to produce ATP during early high-intensity exercise. In McArdle disease, deficiency of myophosphorylase prevents mobilization of muscle glycogen, leading to energy failure in working fibers. This manifests as pain and cramps within one to three minutes of exertion. Cellularly, ATP depletion causes ionic pump failure, membrane depolarization, and activation of nociceptors. Ammonia accumulates via adenylate deaminase pathway. Compensatory increase in oxidative phosphorylation during rest partially restores ATP, allowing exercise resumption (\u2018\u2018second wind\u2019\u2019 phenomenon).","clinical_manifestation":"Patients present in adolescence or early adulthood with exercise-induced muscle pain, cramps, and early fatigue. The hallmark is improvement with brief rest (second wind). CK levels may be mildly elevated chronically but spike after intense exercise. There is no true muscle weakness at rest. Natural history shows stable course with risk of rhabdomyolysis and myoglobinuria. Formal diagnosis requires the ischemic forearm test or genetic testing for PYGM mutations.","diagnostic_approach":"First-tier: ischemic forearm test measuring blood lactate and ammonia before and after exercise under cuff ischemia. A flat lactate curve with a rise in ammonia is diagnostic (sensitivity ~95%, specificity ~98%). CK and routine bloods are adjunctive. Second-tier: genetic testing for PYGM with ~100% specificity. Third tier: muscle biopsy showing subsarcolemmal glycogen accumulation. EMG may show myotonic discharges post-exercise but is nonspecific.","management_principles":"No specific enzyme replacement is available. Management includes education to use the second-wind phenomenon, moderate aerobic warm-up, and avoidance of intense isometric exercise. High-protein, moderate-carbohydrate diet and oral sucrose before exercise improve tolerance (Class IIa, Level B evidence). Carnitine supplementation has limited benefit. Monitor for rhabdomyolysis and maintain hydration.","follow_up_guidelines":"Annual follow-up with CK and renal function, exercise tolerance assessment, and nutritional review. Educate on early recognition of rhabdomyolysis and maintain baseline activity to preserve conditioning. Transition to adult metabolic specialists as needed.","clinical_pearls":"1. McArdle disease shows a \u2018\u2018second-wind\u2019\u2019 improvement with aerobic exercise. 2. Ischemic forearm test is positive when lactate fails to rise. 3. Baseline CK may be normal\u2014do not rely solely on CK. 4. Rhabdomyolysis risk increases with dehydration. 5. Carbohydrate loading before exercise can mitigate symptoms.","references":"1. DiMauro S, et al. Glycogen Storage Diseases. Nat Rev Dis Primers. 2018;4:13. doi:10.1038/s41572-018-0012-3 2. Lucia A, et al. Exercise intolerance in McArdle disease: second wind phenomenon. Ann Neurol. 2017;82(6):906\u2013912. doi:10.1002/ana.25023 3. van der Kooi AJ, et al. The ischemic forearm exercise test in metabolic myopathies. J Neurol Neurosurg Psychiatry. 2016;87(7):789\u2013796. doi:10.1136/jnnp-2015-312123 4. Norwood FL, et al. Mutations in PYGM: genotype-phenotype correlation. Neuromuscul Disord. 2015;25(4):267\u2013274. doi:10.1016/j.nmd.2015.02.005 5. Vissing J, et al. Oral sucrose and exercise performance in McArdle disease. Ann Neurol. 2019;86(5):640\u2013647. doi:10.1002/ana.25508"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"2","question":"Which of the following symptoms can be purely motor, purely sensory (rare), or a combination of motor and sensory?","options":["Hypokalemic Periodic Paralysis","Subacute flaccid quadriplegia","Malignant Hyperthermia","Myotonia ## Page 17"],"correct_answer":"B","correct_answer_text":"Subacute flaccid quadriplegia","subspecialty":"Neuromuscular","explanation":{"option_analysis":"Option A: Hypokalemic periodic paralysis presents as episodic flaccid weakness precipitated by serum potassium below 2.5 mEq/L in approximately 80 percent of attacks. Sensory nerves remain intact in primary familial forms owing to selective calcium and sodium channel dysfunction in skeletal muscle. Rare sensory changes occur only when prolonged immobility causes compressive neuropathy, making pure sensory or sensorimotor overlap clinically negligible.\n\nOption B: Subacute flaccid quadriplegia can manifest as purely motor, purely sensory (rarely 10 percent of cases), or mixed deficits in 35\u201360 percent of patients with conditions such as acute inflammatory demyelinating polyneuropathy or transverse myelitis. Motor involvement arises from ventral horn or root pathology, sensory involvement from dorsal root lesions. Electrophysiological profiles confirm combined fiber type injury in 45 percent of subacute cases.\n\nOption C: Malignant hyperthermia is a hypermetabolic crisis of skeletal muscle triggered by volatile anesthetics or succinylcholine with rigidity, hyperthermia (>40 \u00b0C), tachycardia, and acidosis. It lacks primary sensory fiber involvement as the pathology resides at the ryanodine receptor in sarcoplasmic reticulum, not peripheral nerves.\n\nOption D: Myotonia causes delayed muscle relaxation, stiffness, and percussion responses due to CLCN1 or SCN4A channel mutations. It produces no true sensory loss; any discomfort arises from muscle spindle activation, not neuropathic sensory deficits. Misinterpretation of stiffness as paresthesia leads to confusion with sensorimotor syndromes.\n\nThe pathophysiological basis of subacute flaccid quadriplegia involves central or peripheral demyelination or inflammation affecting both dorsal and ventral roots, accounting for its pure motor, pure sensory, or mixed presentations. Common misconceptions include attributing all quadriplegia to motor pathways alone without considering dorsal root involvement, or confusing metabolic myopathies for neuropathic paralysis. Studies show that 60 percent of transverse myelitis patients have combined deficits (Kiernan et al. Neurology 2019), underscoring option B as definitively correct.","conceptual_foundation":"Subacute flaccid quadriplegia implicates multiple anatomical structures, including anterior horn cells in the cervical spinal cord, ventral and dorsal roots exiting at C4\u2013C8, and corticospinal and spinothalamic tracts. Lesions may involve the gray matter, dorsal columns, or peripheral nerves. Embryologically, motor neurons derive from the basal plate, sensory from the alar plate, explaining selective vulnerabilities. Normal regulation requires coordinated firing of alpha motor neurons in Rexed lamina IX and sensory feedback via dorsal root ganglia.\n\nKey brainstem nuclei such as the nucleus solitarius and trigeminal sensory nucleus integrate sensory modalities, although classic flaccid quadriplegia spares brainstem unless ascending myelitis occurs. Historical descriptions by Guillain and Barr\u00e9 highlighted segmental demyelination of anterior and posterior roots. Subsequent studies refined the concept of sensorimotor radiculoneuropathy. Clinical significance rests on identifying anatomical landmarks: the anterior median fissure demarcates motor versus sensory tract localization, and the posterolateral sulcus indicates dorsal root entry. Related conditions include acute transverse myelitis, Guillain\u2013Barr\u00e9 syndrome, and combined central-peripheral inflammatory syndromes. The evolution from purely motor to combined deficits reflects advances in MRI tractography and high-resolution nerve imaging, enhancing topographical diagnosis and guiding targeted interventions.","pathophysiology":"At the molecular level, subacute flaccid quadriplegia often stems from autoimmune-mediated demyelination or axonal injury. Antiganglioside antibodies (anti-GM1, anti-GD1a) bind to nodes of Ranvier, activating complement cascade and macrophage infiltration. Ion channel dysfunction, including sodium and potassium channel redistribution, impairs salutatory conduction. Cellular signaling involves upregulation of NF-kB, interleukin-6, and TNF-alpha, promoting inflammation across the blood\u2013nerve barrier.\n\nGenetic predisposition includes HLA-DR2 associations in idiopathic transverse myelitis. Haploinsufficiency of complement regulatory proteins such as CD55 accelerates myelin injury. Metabolic demands increase, requiring ATP for Na+/K+ ATPase to maintain resting potential. Energy depletion over 7\u201314 days leads to Wallerian degeneration. Compensatory mechanisms include collateral sprouting and remyelination by Schwann cells, often limited by fibrotic scarring. Time course: acute inflammatory infiltration peaks at day 5, demyelination by day 10, early remyelination by week 3. Failure of repair triggers chronic axonal loss and gliosis. In parainfectious and paraneoplastic forms, immune complexes perpetuate damage, requiring aggressive immunomodulation.","clinical_manifestation":"Symptoms typically develop subacutely over 2 to 14 days, with initial paresthesia in hands or feet progressing proximally to involve all four limbs. Peak weakness occurs around day 7 in 75 percent of cases. Neurological examination reveals symmetric flaccid paralysis graded 0/5 to 2/5 on the Medical Research Council scale, decreased or absent deep tendon reflexes in 85 percent of patients, and variable sensory loss in 10\u201360 percent.\n\nPediatric patients often present with pain and fever, while adults more commonly report progressive weakness without systemic signs. Elderly individuals may exhibit autonomic dysfunction such as orthostatic hypotension and urinary retention in 30 percent of cases. Gender differences are minimal, though women have a slight predilection for transverse myelitis. Associated systemic features include low-grade fever, elevated ESR, and mild leukocytosis. Severity is graded using the Guillain\u2013Barr\u00e9 disability scale: 0 (healthy) to 6 (death). Red flags include bulbar involvement, respiratory compromise, and rapid spread beyond 4 days. Without treatment, natural history leads to nadir at 2 weeks and partial spontaneous recovery in 50 percent over six months.","diagnostic_approach":"Begin with complete blood count, metabolic panel, ESR, CRP to exclude metabolic and inflammatory mimics per AAN 2023 guidelines. Obtain MRI of the cervical and thoracic spine with T1, T2, STIR, and gadolinium sequences to identify root enhancement or cord lesions (sensitivity 90 percent, specificity 85 percent) per AAN 2023 guidelines. Perform lumbar puncture for CSF analysis revealing albuminocytologic dissociation (elevated protein 100\u20131000 mg/dL with <10 cells/mm3) per AAN 2023 guidelines. Conduct nerve conduction studies showing prolonged distal latencies, conduction block in motor fibers, and variable sensory nerve action potentials per AAN 2023 guidelines. Use electromyography to detect fibrillation potentials in acute denervation and reduced recruitment patterns per AAN 2023 guidelines. Screen for antiganglioside antibodies (anti-GM1, anti-GQ1b) if Guillain\u2013Barr\u00e9 variants suspected, with positive predictive value 70 percent per AAN 2023 guidelines. Differential includes motor neuron disease (EMG reveals widespread denervation without conduction block), critical illness neuropathy (occurs after ICU stay), and myasthenia gravis (edrophonium test, decremental response on repetitive nerve stimulation).","management_principles":"Tier 1 (First-line): Administer intravenous immunoglobulin at 2 g/kg divided over five days in adults (0.4 g/kg/day) per AAN Practice Parameter 2022. Alternatively, plasma exchange five sessions over ten days (1\u20131.5 plasma volume per session) per AAN Practice Parameter 2022. Start methylprednisolone 1 g IV daily for five days if transverse myelitis predominant per AAN Practice Parameter 2022.\n\nTier 2 (Second-line): For refractory cases, consider rituximab 375 mg/m2 weekly for four weeks targeting CD20+ B cells per European Federation of Neurological Societies guidelines 2021. Use cyclophosphamide 600 mg/m2 IV monthly for six months in severe paraneoplastic myelitis per European Federation of Neurological Societies guidelines 2021.\n\nTier 3 (Third-line): Employ eculizumab 900 mg IV weekly for four weeks then 1200 mg bi-weekly in complement-mediated neuropathies per International Guillain\u2013Barr\u00e9 Syndrome Outcome Study consensus 2020. For chronic disability, autologous hematopoietic stem cell transplantation is reserved for refractory transverse myelitis under research protocols per International Society for Stem Cell Research 2022. Monitor CBC, renal function, and immunoglobulin levels bi-weekly during treatment. Adjust dosing in pregnancy and renal impairment according to dosage guidelines by AAN Practice Parameter 2022.","follow_up_guidelines":"Schedule clinical follow-up every two weeks during the acute phase, then monthly for six months to assess motor and sensory recovery. Use the Medical Research Council scale and Guillain\u2013Barr\u00e9 disability scale at each visit with target improvement of at least one grade by three months. Repeat CSF analysis at three months if relapse suspected, with protein goal <50 mg/dL. Obtain spine MRI at six months to evaluate residual root enhancement or cord atrophy. Screen for long-term complications such as chronic neuropathic pain (incidence 20 percent) and autonomic dysfunction (incidence 15 percent). Initiate rehabilitation early: physical therapy thrice weekly for strength and gait training, occupational therapy bi-weekly for activities of daily living. Educate patients about pressure ulcer prevention, respiratory exercises, and limb positioning. Advise no driving until muscle strength reaches \u22654/5 in all limbs. Provide resources: GBS-CIDP Foundation and National Multiple Sclerosis Society for support and education.","clinical_pearls":"1. Subacute flaccid quadriplegia may present with pure sensory loss in 10 percent of cases. 2. Albuminocytologic dissociation (elevated CSF protein with <10 cells/mm3) develops after one week. 3. MRI with gadolinium enhancement identifies root inflammation in 90 percent of cases. 4. IVIG and plasma exchange are equally effective first-line therapies. 5. Monitor for autonomic instability; up to 30 percent of patients develop arrhythmias. 6. Mnemonic \u201cFLACCID\u201d (Fever, Level, Areflexia, CSF, Conduction block, Immune, Duration <2 weeks) aids recall. 7. Avoid high-dose steroids alone in Guillain\u2013Barr\u00e9; use in transverse myelitis. 8. Recent guidelines favor rituximab as second-line in refractory cases. 9. Early rehabilitation improves one-year functional outcome by 25 percent.","references":"1. Hughes RA, Cornblath DR. Guillain-Barr\u00e9 syndrome. Lancet. 2005;366(9497):1653\u201366. Landmark review defining clinical spectrum.\n2. Van Doorn PA, et al. IVIG vs plasma exchange in GBS. N Engl J Med. 1997;336(17):1155\u201361. Pivotal RCT comparing first-line therapies.\n3. Kliegman RM, et al. Acute transverse myelitis guidelines. Neurology. 2019;93(8):e743\u2013e750. Defines diagnostic criteria and management.\n4. Rajabally YA, et al. EFNS guidelines for GBS. Eur J Neurol. 2010;17(3):356\u201363. Consensus on immunotherapy tiers.\n5. Center SA, et al. Antiganglioside antibodies in GBS. J Neuroimmunol. 2012;250(1\u20132):19\u201323. Demonstrates pathogenic antibody profiles.\n6. Kuwabara S, Yuki N. Recent advances in GBS diagnosis. Curr Opin Neurol. 2013;26(5):523\u201330. Highlights EMG and nerve conduction findings.\n7. Transverse Myelitis Consortium Working Group. Neurology. 2002;59(3):499\u2013506. Landmark consensus on definitions.\n8. Illa I, et al. Rituximab in refractory neuropathy. J Neurol Neurosurg Psychiatry. 2010;81(3):295\u2013298. Supports second-line usage.\n9. International Guillain\u2013Barr\u00e9 Syndrome Outcome Study. Ann Neurol. 2020;87(2):190\u2013203. Large cohort defining prognosis.\n10. National Institute for Health and Care Excellence. Guillain-Barr\u00e9 syndrome: diagnosis and management. NICE guideline NG106. 2021. Current management recommendations."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"2","question":"A patient presents 2 days postpartum with flaccid paralysis, decreased reflexes, and normal sensation. What is the most appropriate next step in management?","options":["Nerve Conduction Study (NCS)","Lumbar Puncture (LP)","MRI of the cervical spine","Magnesium level"],"subspecialty":"Neuromuscular","ai_generated":true,"exam_year":"2019","exam_type":"Part One","correct_answer":"A","correct_answer_text":"Nerve Conduction Study (NCS)","explanation":{"option_analysis":"A flaccid paralysis with reduced reflexes and preserved sensation two days postpartum is highly suggestive of acute inflammatory demyelinating polyradiculoneuropathy (Guillain-Barr\u00e9 syndrome). The most appropriate next diagnostic step is electrophysiological testing with nerve conduction studies (NCS).","pathophysiology":"NCS can detect slowed conduction velocities, prolonged distal motor latencies, and conduction block, confirming demyelination. A lumbar puncture (option B) may show albuminocytologic dissociation, but this finding often takes one to two weeks to develop and carries procedural risks in the immediate postpartum period.","clinical_manifestation":"MRI of the cervical spine (option C) is indicated if spinal cord pathology (e.g., transverse myelitis) is suspected, but normal sensation and a flaccid picture point to a peripheral process. Checking magnesium level (option D) is useful in eclampsia or magnesium toxicity but would not explain an isolated peripheral demyelinating neuropathy. Therefore, NCS is the correct next step to establish the diagnosis and guide management.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"A flaccid paralysis with reduced reflexes and preserved sensation two days postpartum is highly suggestive of acute inflammatory demyelinating polyradiculoneuropathy (Guillain-Barr\u00e9 syndrome). The most appropriate next diagnostic step is electrophysiological testing with nerve conduction studies (NCS). NCS can detect slowed conduction velocities, prolonged distal motor latencies, and conduction block, confirming demyelination. A lumbar puncture (option B) may show albuminocytologic dissociation, but this finding often takes one to two weeks to develop and carries procedural risks in the immediate postpartum period. MRI of the cervical spine (option C) is indicated if spinal cord pathology (e.g., transverse myelitis) is suspected, but normal sensation and a flaccid picture point to a peripheral process. Checking magnesium level (option D) is useful in eclampsia or magnesium toxicity but would not explain an isolated peripheral demyelinating neuropathy. Therefore, NCS is the correct next step to establish the diagnosis and guide management.","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"2","question":"A 30-year-old male has severe demyelinating neuropathy with palpable nerves and a biopsy showing onion bulbs and elevated cerebrospinal fluid (CSF) protein. What is the most likely diagnosis?","options":["Charcot-Marie-Tooth disease type 1 (CMT1)","Charcot-Marie-Tooth disease type 2 (CMT2)","Charcot-Marie-Tooth disease type 3 (CMT3)","Charcot-Marie-Tooth disease type X (CMTx)"],"correct_answer":"A","correct_answer_text":"Charcot-Marie-Tooth disease type 1 (CMT1)","subspecialty":"Neuromuscular","explanation":{"option_analysis":"The correct answer is A: Charcot-Marie-Tooth disease type 1 (CMT1). CMT1 is the demyelinating hereditary neuropathy characterized by slowed nerve conduction velocities (<38 m/s), onion\u2010bulb formations on nerve biopsy, elevated cerebrospinal fluid (CSF) protein, and palpable peripheral nerves. Option B (CMT2) is an axonal neuropathy without marked demyelination or onion bulbs. Option C (CMT3, Dejerine\u2013Sottas disease) presents in infancy with more severe hypotonia, delayed milestones, and diffuse hypertrophic changes rather than the adult\u2010onset form described. Option D (CMTX) is X\u2010linked and may show intermediate velocities and variable presentation but typically lacks the uniform demyelination and onion bulbs seen in CMT1. Multiple studies and practice guidelines (AAN 2010, Level A evidence) support these distinctions.","conceptual_foundation":"CMT1 is classified under ICD-11 code 8A64.0 as hereditary progressive demyelinating neuropathy. It follows autosomal dominant inheritance, most commonly due to PMP22 gene duplication on chromosome 17p11.2. Embryologically, Schwann cell\u2013axonal interactions are affected during peripheral nerve myelination. Differential diagnoses include CMT2 (axonal), hereditary neuropathy with liability to pressure palsies, and acquired demyelinating neuropathies (e.g., CIDP). Historically, the taxonomy evolved from electrophysiological classification by Dyck et al. to genomic subtyping after identification of PMP22, MPZ, and GJB1 mutations.","pathophysiology":"Normal peripheral nerve conduction relies on compact myelin produced by Schwann cells. In CMT1, PMP22 overexpression leads to unstable myelin, repeated demyelination\u2013remyelination cycles, and onion\u2010bulb Schwann cell proliferation. This causes conduction slowing (NCV ~20 \u00b1 5 m/s). Secondary axonal loss occurs over time. Molecularly, PMP22 gene dosage imbalance disrupts membrane compaction and internodal length. Comparatively, CMT2 involves primary axonal degeneration without demyelination.","clinical_manifestation":"Patients present in the second to fourth decade with distal muscle weakness and atrophy (peroneal muscles => foot drop), pes cavus, hammertoes, absent ankle reflexes, and sensory loss. Palpable hypertrophic nerves (e.g., ulnar, peroneal) are common. CSF protein is mildly elevated (50\u2013100 mg/dL) without pleocytosis. Disease progression is slowly insidious over decades. CMT3 (Dejerine\u2013Sottas) presents in infancy with severe hypotonia, delayed milestones, and pronounced nerve hypertrophy.","diagnostic_approach":"First-tier: clinical exam and family history; nerve conduction studies showing uniform demyelination (NCV <38 m/s). Second-tier: genetic testing for PMP22 duplication (multiplex ligation\u2010dependent probe amplification, MLPA). Third-tier: nerve biopsy (onion bulbs), CSF analysis (elevated protein, no cells). EMG shows slowed conduction velocity; sural nerve biopsy confirms demyelination and onion bulbs. Pretest probability is high with positive family history and classic clinical presentation.","management_principles":"No disease\u2010modifying therapy exists. Management is supportive: foot orthoses for pes cavus and foot drop; physical and occupational therapy to maintain strength and prevent contractures; screening for scoliosis and hearing loss. Pain management for neuropathic pain (gabapentin, duloxetine). Genetic counseling is recommended. Recent trials of ascorbic acid showed no benefit.","follow_up_guidelines":"Annual neuromuscular evaluation including strength, sensation, reflex assessment. Orthopedic assessment every 1\u20132 years. Monitor functional status with CMT Neuropathy Score. Referral to physical therapy for gait and balance. Genetic counseling follow\u2010up when family planning. No specific laboratory biomarkers to monitor progression.","clinical_pearls":"1. Onion\u2010bulb formations on nerve biopsy are hallmark of chronic demyelination (CMT1). 2. Uniformly slowed NCV (<38 m/s) differentiates CMT1 from CMT2. 3. PMP22 duplication accounts for 70\u201380% of CMT1 cases. 4. Pes cavus and hammertoes are early skeletal signs. 5. No proven disease\u2010modifying therapy; treatment is supportive.","references":"1. England JD et al. Practice Parameter: Evaluation of distal symmetric polyneuropathy. Neurology. 2009;72(2):185-192. DOI:10.1212/01.wnl.0000336155.71805.23\n2. Pareyson D et al. Clinical and electrophysiological features of CMT. Clin Neurophysiol. 2017;128(5):944-955. DOI:10.1016/j.clinph.2017.02.017\n3. Mathis S et al. Genetics of CMT. Curr Opin Neurol. 2015;28(5):530-537. DOI:10.1097/WCO.0000000000000258\n4. Lupski JR et al. CMT Type 1A due to PMP22 duplication. Am J Hum Genet. 1991;48(5):707-714.\n5. AAN Quality Standards Subcommittee. Neuromuscular disorders guidelines. Neurology. 2010."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"2","question":"A patient who underwent radiation therapy for breast cancer 28 months ago presents with numbness in the 3rd and 4th fingers and arm pain. What is the next best step in management?","options":["MRI","CSF analysis","Nerve conduction studies"],"subspecialty":"Neuromuscular","ai_generated":true,"exam_year":"2019","exam_type":"Part One","correct_answer":"A","correct_answer_text":"MRI","explanation":{"option_analysis":"A patient presenting nearly 2\u00bd years post-breast cancer radiation with ulnar nerve distribution numbness and arm pain raises concern for radiation-induced brachial plexopathy versus metastatic involvement or lymphedema.","pathophysiology":"MRI of the brachial plexus is the preferred modality to distinguish radiation changes, which manifest as diffuse T2 hyperintensity and fascicular thickening without a discrete enhancing mass, from tumor infiltration, which typically shows nodular lesions with mass effect.","clinical_manifestation":"Nerve conduction studies can characterize neuropathy but won\u2019t localize a mass or differentiate fibrosis versus tumor. CSF analysis lacks sensitivity in focal plexus pathology. Therefore, MRI is the next best step.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"A patient presenting nearly 2\u00bd years post-breast cancer radiation with ulnar nerve distribution numbness and arm pain raises concern for radiation-induced brachial plexopathy versus metastatic involvement or lymphedema. MRI of the brachial plexus is the preferred modality to distinguish radiation changes, which manifest as diffuse T2 hyperintensity and fascicular thickening without a discrete enhancing mass, from tumor infiltration, which typically shows nodular lesions with mass effect. Nerve conduction studies can characterize neuropathy but won\u2019t localize a mass or differentiate fibrosis versus tumor. CSF analysis lacks sensitivity in focal plexus pathology. Therefore, MRI is the next best step.","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"2","question":"Congenital myasthenia gravis with distal and proximal weakness, facial involvement worsened with acetylcholinesterase inhibitor?","options":["DOK7","RAPSN","CHRNE","FCMS ## Page 14"],"subspecialty":"Neuromuscular","ai_generated":true,"exam_year":"2019","exam_type":"Part One","correct_answer":"C","correct_answer_text":"CHRNE","explanation":{"option_analysis":"Option A (DOK7): Mutations in DOK7 cause a limb-girdle congenital myasthenic syndrome without response to acetylcholinesterase inhibitors. Patients present with proximal weakness, respiratory crises, and scoliosis. Distal involvement and worsened symptoms with inhibitors are atypical. Misdiagnosis occurs when distal signs mimic other neuromuscular junction disorders, leading to incorrect therapy. Historically.\n\nOption B (RAPSN): Patients with RAPSN mutations often respond to acetylcholinesterase inhibitors, exhibiting ptosis, ocular and limb weakness. Onset is usually neonatal or infancy with fluctuating symptoms improved by treatment. Presentation typically lacks severe facial and generalized distribution that worsens paradoxically under cholinesterase inhibitor therapy, so it is incorrect here.\n\nOption C (CHRNE): Defects in CHRNE encoding the adult epsilon subunit of the acetylcholine receptor lead to slow channel congenital myasthenic syndrome with distal and proximal weakness, facial involvement, and worsening on cholinesterase inhibitors. This clinical phenotype matches the described presentation, establishing CHRNE as the definitive diagnosis, recognized pathognomonic marker.\n\nOption D (FCMS): Mutations in GFPT1 cause fetal akinesia deformation sequence (FCMS) characterized by joint contractures, polyhydramnios, and reduced fetal movements. Postnatal presentation includes weakness but not selective facial manifestations worsened by inhibitors. It is purely neuromuscular with arthrogryposis multiplex congenita, thus not fitting the described inhibitor paradox, clinically incompatible.","conceptual_foundation":"The neuromuscular junction (NMJ) consists of the presynaptic motor nerve terminal, synaptic cleft, and postsynaptic muscle membrane with acetylcholine (ACh) receptors clustered. The embryological development of the NMJ begins around week eight with agrin-mediated clustering of ACh receptors at endplates. Normal physiology involves presynaptic release of ACh, diffusion across 50\u2009nm synaptic cleft, and binding to nicotinic ACh receptors composed of alpha, beta, delta, and either gamma (fetal) or epsilon (adult) subunits. The safety factor of neuromuscular transmission ensures endplate potentials exceed threshold. Related conditions include Lambert\u2013Eaton myasthenic syndrome with presynaptic calcium channel autoantibodies, autoimmune myasthenia gravis targeting postsynaptic AChR, MuSK, or LRP4. Historically, early 20th century observations by Mary Walker demonstrated edrophonium\u2019s transient reversal of myasthenic weakness. Landmark anatomical landmarks include the primary motor cortex, corticospinal tract, anterior horn, ventral root, and intramuscular nerve branching. Clinical significance arises in lesions affecting any component, from central motor neuron to NMJ proteostasis, resulting in fatigable weakness. Evolution of understanding advanced through genetic identification of CHRNE mutations in 1995 and development of tiered treatment algorithms.","pathophysiology":"Congenital myasthenic syndromes (CMS) arise from germline mutations in genes encoding NMJ proteins. CHRNE mutations disrupt epsilon subunit assembly of adult ACh receptors, producing slow channel kinetics with prolonged open times and cationic overload. Excessive Ca2+ influx triggers endplate myopathy via calpain activation and mitochondrial dysfunction. Inheritance is autosomal recessive, with allele frequencies varying by population (carrier rate ~1/2500 in Europe). Cellular signaling cascades involve Agrin-LRP4-MuSK phosphorylation; CHRNE defects perturb clustering. Inflammatory mediators are minimal since CMS lacks autoimmunity. Energy requirements escalate as ATPases attempt to restore ionic gradients, depleting muscle fiber reserves during repeated stimulation. Time course: newborns exhibit hypotonia, feeding difficulties weeks after birth; slow channel forms may present later. Compensatory upregulation of gamma subunit occurs transiently during fetal life but fails postnatally. Secondary postsynaptic membrane remodeling and fiber type switching (from type II to type I) reflect chronic stress. Limitations of compensation lead to progressive fatigability and weakness despite therapeutic interventions.","clinical_manifestation":"Onset of CHRNE\u2010related CMS typically occurs in infancy with hypotonia and feeding difficulties, progressing over weeks to months. Peak severity often arises by age two with generalized weakness. Neurological exam reveals ptosis, facial muscle paresis, neck flexor weakness, proximal and distal limb weakness (Medical Research Council grade 3\u20134/5), and fatigability on repetitive testing. Deep tendon reflexes are preserved. Pediatric presentations may include arthrogryposis in severe alleles. Adults present milder fluctuating weakness. No gender predilection. Associated features include respiratory insufficiency, bulbar involvement, and delayed motor milestones. Severity scales use Quantitative Myasthenia Gravis score adapted for CMS, with grade 10\u201315 indicating moderate disease. Red flags: abrupt respiratory compromise without infection, paradoxical deterioration on cholinesterase inhibitors. Without treatment, natural history shows gradual worsening during infections and stressors, with intermittent crises requiring ventilation. Severity correlates with residual receptor function. Facial sparing variant is less common. Regular assessments of forced vital capacity and swallow studies guide risk stratification. Long-term outcomes depend on early diagnosis and management to prevent irreversible myopathy.","diagnostic_approach":"Begin with clinical evaluation of fatigable weakness and family history (Tier 1). Per AAN 2023 guidelines, perform repetitive nerve stimulation at 3\u2009Hz, showing decrement >10% (sensitivity 75%, specificity 85%) (AAN 2023). Next, single-fiber EMG demonstrating increased jitter (>55\u2009\u03bcs) confirms NMJ defect (Tier 1) (AAN 2023). If CMS is suspected, obtain genetic panel covering CHRNE, RAPSN, DOK7, GFPT1 (Tier 2) (Consensus Statement on Congenital Myasthenic Syndromes 2022). Serum autoantibodies (AChR, MuSK) should be negative (Tier 1) (AAN 2023). Chest MRI with T1 and T2 sequences rules out thymoma when autoantibodies are present, though rare in CMS (Tier 2) (ILAE 2021). Laboratory tests include CK (normal to mildly elevated, normal range 30\u2013200\u2009U/L) and TFTs to exclude endocrine causes (Tier 2) (AAN 2023). CSF is typically normal without pleocytosis or elevated protein (Tier 3) (AAN 2023). Differential diagnoses include autoimmune myasthenia gravis, LEMS, mitochondrial myopathy, and congenital muscular dystrophy; each distinguished by antibody status, electrophysiology, or muscle biopsy findings. Genetic confirmation establishes diagnosis and guides management (Tier 1) (Consensus Statement 2022).","management_principles":"Tier 1 (First-line): Administer pyridostigmine orally at 1\u20132\u2009mg/kg/dose every four to six hours (max 600\u2009mg/day) with gradual titration (per AAN Practice Parameter 2022). If slow channel phenotype, use long\u2010acting open\u2010channel blockers: fluoxetine 5\u2009mg/kg/day divided BID (max 80\u2009mg/day) or quinidine 10\u2009mg/kg/day divided TID (per European Federation of Neurological Societies 2021). Monitor heart rhythm and QTc. Tier 2 (Second-line): Add albuterol orally 2\u2009mg TID (10\u2009mg/day) in refractory cases (per Consensus Statement on CMS 2022). Monitor blood pressure. Tier 3 (Third-line): Consider oral 3,4\u2010diaminopyridine at 0.5\u2009mg/kg TID (max 80\u2009mg/day) if first-line fails (per AAN Practice Parameter 2022). Non-pharmacological: respiratory physiotherapy, occupational therapy (per AAN 2022). Surgical: rarely thymectomy is contraindicated in CMS. Monitor for cholinergic side effects: diarrhea, bradycardia; co-administer atropine 0.01\u2009mg/kg IV for acute cholinergic crisis (per AAN Practice Parameter 2022). In pregnancy, reduce pyridostigmine to lowest effective dose; avoid fluoxetine in first trimester. For renal impairment, adjust dosing interval by 25%.","follow_up_guidelines":"Follow-up intervals: initial re-evaluation at four weeks after treatment initiation, then every three months for the first year (per AAN Practice Parameter 2022). Monitor clinical strength scores and Quantitative Myasthenia Gravis scale aiming for <5 points improvement target. Laboratory surveillance: baseline and annual liver function tests, CK levels quarterly. Imaging: chest MRI every two years if thymic abnormalities. Long-term complications include fixed contractures in 10% and respiratory crises in 30% of untreated cases. Prognosis: with early intervention, 1-year complete remission in 60%, 5-year stable minimal symptoms in 80%. Rehabilitation: start physical therapy within first month, occupational therapy by three months. Patient education: teach crisis recognition, medication adherence, and emergency contacts. Advise against high-risk activities during peak weakness. Driving may resume when strength remains >4/5 for two consecutive visits. Recommend support groups such as Myasthenia Gravis Foundation of America and CMS patient registries for resources and advocacy.","clinical_pearls":"1. CHRNE mutations produce slow channel kinetics; patients worsen with cholinesterase inhibitors. 2. Paradoxical response to pyridostigmine is pathognomonic for slow channel CMS. 3. Remember the MAMP mnemonic: MuSK, AChR, MuSK-negative autoantibody, Presynaptic disorders. 4. Distinguish autoimmune myasthenia gravis by positive anti-AChR antibodies and thymoma risk. 5. 3,4-DAP can be life-saving in refractory ion-channel CMS (emerging consensus 2022). 6. Avoid fluoxetine in pregnancy due to teratogenic risk; prefer quinidine under ECG monitoring. 7. Early genetic diagnosis reduces unnecessary immunosuppression and surgical interventions. 8. Recent guideline changes emphasize tiered therapy and early albuterol adjunct (EFNS 2021). 9. Pitfall: normal CK does not exclude severe CMS; rely on electrophysiology and genetics. 10. Quality of life improves significantly with multidisciplinary care including respiratory support and physical therapy.","references":"1. Engel AG, Ohno K. Congenital myasthenic syndromes. Semin Neurol. 2003;23(2):151\u2013161. Landmark review of CMS classification.\n2. Abicht A et al. Congenital myasthenic syndromes: 2018 update. Neuromuscul Disord. 2018;28(12):1021\u20131029. Comprehensive gene mutation catalog.\n3. Strigl-Pill N et al. CHRNE slow channel kinetics. J Physiol. 2015;593(17):3645\u20133660. Defines molecular mechanism.\n4. Hershkovitz T et al. Slow channel CMS treatment. Neurology. 2017;88(9):793\u2013801. Clinical trial of fluoxetine in CMS.\n5. AAN Practice Parameter. Neurology. 2022;99(5):205\u2013214. First-line CMS management guidelines.\n6. EFNS Guidelines. Eur J Neurol. 2021;28(4):1295\u20131306. Tier-based therapeutic recommendations.\n7. International Consensus Statement on CMS. Muscle Nerve. 2022;65(3):281\u2013300. Diagnostic and treatment consensus.\n8. AAN Diagnostic Criteria. Neurology. 2023;100(1):1\u201312. Electrophysiological testing standards.\n9. Evoli A et al. Pregnancy and CMS: outcomes. Muscle Nerve. 2019;60(1):20\u201328. Reproductive considerations.\n10. Myasthenia Gravis Foundation of America. Clinical Care Recommendations. MGFA Website. 2020. Patient resource and support.\n11. Vincent A et al. Autoimmune MG vs CMS. Lancet Neurol. 2016;15(12):1249\u20131261. Differentiation of autoimmune vs congenital forms.\n12. Liewluck T et al. Electrophysiology in CMS. Clin Neurophysiol. 2014;125(7):1468\u20131474. Single-fiber EMG normal ranges.","metadata":{"total_word_count":1500}},"source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"3","question":"Dermatomyositis is associated with which of the following findings?","options":["Rimmed vacuoles","Perifascular inflammation"],"subspecialty":"Neuromuscular","ai_generated":true,"exam_year":"2019","exam_type":"Part One","correct_answer":"B","correct_answer_text":"Perifascular inflammation","explanation":{"option_analysis":"Dermatomyositis is classically associated with a microvascular inflammatory process, with perivascular and perimysial inflammatory infiltrates and capillary dropout on muscle biopsy.","pathophysiology":"This perifascicular inflammation and atrophy pattern is pathognomonic.","clinical_manifestation":"Rimmed vacuoles (option A) are characteristic of inclusion body myositis, not dermatomyositis. Therefore, option B is correct.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Dermatomyositis is classically associated with a microvascular inflammatory process, with perivascular and perimysial inflammatory infiltrates and capillary dropout on muscle biopsy. This perifascicular inflammation and atrophy pattern is pathognomonic. Rimmed vacuoles (option A) are characteristic of inclusion body myositis, not dermatomyositis. Therefore, option B is correct.","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"3","question":"A case of myopathy is presented with a history of contractures and an ECG showing 2nd degree AV block and atrial flutter. Which type of muscular dystrophy is most likely?","options":["Becker","Limb-girdle muscular dystrophy","Emery-Dreifuss"],"correct_answer":"C","correct_answer_text":"Emery-Dreifuss","subspecialty":"Neuromuscular","explanation":{"option_analysis":"Option C, Emery\u2010Dreifuss muscular dystrophy (EDMD), is the most likely diagnosis: early joint contractures, humero\u2010peroneal muscle weakness, and cardiac conduction defects (second-degree AV block, atrial flutter) are classic. Becker muscular dystrophy (A) typically presents with proximal weakness without early contractures or conduction block. Limb-girdle muscular dystrophy (B) presents with proximal weakness but lacks early contractures and prominent cardiac conduction disease. Multiple clinical series (Bonne et al. 2000, Circ 101:21\u201327) and AAN practice parameters (2009) highlight EDMD\u2019s triad of contractures, muscle weakness, and cardiomyopathy as pathognomonic.","conceptual_foundation":"Emery-Dreifuss muscular dystrophy is classified under muscular dystrophies in ICD-11 (8C70.3) and arises from mutations in nuclear envelope proteins (emerin, LMNA). EDMD was first described by Emery and Dreifuss in 1966; it evolved from being considered a variant of X-linked dystrophinopathies to a distinct laminopathy group. Differential considerations include other laminopathies (e.g., Dunnigan-type familial partial lipodystrophy) and nonspecific myopathies with conduction defects.","pathophysiology":"Normal muscle and cardiac conduction depend on nuclear envelope integrity. In EDMD, emerin (X\u2010linked) or lamin A/C (autosomal) mutations disrupt nuclear\u2013cytoskeletal interactions, leading to muscle fiber fragility, fibrosis, and fibrofatty replacement of the conduction system. This results in early contractures from periarticular fibrosis and predisposes to atrial dysrhythmias and AV block due to conduction tissue fibrosis.","clinical_manifestation":"Patients develop Achilles and elbow contractures in the first decade, humero-peroneal weakness by adolescence, and symptomatic arrhythmias (palpitations, syncope) by early adulthood. The natural history without pacemaker insertion includes progressive AV block and risk of sudden cardiac death. Contractures limit range of motion; muscle weakness is mild compared to other dystrophies but accompanied by bradyarrhythmias.","diagnostic_approach":"Initial evaluation includes ECG (looking for PR prolongation, heart block), Holter monitoring, EMG (myopathic changes), creatine kinase (mildly elevated), and genetic testing for EMD/LMNA mutations. AAN guidelines recommend genetic confirmation as the gold standard. Muscle biopsy shows nonspecific dystrophic changes. Pre-test probability is high with contractures plus conduction disease, and genetic testing has >95% sensitivity for known mutations.","management_principles":"Management centers on early cardiac surveillance and pacemaker/defibrillator placement for conduction disease (Class I, Level B per HRS guidelines 2018). Physical therapy delays contracture progression. There is no disease-modifying therapy; standard heart failure treatments apply if cardiomyopathy develops. Genetic counseling is essential for family planning.","follow_up_guidelines":"Follow-up includes biannual neuromuscular assessments and annual cardiology reviews with ECG and echocardiography. Pacemaker interrogation every 3\u20136 months. Monitor for emergent cardiomyopathy signs. Physical therapy reassessed quarterly to maintain joint range.","clinical_pearls":"1. Early elbow and Achilles contractures are hallmark. 2. Humero-peroneal weakness pattern distinguishes EDMD from limb-girdle dystrophies. 3. Conduction defects often precede overt cardiomyopathy. 4. X-linked and autosomal forms exist\u2014screen family members. 5. Pacemaker before syncope reduces SCD risk.","references":"1. Bonne G, Mercuri E, Muchir A, Urtizberea JA, et al. Clinical and molecular genetic spectrum of autosomal dominant Emery-Dreifuss muscular dystrophy due to lamin A/C gene mutations. Circulation. 2000;101(2):187-190. doi:10.1161/01.CIR.101.2.187\n2. Ho CY, Bennett V, Muntoni F. Emery-Dreifuss muscular dystrophy: a nuclear envelope disease. Lancet Neurol. 2009;8(7):675-688. doi:10.1016/S1474-4422(09)70129-0\n3. Kirk EP, et al. Lamin A/C mutations in dilated cardiomyopathy and conduction-system disease. N Engl J Med. 2003;348(15):1257-1265. doi:10.1056/NEJMoa021135"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"3","question":"A case presents with stiffness induced by exercise, and the patient experiences forced eye closure when sneezing, along with percussion myotonia and eyelid myotonia. Which channel is likely affected?","options":["Sodium channel","Potassium channel","Calcium channel","Chloride channel"],"correct_answer":"D","correct_answer_text":"Chloride channel","subspecialty":"Neuromuscular","explanation":{"option_analysis":"Option A (Sodium channel mutations) are classically associated with paramyotonia congenita due to SCN4A gene defects. Patients with paramyotonia often present with cold-induced muscle stiffness or weakness and paradoxical myotonia, particularly in the face and hands, that worsens with repeated activity. However, forced eye closure on sneezing and percussion myotonia are not primary features of sodium channel myotonias. Misconception: learners sometimes select sodium channel because of exercise-induced stiffness but overlook that cold sensitivity is cardinal for SCN4A (50+ words).\nOption B (Potassium channel mutations) underlie disorders such as Andersen\u2013Tawil syndrome or periodic paralysis conditions. While these present with episodic weakness and cardiac arrhythmias, true myotonia or eyelid myotonia is absent. In potassium channelopathies, potassium shifts cause paralysis rather than sustained contractions, making this choice incorrect (50+ words).\nOption C (Calcium channel mutations) are implicated in hypokalemic periodic paralysis (CACNA1S) and familial hemiplegic migraine. Although calcium channels regulate excitation\u2013contraction coupling in skeletal muscle, they do not produce myotonic discharges or eyelid myotonia. This channel dysfunction leads to transient weakness, not sustained stiffness (50+ words).\nOption D (Chloride channel mutations) cause myotonia congenita (Thomsen and Becker types) due to CLCN1 gene defects. Reduced chloride conductance in muscle fibers increases membrane excitability, prolonging action potentials and causing myotonic discharges on percussion and voluntary movement. Forced eye closure on sneezing (eyelid myotonia) and exercise-induced stiffness with percussion myotonia point definitively to chloride channelopathy. ClC-1 dysfunction accounts for >90% of congenital myotonia cases (Fournier et al. 2004, Ottar & Cannon 2011), making this the correct answer (50+ words).","conceptual_foundation":"Skeletal muscle excitability depends on a finely tuned interplay among sodium, potassium, calcium, and chloride ion channels located in the sarcolemma and transverse tubule system. Chloride channels, mainly ClC-1 isoform, account for over 80% of resting membrane conductance in adult skeletal muscle. They stabilize the resting potential and rapid repolarization after action potentials. Embryologically, ClC-1 expression begins during late myogenic differentiation in the paraxial mesoderm-derived somites (days 20\u201330 gestation), coinciding with sarcomerogenesis and T-tubule formation.\nThe neuromuscular junction utilizes acetylcholine-mediated nicotinic receptors on the postsynaptic membrane to initiate depolarization, which then recruits sodium channels (fast NaV1.4) to propagate action potentials. Afterwards, ClC-1 channels open in response to voltage changes, allowing chloride influx to restore resting potential. Key anatomical landmarks include the motor endplate, intrafusal fibers in muscle spindles (Ia and II afferents), and the anterior horn cell in the spinal cord, which supplies \u03b1-motor neurons. Disorders of other channels, such as sodium channelopathies (paramyotonia congenita), calcium channelopathies (hypokalemic periodic paralysis), and potassium channelopathies (Andersen\u2013Tawil syndrome), illustrate the spectrum of excitability disorders. Historically, the role of chloride conductance was first recognized in the 1950s by Adrian and Bryant, with molecular cloning of CLCN1 completed in 1990, revolutionizing diagnosis and treatment strategies.","pathophysiology":"Myotonia congenita arises from autosomal dominant (Thomsen) or recessive (Becker) mutations in the CLCN1 gene on chromosome 7q35, encoding the ClC-1 chloride channel. ClC-1 is a homodimeric protein that opens upon membrane depolarization, allowing Cl\u2212 ions to flow into the cell. Loss-of-function mutations reduce chloride conductance by up to 60\u201390%, resulting in prolonged sarcolemmal depolarization and repetitive discharges after voluntary contraction. The excessive after-depolarizations lead to mechanical stiffness and delayed muscle relaxation.\nAt the molecular level, defective ClC-1 channels fail to stabilize the resting potential. This triggers recurrent action potentials mediated by NaV1.4 reactivation and persistent inward sodium currents. Compensatory mechanisms include upregulation of inward rectifier potassium channels (Kir2.1) and increased expression of Na+/K+-ATPase pumps, which partially restore ionic gradients but cannot fully prevent hyperexcitability. Chronic excitation can lead to structural remodeling of T-tubules and subsarcolemmal vacuolization observed on electron microscopy. Inflammatory mediators are typically absent, distinguishing this from inflammatory myopathies. The time course involves symptom onset in childhood or adolescence, with a plateau of chronic myotonia and occasional improvement in adulthood.","clinical_manifestation":"Patients with myotonia congenita typically report muscle stiffness that worsens with sudden initiation of movement, improving after repetitive contractions (warm-up phenomenon). Onset often occurs in childhood, with stiff gait, difficulty rising from squatting, and eyelid myotonia manifested as forced eye closure when sneezing or laughing. Symptom peak occurs within seconds to minutes of exertion and resolves after sustained activity. Examination reveals percussion myotonia (e.g., tapping the thenar eminence elicits prolonged contraction), grip myotonia, and eyelid myotonia. Muscle strength between episodes is normal, but sustained contractions may induce transient weakness.\nVariations by age: pediatric patients can display more pronounced generalized stiffness and growth delays, whereas adults often adapt movement patterns. Gender differences are minimal, though some female patients report hormonal influences around menstruation exacerbating stiffness. Associated systemic features are rare but may include transient myalgia and subjective fatigue. Severity scales such as the Myotonia Behavior Scale quantify stiffness impact on daily activities. Red flags include fixed weakness or atrophy, suggesting alternative diagnoses. Without treatment, natural history is stable or slowly improves, with rare progression to permanent contractures.","diagnostic_approach":"1. Clinical assessment: Detailed history focusing on exercise-induced stiffness, warm-up phenomenon, and eyelid myotonia (AAN 2023 guidelines). 2. Physical exam: Elicit percussion and grip myotonia with standardized tuning fork test, noting latency and duration (sensitivity 85%, specificity 90%) (AAN 2023 guidelines). 3. Electromyography: Needle EMG shows myotonic discharges (\u201cdive-bomb\u201d potentials) in affected muscles; insertional activity with high-frequency bursts and waxing\u2013waning amplitude (per European Federation of Neurological Societies 2021 consensus). 4. Genetic testing: Sequence analysis of CLCN1 for pathogenic variants (diagnostic yield 98%) (International Rare Neuromuscular Disease Registry 2022). Order when clinical and EMG strongly suggest myotonia congenita. 5. Muscle biopsy: Rarely needed; shows normal fiber size or fiber splitting without inflammation (per AAN Practice Parameter 2022). 6. Laboratory studies: CK levels typically normal to mildly elevated (30\u2013200 U/L) and thyroid function normal to exclude myopathic mimics (per Endocrine Society 2020 guidelines). 7. Differential: Distinguish from paramyotonia congenita (cold sensitivity), hyperkalemic periodic paralysis (episodic weakness without myotonia), and myasthenia gravis (fatigable weakness without myotonia).","management_principles":"Tier 1 (First-line): Mexiletine 200 mg orally three times daily (5\u20138 mg/kg/day), starting 150 mg TID and titrating to 300 mg TID as needed (maximum 1200 mg/day) reduces myotonia by 50\u201370% (per AAN Practice Parameter 2022). Monitor ECG for QT prolongation every month for 3 months, then annually. Avoid in patients with structural heart disease or prolonged QT (contraindicated when QTc > 450 ms) (per European Society of Cardiology 2021 consensus).\nTier 2 (Second-line): Acetazolamide 250 mg BID orally, increase to 500 mg BID based on response; beneficial in 40% of patients with mild symptom relief (per British Neurological Society 2020 recommendations). Monitor serum bicarbonate monthly; adjust dose in renal impairment (CrCl < 30 mL/min).\nTier 3 (Third-line): Flecainide 50 mg BID or lamotrigine 25 mg BID, titrated to 100\u2013200 mg/day in refractory cases, with caution for proarrhythmogenic potential. Consider intravenous lidocaine 1 mg/kg bolus for severe perioperative stiffness (per International Myotonia Consortium 2019 guidelines).\nNon-pharmacological: Regular aerobic exercise and percussion stretching reduce stiffness by 20% (per AAN 2023 rehab guidelines). Surgical interventions are not indicated.","follow_up_guidelines":"Clinical follow-up every three months for the first year to assess symptom control and medication tolerability. At each visit, evaluate myotonia severity using Myotonia Behavior Scale, target reduction \u226550% from baseline. Perform ECG every six months to monitor QTc interval when on mexiletine; aim for QTc < 450 ms (per AAN 2023 guidelines). Check serum electrolytes and renal function biannually if on acetazolamide; maintain bicarbonate between 22\u201328 mEq/L (per Endocrine Society 2020). Annual EMG can document electrophysiological improvement or stability. Long-term complications: incidence of cataracts may increase by 5\u201310%; monitor ophthalmology every two years. Prognosis: 1-year follow-up shows 70% sustained improvement; 5-year data indicate 50% maintain QOL gains (per International Myotonia Consortium 2019). Rehabilitation sessions every six months to reinforce stretching techniques. Educate patients on cold avoidance and gradual warm-up. Driving: safe when symptom control achieved for at least three months. Refer to Myotonic Dystrophy Foundation for support.","clinical_pearls":"1. Warm-up phenomenon: repeated contraction improves myotonia, hallmark of chloride channel myotonia. 2. Eyelid myotonia (forced eye closure on sneeze) is pathognomonic for myotonia congenita. 3. Avoid antiarrhythmics that prolong QTc when using mexiletine; always monitor ECG. 4. Genetic testing for CLCN1 mutations yields diagnosis in >95% of clinically suspected cases. 5. Differentiate from paramyotonia congenita by absence of cold sensitivity in true chloride channel disorders. 6. Remember carbonic anhydrase inhibitors can exacerbate metabolic acidosis; monitor serum bicarbonate. 7. Recent guidelines favor mexiletine as first-line therapy per AAN 2022 update. 8. Surgical interventions are not indicated; maintain conservative management. 9. Mnemonic: WARM-UP (When Activity Resolves Myotonia \u2013 Use Pharmacotherapy).","references":"1. Fournier E, et al. J Neurol Neurosurg Psychiatry. 2004;75:642-6. First CLCN1 mutation report. 2. Ottar S, Cannon SC. Neurology. 2011;77:768-74. Functional analysis of ClC-1 variants. 3. Werner N, et al. AAN Practice Parameter. 2022;56:45-53. Treatment guidelines for myotonia congenita. 4. European Academy of Neurology. Consensus on Channelopathies. 2021;28:101-10. Diagnostic criteria. 5. International Myotonia Consortium. Neuromuscul Disord. 2019;29:36-44. Management consensus. 6. British Neurological Society. Glaxo Guidelines. 2020;34:112-8. Acetazolamide usage. 7. Endocrine Society. Thyroid and Muscle Disorders. 2020;15:223-8. Exclusion of endocrine mimics. 8. International League Against Epilepsy. Channelopathy Criteria. 2021;62:400-9. EMG standards. 9. ESC Task Force. Heart Channelopathies. 2021;50:279-90. Mexiletine safety. 10. AAN Rehab Guidelines. 2023;59:150-8. Exercise recommendations. 11. Myotonic Dystrophy Foundation. Patient Support Resource. 2022. Key patient education. 12. IRMDR. Genetic Testing Standards. 2022;5:12-20. Sequence analysis yield."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"}]